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hydrolase 18 (GH-18) ท่ีไม่สามารถยอ่ยไคตินได ้โปรตีนน้ีถูกจดัเป็นตวับ่งช้ีทางชีวภาพการกระตุน้
ของเซลล์กระดูกอ่อนและการติดตามความก้าวหน้าของโรคขอ้เส่ือม แต่กลไกการทาํงานยงัไม่
ทราบแน่ชดั วทิยานิพนธ์ฉบบัน้ีไดแ้บ่งการศึกษาออกเป็น 2 ส่วน โดยส่วนแรกทาํการศึกษาเก่ียวกบั
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โพลีโคลนอลและโมโนโคลนอลแอนติบอดีท่ีจาํเพาะต่อโปรตีน YKL-39 จากการศึกษาพบวา่ ทั้ง
โพลีโคนอลและโมโนโคลนอลแอนติบอดีมีความจาํเพาะและทาํปฏิกิริยาอย่างสูงต่อโปรตีน   
YKL-39 ผูท้าํวิจยัสามารถคดัเลือกโมโนโคลนท่ีสามารถสร้างโมโนโคลนอลแอนติบอดีจาํเพาะต่อ
โปรตีน YKL-39 ไดจ้าํนวน 2 โคลนให้ช่ือว่า 6H11 และ 8H3 ซ่ึงโคลนทั้งสองสามารถผลิต
แอนติบอดีชนิด IgM จากการศึกษาความจาํเพาะของแอนติบอดีท่ีผลิตไดต้่อโปรตีน YKL-39 ดว้ย
เทคนิค Dot blot พบว่าแอนติบอดีมีความจาํเพาะสูงต่อโปรตีน YKL-39 ในตวัอยา่งนํ้ าไขขอ้ของ
ผูป่้วยโรคข้อเส่ือม และในเซลล์เม็ดเลือดขาวชนิดโมโนไซต์ และทีลิมโฟไซต์ จากการค้นหา
โปรตีนคู่จบัของโปรตีน YKL-39 ในระบบฐานขอ้มูล พบวา่มีไกลโคโปรตีนหลายชนิดท่ีเก่ียวขอ้ง
กับโปรตีน YKL-39 ซ่ึงมีบทบาทในเน้ือเยื่อกระดูกอ่อน การสร้างเน้ือเยื่อเก่ียวพนั และการ
ปฏิสัมพนัธ์ระหวา่งเซลล ์สามารถสรุปไดว้า่โพลิโคลนอลและโมโนโคลนอลแอนติบอดีต่อโปรตีน 
YKL-39 ท่ีผลิตไดมี้ความเหมาะสมในการนาํไปใชป้ระโยชน์ในการศึกษาดา้นภูมิคุม้กนัวิทยา เช่น 
การศึกษาวิถีการควบคุมของโปรตีน YKL-39 และการพฒันาอุปกรณ์ในการตรวจวดัโปรตีนดว้ย
วธีิอิมมินูเซนเซอร์เพื่อติดตามความเสียหายของเน้ือเยือ่กระดูกอ่อน 
 ส่วนท่ี 2 เป็นการศึกษาโครงสร้างสามมิติจากผลึกโปรตีนดว้ยวิธีการหกัเหของรังสีเอกซ์และ
ศึกษาการจบัของโปรตีน YKL-39 ต่อไคตินสายสั้ นโดยวิธีอุณหพลศาสตร์ ผลการทดลองท่ีได้
พบว่าผลึกของโปรตีนสภาพธรรมชาติและท่ีจบักบัไคตินสายสั้ นขนาด 2-6 หน่วย สามารถหักเห
รังสีเอกซ์ไดค้วามละเอียดถึง 1.53 ถึง 2.48 องัสตรอม มีโครงสร้างโดยรวมประกอบดว้ยสองส่วน 
คือ โดเมนหลกัมีโครงสร้างแบบ (β/α)8-TIM-barrel และโดเมนเล็กแทรกระหว่างโดเมนหลกัมี
โครงสร้างเป็น α+β การวเิคราะห์ทางโครงสร้างพิสูจน์ให้เห็นวา่โปรตีน YKL-39 จบักบันํ้ าตาลสาย
 
 
 
 
 
 
 
 
II 
 
สั้นดว้ยแรงไฮโดรโฟบิคและดว้ยเครือข่ายพนัธะไฮโดรเจน ซ่ึงการจบัของนํ้ าตาลสายสั้นส่งผลให้
โปรตีนเกิดการเปล่ียนแปลงโครงรูปเพื่อใหก้ารจบัแน่นข้ึน ผลการวิเคราะห์โครงสร้างแสดงให้เห็น
ว่าโปรตีน YKL-39 มีบริเวณจบักับนํ้ าตาล 5 บริเวณย่อย ซ่ึงครอบคลุมตาํแหน่ง (-3)(-2)(-1) 
(+1)(+2) โดยมีกรดอะมิโนทริปโตแฟนตาํแหน่ง 360 ทาํหน้าท่ีหลกัในการจบักบันํ้ าตาลดว้ยแรง
ไฮโดรโฟบิคท่ีบริเวณศูนย์กลางของร่องจบัของโปรตีน สําหรับการศึกษาอุณหพลศาสตร์ของ
โปรตีนจบักับไคตินสายสั้ นด้วยวิธี isothermal titration calorimetry (ITC) และ intrinsic 
fluorescence spectroscopy ช้ีใหเ้ห็นวา่โปรตีน YKL-39 จบักบันํ้าตาลสายสั้นดว้ยค่าคงท่ีในการแตก
ตวั (Kd) ท่ีความเขม้ขน้ระดบัไมโครโมลาร์ และค่าพลงังานของการจบัจะเพิ่มข้ึนตามจาํนวนหน่วย
ของนํ้ าตาลท่ียาวข้ึน โดยค่าท่ีพบไม่มีความแตกต่างอยา่งมีนยัสําคญัระหวา่งนํ้ าตาลไคติน 5 หน่วย 
และ 6 หน่วย จากผลการทดลองน้ีไดส้นบัสนุนขอ้มูลทางโครงสร้างสามมิติของโปรตีนท่ีแสดง
บริเวณการจบัต่อนํ้ าตาล 5 หน่วย และการวิเคราะห์ทางอุณหพลศาสตร์ช้ีให้เห็นว่าการจบัของ
นํ้ าตาลต่อโปรตีน YKL-39 ถูกขบัเคล่ือนโดยเอนทลัปี จากผลการศึกษาทั้งหมดเสนอให้เห็นว่า
โปรตีน YKL-39 จบักบันํ้าตาลอยา่งไร และอาจส่งผลใหเ้กิดการกระตุน้สัญญาณต่อระบบภูมิคุม้กนั
อตัโนมติัและการปรับรูปร่างของเน้ือเยื่อ 
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FUNCTIONAL AND STRUCTURAL CHARACTERIZATION OF YKL-39, A 
HUMAN CHITINASE-LIKE PROTEIN 
 
Human cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39) is a member of 
family-18 glycoside hydrolases that lacks chitinase activity. YKL-39 is known as a 
potential marker for the activation of chondrocytes and the progression of 
osteoarthritis. This thesis is divided into two parts. The first part involves cloning and 
expression of YKL-39 in the bacterial system that was used as for production of    
anti-YKL39 polyclonal and monoclonal antibodies. Both antibody types were highly 
selective, reacting only with YKL-39. Isotype mapping identified two generated 
hybridoma clones (so called clones 6H11 and 8H3) as the IgM isotype. Dot blot assay 
showed that the monoclonal antibody was strongly active with the synovial fluid of an 
osteoarthritis patient, and human monocyte and T lymphocyte cell lines. A database 
search for protein binding partners gave high hits with several glycoproteins that play 
particular roles in cartilage tissue scaffolding, connective tissue formation, and      
cell-cell interactions. In conclusion, anti-YKL39 polyclonal and monoclonal 
antibodies were raised and tested to be suitable for immunological application, such 
as the investigation of the YKL-39 regulating pathway and the development of an 
immunosensing tool for sensitive detection of cartilage tissue destruction.  
 
 
 
 
 
 
 
 
IV 
 
In the second part, the binding of chitooligosaccharides to YKL-39 was 
investigated by protein crystallography and isothermal titration calorimetry. Four 
crystal structures of human YKL-39 were solved in the absence and presence of 
chitooligosaccharides. The overall structure of YKL-39 comprises a major (β/α)8 TIM 
barrel domain and a small α+β insertion domain. YKL-39 interacts with 
chitooligosaccharides through hydrophobic interactions, as well as a hydrogen 
bonding network. Detailed structural analysis revealed that the binding of chitin 
fragments induces local conformational changes that facilitate the tight binding and 
YKL-39 has the least extended chitin-binding cleft, containing five subsites for 
sugars, namely (-3)(-2)(-1)(+1)(+2), with Trp360 playing a prominent role in the 
sugar-protein interactions at the centre of the chitin binding cleft. Evaluation of 
binding affinities obtained from isothermal titration calorimetry and intrinsic 
fluorescence spectroscopy suggests that YKL-39 binds to chitooligosaccharides with 
Kd values in the micromolar concentration range and that the binding energies 
increase with the chain length. There were no significant differences between the Kd 
values of chitopentaose and chitohexaose, supporting the structural evidence for the 
five-binding subsite topology. Thermodynamic analysis indicates that binding of 
chitooligosaccharide to YKL-39 is mainly driven by enthalpy. In conclusion, our data 
suggest how YKL-39 could possibly interact with endogenous GlcNAc containing 
ligands that may stimulate the signaling cascades triggering autoimmune response and 
tissue remodeling. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Chitin and chitinases 
Chitin is a homopolysaccharide consisting of N-acetyl-glucosamine (GlcNAc) 
units joined together with β-1, 4-glycosidic linkages. Chitin is a highly abundant 
biopolymer in nature, second only to cellulose, and it serves as a major component of 
bacterial and fungal cell walls, exoskeletons of insects, microfilaria sheaths of 
parasitic nematodes, mollusks, protozoa, and crustaceans (Bussink, Speijer, Aerts, and 
Boot, 2007; Lee, 2009) . Although chitin is highly abundant, it does not accumulate in 
ocean floors, since chitin is degraded efficiently by chitinolytic enzymes from marine 
bacteria, especially in family Vibrios (Kawada, Hachiya, Arihiro, and Mizoguchi, 
2007). Chitinases are hydrolytic enzymes that are responsible for the degradation of 
chitin into small oligosaccharide fragments. Chitin degradation is essential in a variety 
of biological processes. For example, bacteria produce chitinases to degrade chitin as 
their carbon and nitrogen sources (Cottrell, Moore, and Kirchman, 1999). Fungal 
chitinases have multiple functions, such as in nutrition, as well as in morphogenesis of 
filamentous fungi (Kuranda and Robbins, 1991).  Plants are known to express 
chitinases for a defense mechanism against chitin-containing pathogens (Sahai and 
Manocha, 1993). Although humans do not contain endogenous chitin, chitinases 
expressed in humans have been reported to be associated with pathological conditions 
of certain infectious and inflammatory diseases (Elias, Homer, Hamid, and Lee, 2005; 
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Kawada et al., 2007; Kzhyshkowska, Gratchev, and Goerdt, 2007; Lee, 2009). In the 
Carbohydrate Active EnZymes (CAZy) database (http://www.cazy.org/), glycoside 
hydrolase families are described based on structurally-related catalytic and 
carbohydrate binding modules (or functional domains). Chitinases are grouped into 
family-18 and family-19 glycoside hydrolases (also referred to as GH-18 and GH-19 
chitinases) (Henrissat and Bairoch, 1993). The two enzyme families do not share 
sequence identity and differ in both structures and mechanisms (Davies and Henrissat, 
1995). GH-18 chitinases are mainly produced by bacteria, fungi, viruses, plants and 
mammals. The catalytic domain of GH-18 chitinases consists of an (α/β)8-TIM barrel 
fold, with a chitin binding domain (ChBD) attached either on the N-terminus or the  
C-terminus (Figures 1.1A and 1.1B). All GH-18 chitinases contain the catalytic 
domain with the DXXDXDXE conserved sequence motif (van Aalten et al., 2000), in 
which a glutamic residue at the end of strand β4 is identified as the proton donor in 
the hydrolytic reaction (Brameld and Goddard, 1998; Kuranda and Robbins, 1991; 
Tews, Terwisscha van Scheltinga, Perrakis, Wilson, and Dijkstra, 1997; Watanabe et 
al., 1997). The catalytic mechanism with retention of the anomeric configuration of 
GH-18 chitinases is achieved by “substrate-assisted catalysis”, by which the carbonyl 
oxygen of the N-acetyl group of the -1 sugar acts as a nucleophile (Cohen-Kupiec and 
Chet, 1998). In contrast, GH-19 chitinases are found mostly in plants (Iseli, Armand, 
Boller, Neuhaus, and Henrissat, 1996) and some Gram-positive bacteria, such as 
Streptomyces species (Iseli et al., 1996; Ohno et al., 1996). The catalytic domain of 
GH-19 chitinases consists of high α-helical content (Figure 1.1C) (Hart, Pfluger, 
Monzingo, Hollis, and Robertus, 1995; Monzingo, Marcotte, Hart, and Robertus, 
1996). The 3D-structure of GH-19 chitinases shares a common fold with family    
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GH-46 chitosanases and lysozymes from families GH-22, GH-23, and GH-24 
(Monzingo et al., 1996). Their catalytic mechanism is a general acid-base mechanism 
that inverts the anomeric configuration of the glycone moiety (Cohen-Kupiec and 
Chet, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The 3D structures of GH-18 and GH-19 chitinases. 
(A) GH-18 chitinase A with the ChBD attached on the N-terminus (blue) 
(Songsiriritthigul, Pantoom, Aguda, Robinson, and Suginta, 2008); (B) GH-18 
chitinase B with the ChBD attached on the C-terminus (blue) (van Aalten et al., 
2001). Both chitinase A and chitinase B contain the TIM barrel catalytic domain; (C) 
GH-19 chitinases with the bilobal catalytic domain (Hart et al., 1995; Monzingo et 
al., 1996). 
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1.2 Human chitinases 
As mentioned earlier, there is no endogenous chitin in mammals. However, it is 
common for humans to be exposed to chitin, which is a major component of allergy-
triggering antigens, such as cockroaches (Chew et al., 2008), house dust mites (Arlian 
and Platts-Mills, 2001) and helminthes, in daily life (Lee, Da Silva, Lee, Hartl, and 
Elias, 2008). To date, there are two human chitinases have been identified, 
Chitotriosidase and Acidic mammalian chitinase. They have been suggested to play a 
role in the defense mechanism against chitin-containing pathogens in the innate 
immunity of human (van Eijk et al., 2005).  
 
Human macrophage chitinase (later known as chitotriosidase, CHIT1) was 
originally identified from the spleen of a symptomatic patient with Gaucher disease 
(GD, glucosylceramidosis). The source of the secreted chitotriosidase was found to be 
abnormal lipid-laden macrophages formed in tissues of Gaucher disease patients 
(Gaucher cells). The level of chitotriosidase in the plasma of Gaucher disease patients 
was found to be increased more than 600 times when compared with healthy people 
(Hollak, van Weely, van Oers, and Aerts, 1994). Thus, it has been proposed as a 
biomarker for diagnosis and monitoring the effectiveness of therapeutic approaches 
for treatment of GD (de Fost et al., 2006; Hollak et al., 1994; Pastores and Barnett, 
2005). The expression of chitotriosidase at the mRNA level was also detected in 
lymph nodes, lung, and bone marrow that are involved in immune system (Boot, 
Bussink, and Aerts, 2005). Moreover, macrophages and neutrophils were also 
discovered to be a source of chitotriosidase in human (van Eijk et al., 2005). In vitro, 
monocyte-derived macrophages can be indeed to express chitotriosidase by stimulus 
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with proinflammatory cytokines, GM-CSF, TNF-α, and lipopolysaccharide (LPS), 
while IFN-γ and IL-4 inhibit the expression of chitotriosidase (Di Rosa et al., 2006; 
Malaguarnera, Musumeci, Di Rosa, Scuto, and Musumeci, 2005). In vivo, 
overexpression of chitotriosidase was found in several of diseases including 
atherosclerosis and sarcoidosis that are involved in chronic inflammation (Boot et al., 
1999). Expression of chitotriosidase mRNA was also identified in Alzheimer’s 
disease (AD), Ischemic cerebrovascular dementia (CvD), nonalcoholic fatty liver 
disease steatohepatitis (NASH) (Di Rosa et al. 2006; Malaguarnera et al. 2005). 
Moreover, chitotriosidase is the only biomarker for the monitoring of lipid-laden 
macrophages and Fabry disease; an X-linked globotriaosylceramidosis caused by the 
deficiency in the lysosomal α-galactosidase A (AGA) (Vedder et al., 2006). 
Treatment with recombinant AGA results in normalization of plasma chitotriosidase 
levels (Vedder et al., 2006). There are two major enzymatic isoforms of 
chitotriosidase, including 50 kDa and 39 kDa forms (Renkema, Boot, Muijsers, 
Donker-Koopman, and Aerts, 1995). The 39 kDa isoform which lacks a C-terminal 
chitin-binding domain is made during the posttranslational processing, as showed in 
Figure 1.3 (Renkema et al., 1997). Chitotriosidase has been classified into GH-18 
chitinases based on its amino acid sequence, structure, and ability to hydrolyze natural 
chitin in the cells wall of the fungal pathogen Candida albicans (Boot et al., 2001; 
Boot, Renkema, Strijland, van Zonneveld, and Aerts, 1995; Boot et al., 1998; Hollak 
et al., 1994).  Increased chitotriosidase activity was identified in plasma of neonates 
with fungal and bacterial infections, suggesting that it can be used as an indicator of 
macrophage activity during the progression of infectious diseases (Labadaridis et al., 
2005). In addition, enzymatically chitinase activity to hydrolyzed chitin was found in 
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both in vitro and in an animal model, suggesting that it may play a role in defense 
mechanism against chitin-containing pathogens in innate immunity (van Eijk et al., 
2005).  
The structure of CHIT1, with the N-terminal catalytic domain adopts the (α/β)8 
TIM-barrel structure that has a chitin-binding domain at its C-terminus. Like other 
GH-18 chitinases, the β4 strand within the TIM barrel domain of CHIT1 (also 
AMCase) contains a conserved sequence motif D133XXD136XD138XE140 that forms the 
active site of the enzyme with the last glutamic acid acting as the proton donor 
required for hydrolyzing the β (1, 4) glycosidic bond in a chitin chain as showed in 
Figure 1.3 (Brameld and Goddard, 1998; Kuranda and Robbins, 1991; Tews et al., 
1997; Watanabe et al., 1997). Although no endogenous substrate for these true 
chitinases has been identified in mammals, recent studies suggest that they have 
significant roles in inflammation, tissue injury responses, and pathogenesis of human 
diseases (Lee et al., 2011). 
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Figure 1.2 The 3D structure of 39 kDa isoform of human chitotriosidase that lacks 
ChBD at C-terminus.  
The TIM barrel domain is made up of a cylinder of 8 parallel β-strands surrounded by 
8 parallel α-helices (dark gray color) with small insertion domain (green clolor). The 
critical aspartic acid (D) and catalytic glutamic acid residue (E) at conserved sequence 
motif D133XXD136XD138XE140 are indicated in blue (Fusetti et al., 2002). The 
substrate GlcNAc2 is showed as ball-stick yellow color. 
 
Acidic mammalian chitinase (AMCase) is human form of GH-18 chitinase, 
which was initially identified in human stomach. AMCase is stable at extremely low 
pH and has an optimum pH of approximately 2 (Boot et al., 2001). AMCase has been 
suggested to be particularly involved in progression of asthma (Elias et al., 2005, a 
chronic disease characterized by exaggerated Th2 airway inflammation (Ray and 
Cohn, 1999). AMCase was reported to be highly up-regulated in the airways of 
asthmatic patients (Zhu et al., 2004) and in patients with pulmonary T helper 2 (Th2) 
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inflammations, but not with T helper 1 (Th1) inflammation (Robert et al., 2006). 
Another study in a mouse model of ovalbumin-induced bronchial asthma suggested 
that the AMCase was involved in the pathophysiology of asthma and acted 
downstream of interleukin-13 (Zhu et al., 2004). Administration of anti-AMCase 
antibody led to a significant decrease of Th2-inflammation, tissue eosinophilia and 
lymphocyte accumulation. Similar effects were detected after the application of a 
potent chitinase inhibitor, allosamidin (Zhu et al., 2004). Although the mechanism 
underlying the human chitinase activation is unknown, human chitinases may 
function as host defense against pathogenic infection and inflammatory responses 
(Shuhui, Mok, and Wong, 2009). Chitin-containing pathogens, such as dust mites, 
cockroaches or fungi, may be introduced into human’s airway via inhalation. These 
allergens may also be introduced into the lungs, the pulmonary circulation and the 
gastrointestinal tract. These pathogens stimulate macrophages, which recruit 
eosinophils and basophils and inflammatory cells of the innate immune system to 
produce the type 2 helper T-cell (Th2 cell) cytokines interleukin-4 (IL-4) and 
interleukin-13 (IL-13). Such cytokines are known to induce the asthmatic phenotype. 
Secretion of the Th2 cytokines leads to an increase in the production of macrophages 
chitinase (chitotriosidase) and AMCase, both of which function enzymatically to kill 
chitin-producing pathogens and reduce inflammatory signaling by chitin (Figure 1.2). 
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Figure 1.3 The role of human chitinases in host defense against pathogen infection 
and inflammatory responses of allergic inflammation in the airway of the asthmatic 
lungs (Kawada et al., 2007).  
 
1.3 Human chitinase-like proteins 
Recently, a number of chitinase-like proteins (CLPs) were identified in secretions 
of epithelial tissues and blood circulation (Chupp et al., 2007; Hakala, White, and 
Recklies, 1993; Johansen et al., 1996; Knorr, Obermayr, Bartnik, Zien, and Aigner, 
2003). Expression of chitinase-like proteins is associated directly with pathogenesis of 
certain types of inflammatory diseases (Kzhyshkowska et al., 2007. CLPs have amino 
acid sequences homologous to GH-18 chitinases but lack chitinase activity due to 
substitution of the essential catalytic residue (glutamic acid) at the conserved 
sequence motif with leucine, isoleucine or tryptophan, as showed in Figure 1.4 
(Kawada et al., 2007. Despite the lack of enzymatic activity, all CLPs contain the 
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(α/β)8 TIM-barrel domain and retain the ability to bind chitin and chitin 
oligosaccharides with high affinity (Figure 1.5) (Houston, Recklies, Krupa, and van 
Aalten, 2003). To date, four members of CLPs have been identified, including 
chitinase 3-like 1 protein (CHI3L1 or YKL-40 or HC gp-39) (Johansen et al., 1996), 
chitinase 3-like 2 protein (YKL-39) (Hu, Trinh, Figueira, and Price, 1996), oviduct-
specific glycoprotein (oviductin or, Mucin9) (Arias, Verhage, and Jaffe, 1994), and 
stabilin-1 interacting chitinase-like protein (SI-CLP) (Kzhyshkowska et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Human chitinases and chitinase-like proteins as members of GH-18. 
(A) A schematic representation of domain organization of GH-18 members, which 
include the TIM barrel domain, the ChBD, the O-glycosylated region, and the 
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cleavage site; (B) The conserved sequence motif within the GH-18 family. 
Chitotriosidase (CHIT) and AMCase contain Glu140, which acts as proton donor. For 
CLPs, the glutamic acid is substituted to Leu, Ile and Trp, making them lack catalytic 
activity (Kzhyshkowska et al., 2006).  
 
YKL-40 (also called human cartilage glycoprotein-39 or HC gp-39, CHI3L1) 
was originally isolated as one of the major proteins secreted from cultured human 
osteosarcoma cell line MG63 (Johansen, Williamson, Rice, and Price, 1992). YKL-40 
was named based on its three specific N-terminal amino acids: tyrosine (Y), lysine (K) 
and leucine (L), and its apparent molecular weight on SDS-PAGE analysis (about 40 
kDa) (Johansen et al., 1992).   
YKL-40 is secreted by macrophages and neutrophils (Volck et al., 1998), 
presumably in response to primary infection (Renkema et al., 1998). Because YKL-40 
was highly expressed during pathological conditions associated with tissue 
inflammation, and development of fibrosis, it has been proposed that YKL-40 may 
involve in inflammation and tissue remodeling (Johansen et al., 2003; Kirkpatrick et 
al., 1997; Malinda, Ponce, Kleinman, Shackelton, and Millis, 1999; Shackelton, 
Mann, and Millis, 1995). Previous reports showed high levels of YKL-40 mRNA and 
protein expression in differentiated macrophages (Rehli, Krause, and Andreesen, 
1997), and in a subset of macrophages under pathological conditions, such as 
rheumatoid arthritis (Kirkpatrick et al., 1997), giant cell arteritis (Johansen et al., 
1999), arteriosclerosis (Boot et al., 1999), osteoarthritis (Volck et al., 2001) and small 
cell lung cancer (Junker, Johansen, Hansen, Lund, and Kristjansen, 2005). In vitro 
studies also confirmed high expression of YKL-40 in numerous human cancer cell 
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lines, including glioblastoma, colon cancer, ovarian cancer, prostate cancer, 
osteosarcoma, and malignant melanoma (Johansen, Jensen, Roslind, Nielsen, and 
Price, 2006). In addition, in vivo studies also reported elevated levels of YKL-40 in 
the circulating serum in number of solid tumors, such as breast cancer (Johansen et 
al., 2003), colorectal cancer (Cintin et al., 2002), ovarian cancer (Dupont et al., 2004, 
gastrointestinal cancer (Johansen et al., 2009), glioblastoma (Francescone et al., 2011, 
metastatic renal and prostate cancer (Brasso et al., 2006), malignant melanoma 
(Schmidt et al., 2006), small cell lung cancer (Johansen, Drivsholm, Price, and 
Christensen, 2004), and cervical adenocarcinoma (Mitsuhashi et al., 2009). However, 
the physiological roles of YKL-40 in cancer development are not yet known. 
Although serum concentrations of YKL-40 are not specific to a primary stage of solid 
tumors, YKL-40 has been proposed as a novel biomarker for the detection of 
advanced stages of various types of cancer (Johansen et al., 2006). Also, several 
studies demonstrated that high levels of YKL-40 expression are especially found in 
cancer patients with poor prognosis (Dehn et al., 2003; Jensen, Johansen, and Price, 
2003; Johansen et al., 2006; Yamac et al., 2008). 
The 3D structure of YKL-40 was solved by X-ray crystallography in a native 
form in complex with chitin oligosaccharides (Fusetti, Pijning, Kalk, Bos, and 
Dijkstra, 2003). The structural complexes showed that YKL-40 contained the (α/β)8 
TIM-barrel structure with a small insertion domain in a fashion identical to GH-18 
chitinases. In contrast to human chitinases, YKL-40 lacks the ChBD domain (Figure 
1.5).  
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Figure 1.5 The ribbon representation of YKL-40 in complex with chitin 
oligosaccharide GlcNAc8. 
The (α/β)8 TIM barrel domain shown as purple color, while a small insertion domain 
shown as green color. The side chain of Leu140 that substitutes the catalytic Glu in 
GH-18 chitinases is shown as purple sticks. Chitin oligosaccharide is represented in 
ball and stick with carbons of GlcNAc8 in yellow, nitrogen in blue and oxygen in red 
(Houston et al., 2003).  
 
The crystal structures of YKL-40 complexed with various chitin 
oligosaccharides identified nine GlcNAc-binding subsites that are formed by a 
number of conserved aromatic residues (Trp71, Trp99, Tyr141, Phe208, Trp212, and 
Trp352) that provide hydrophobic interactions with the hydrophobic faces of the sugar 
rings (Figure 1.6). Of all, Trp99 and Trp352 participate in ligand recognition by 
making hydrogen bonds with the C3-OH of the (-1)GlcNAc and the C7-O of the       
(-2)GlcNAc, respectively. Moreover, the crystal structure of YKL-40 with GlcNAc8 
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showed that binding of the chitooligosaccharide to YKL-40 induced a large 
conformational change in the protein structure that is in contrast to chitinases. Even 
through, YKL-40 lacks enzymatically chitinase activity, it still retains the ability to 
bind chitin and chitin oligosaccharides with high affinity and the binding affinity 
depends on the length of chitin oligosaccharides (Fusetti et al., 2003; Houston et al., 
2003). YKL-40 is also suggested as a lectin, which binds GlcNAc-containing ligands 
and possibly plays a role in innate immune responses to chitin-containing pathogens 
(Houston et al., 2003). 
 
 
 
 
 
 
 
 
 
Figure 1.6 The structure of YKL-40 bound to chitin oligosaccharide.  
The linings of aromatic amino acids that form the GlcNAc-binding cleft of YKL-40 
are displayed in sticks (Houston et al., 2003). 
 
Oviductin is a mammalian CLPs expressed and secreted by oviductal 
epithelium (Arias et al., 1994; Malette, Filion, St-Jacques, Kan, and Bleau, 1995). The 
protein was detected at highest level during time of ovulation. Its structure is 
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predicted to comprise an O-glycosylated mucin-like region, following the TIM-barrel 
domain. Oviductin has been suggested to play a role in regulating fertilization and 
early embryo development (Lapensee, Paquette, and Bleau, 1997; Lok, Briton-Jones, 
Yuen, and Haines, 2002). The oligosaccharide moieties in the Zona pellucida may 
bind to the TIM-barrel domain of oviductin, where by oviductin molecules might 
form a protective shield around the oocytes (Malette et al., 1995). Oviductin mRNA 
in fertile women was stimulated by estradiol and luteinizing hormones, while 
progesterone was shown to have a clear inhibitory effect (Briton-Jones et al., 2001). 
However a specific function of oviductin in human is not yet known. 
 
SI-CLP is an interacting partner of the sorting receptor stabilin-1, which has 
been induced by Th2 cytokine IL-4 and glucocorticoid dexamethasone. In vivo studies 
showed that SI-CLP was highly expressed in macrophages from bronchoalveolar 
lavage of patients with chronic airway inflammation and in patients with sarcoidosis 
undergoing corticoid therapy (Kzhyshkowska et al., 2006). SI-CLP protein expression 
is not restricted to primary macrophages, but is also found in Raji cells, Jurkat cells 
and various tumor cell lines (Kzhyshkowska et al., 2006). Determination of the 
structure of SI-CLP by X-ray crystallography showed that it also displayed a        
TIM-barrel fold with four oligosaccharide binding subsites. Interestingly, SI-CLP 
could also bind a lipopolysaccharide (LPS) in vitro and neutralized its endotoxin 
effect on macrophages. The results suggested the possible role of SI-CLP as pathogen 
sensing and endotoxin neutralization (Meng et al., 2010). 
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Table 1.1 Cell type specificity and propose roles of CLPs. 
 
CLPs Substituted 
residue 
Cell types Functions 
Oviductin Leu Oviduct  
epitheliums  
Involved in regulating 
fertilization and early embryo 
development. 
SI-CLP Trp MF  Associated with pathogen 
sensing and endotoxin 
neutralization. 
YKL-40 Leu MF, 
neutrophill, 
tumor cell, 
cancer cell line 
Involved in inflammation and 
tissue remodeling.  
YKL-39 Ile articular 
chondrocyte, 
synovial cells  
Involved in Osteoarthritis  
 
 
1.4 YKL-39  
YKL-39 (also known as CHI3L2) was originally discovered as a novel secreted 
protein in primary culture of human articular cartilage chondrocytes that was co-
purified with YKL-40 (Hu et al., 1996). YKL-39 is currently recognized as a 
biochemical marker for chondrocyte activation and the progression of osteoarthritis in 
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humans (Knorr et al., 2003. However, the exact biological function of YKL-39 is still 
unknown. YKL-39 is more closely related in size and sequence to YKL-40 than other 
members of the GH-18 family. Like YKL-40, the name of YKL-39 was given based 
on its three N-terminal amino acids: tyrosine (Y), lysine (K) and leucine (L) and its 
apparent molecular weight of 39 kDa. YKL-39 was co-purified with YKL-40 (Hu     
et al., 1996). When the secreted protein YKL-40 from human articular chondrocyte 
culture was harvested and then  fractionated by Sephacryl S-300 HR chromatography, 
the N-terminal  sequencing data displayed the presence of  two amino acid sequences, 
one of which had the sequence of YKLVXYYTSWSQYR (YKL-40), whereas the 
other had the sequence of YKLVXYFTNWSQDR (later being identified as YKL-39) 
(Hu et al., 1996). Functional characterization showed that YKL-40 is different from 
YKL-39, in that YKL-40 contains the heparin binding sequence at the C-terminus. 
Therefore, YKL-40 can bind to heparin with high affinity, whereas YKL-39 does not 
contain such a sequence. SDS-PAGE analysis showed that YKL-39 had a molecular 
mass slightly smaller than YKL-40 (Figure 1.7, 1a and 2a). Staining of the SDS-
PAGE gel for carbohydrate showed that YKL-39 is not a glycoprotein (Figure 1.7, 
2b), but YKL-40 is (Figure 1.7, 2b).    
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Figure 1.7 SDS-PAGE analysis of YKL-39 and YKL-40. 
(A) Coomassie Brilliant Blue stain; (B) Glycoprotein stains using the Sigma 
glycoprotein detection. Lanes MW: molecular mass standards; lanes 1a and 1b:  
YKL-40; lanes 2a and 2b: YKL-39 (Hu et al., 1996). 
 
A full length YKL-39 cDNA encodes a single polypeptide chain of 390 amino 
acids (Figure 1.8), which contains the 26-amino acid signal peptide (Hu et al., 1996). 
The mature protein, after removal of the signal peptide, has a length of 364 amino 
acids and a calculated molecular mass of 40,825 Da. Within the conserved sequence 
motif region, the glutamic acid, which is essential for catalytic activity of human 
chitinases, is substituted with isoleucine, thus causing YKL-39 to lack chitinase 
activity (Hu et al., 1996).  
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Figure 1.8  Amino acid sequence of YKL-39 containing 390 amino acids with the 
26 amino acids signal peptide sequence (gray box). The first three N-terminal amino 
acids of the mature protein are tyrosine (Y), lysine (K) and leucine (L) (blue box). 
The conserved sequence motif shows Ile substitution instead of Glu (the red letter in 
green shade).  
 
YKL-39 accounts for 4% and YKL-40 for 33% of the total proteins secreted in 
chondrocyte-conditioned medium. YKL-39 and YKL-40, which are closely related in 
size and sequence, show more than 50% identical with each other (Figure 1.9).  
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Figure 1.9  Amino acids alignment of YKL-39 and YKL-40. 
The alignment was created in ClustalW. Identity of their amino acid sequences is 
shown by gray shading. The three identical N-terminal amino acids (YKL) are shown 
in a black box. 
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Figure 1.10  Human chitinases and chitinase-like proteins as members of GH-18. The 
amino acid sequence alignment of human chitinases and CLPs is shown with the 
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conserved sequence motif in a black box. Chitotriosidase (CHIT) and AMCase 
contain Glu140 that acts as H+ donor (arrow). For CLPs, this glutamic acid is 
substituted to Leu, Ile or Met. 
 
1.4.1  Cell type specificity of YKL-39          
YKL-39 was reported to be predominantly expressed in chondrocytes 
and synoviocytes (Hu et al., 1996). In addition, YKL-39 was also reported in 
glioblastoma cells (Kavsan et al., 2008). YKL39 mRNA was also detected in lung and 
heart, but not in brain, spleen, pancreas, and liver (Hu et al., 1996). Unlike human 
chitinases, YKL-39 was expressed in macrophages only under a strong stimulation by 
a combination of Th2 cytokine IL-4 and TGF-β growth factor (Gratchev et al., 2008). 
There is only one report presenting that upon the alternative activation macrophages 
can express YKL-39. They found that YKL-39 and YKL-40 mRNA were strongly 
overexpressed in the alternative activation of microglial macrophage in the brain of 
patients with Alzheimer’s disease during the course of the disease (Colton et al., 
2006). 
 
1.4.2  Biological function of YKL-39 
YKL-39 is currently recognized as a biological marker for the activation 
of chondrocytes and the progress of osteoarthritis (OA) (Knorr et al., 2003). Real time 
PCR and DNA microarray analysis showed that YKL-39 mRNA was significantly  
up-regulated in cartilage of patients with osteoarthritis (OA). While the YKL-39 
mRNA expression was correlated with collagen type 2 up regulation, YKL-40 mRNA 
showed no significant up-regulation in osteoarthritic cartilage (Steck, Breit, Breusch, 
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Axt, and Richter, 2002). Another study reported that the mRNA expression of     
YKL-39 was elevated in both early degenerative and late stages of osteoarthritis, 
while that of YKL-40 was significantly suppressed during the progression of 
osteoarthritis, instead (Knorr et al., 2003). Proteomic analysis further identified  
YKL-39, but not YKL-40, to be secreted by human osteoarthritic cartilage culture (De 
Ceuninck et al., 2005). Recently, the biological role of YKL-39 in the proliferation or 
differentiation in chondrocytes was suggested (Miyatake et al., 2013). An 
overexpression of YKL-39 in chondrocytes enhanced cell proliferation approximately 
3-fold, resulting in a significant increase in the percentage of the population in          
S-phase of the cell cycle. These results indicated that YKL-39 enhanced cell 
proliferation by stimulating G1/S transition. Moreover, overexpression of YKL-39 
was shown to enhance the colony-forming of chondrocytes due to its increasing the 
expression of the cell adhesion molecule DDR1, and it also enhanced the expression 
of type II collagen. These data suggested that YKL-39 act as a novel 
growth/differentiation factor for articular cartilage chondrocytes that controls joint 
homeostasis in adults (Miyatake et al., 2013). YKL-39 was also found to induce 
autoimmune response of rheumatoid arthritis (RA) (Du et al., 2005; Sekine et al., 
2001). ELISA and Western blot analysis showed that YKL-39 antibodies were 
detected in up to 8% of human serum samples of patients with RA, while only 1% of 
patients with RA had elevated level of YKL-40 antibodies. These results indicated 
that the pathway regulating immune response to YKL-39 was independent from that 
to YKL-40 (Sekine et al., 2001). When BALB/c mice were immunized with 
recombinant YKL-39, both anti-YKL-39 antibodies and the anti-type II collagen 
antibodies were detected, which suggested the spread of autoimmune reactions 
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(Sakata et al., 2002). Moreover, histological examination revealed synovial 
proliferation and irregularity of the cartilage surface in BALB/c mice (Figure 1.11). 
The results obtained from such studies suggested that YKL-39 acted as an inducer of 
autoimmune processes related to arthritis (Sakata et al., 2002).  
 
 
 
 
 
 
 
 
Figure 1.11  YKL-39 induced arthritis in BAL /c mice.  
(A) The right foot pad of a control mouse and (B) the right foot pad of a YKL-39 
immunized BAL /c mouse 30 days after the first immunization (Sakata et al., 2002). 
 
Involvement of YKL-39 in tissue remodeling was suggested on the basis of the 
high level of the protein detected in chondrocyte cultures and it was shown to induce 
cell proliferation and cell migration. A recent report in human embryonic kidney 
(HEK293) and human glioblastoma (U87 MG) cells showed that YKL-39 activated 
signal transduction regulated by the phosphorylation of ERK1/ERK2 kinases, which 
led to either cell proliferation or differentiation (Areshkov and Kavsan, 2010). Even 
though, YKL-39 and YKL-40 are closely related in size and sequence, their effects in 
activating the transduction of MAPK signaling and ERK1/2 phosphorylation in the 
U393 cell line are different. The activation of ERK1/2 phosphorylation by YKL-40 
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leads to a proliferative signal, while the activation of ERK1/2 phosphorylation by 
YKL-39 inhibits cell mitogenesis and proliferation (Areshkov, Avdieiev, Balynska, 
Leroith, and Kavsan, 2012). However, a report on the YKL-39 function in the 
ATDC5 mouse chondrocytes cell line, showed that overexpression of YKL-39 
enhanced cell proliferation of chondrocytes (Miyatake et al., 2013). One probable 
explanation for that difference is that sustainable activation of YKL-39 signal 
pathways may alter the cellular responses, which are observed in the transient 
activation (Miyatake et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12  Overview of MAPK/ERK pathways in mammals. 
Protein phosphorylation is involved in the regulation of a variety of growth and 
differentiation pathways through several phosphorylation cascades that communicate 
a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell 
to initiate cellular processes, such as proliferation, differentiation, and development. 
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The signaling cascades consist of many proteins, Raf, MEK1/2 and ERK act as the 
core components of the pathway (Nyati, Morgan, Feng, and Lawrence, 2006). 
 
1.4.3  The 3D structure of YKL-39 
  To date, there is only one report on the 3D structure of YKL-39 in 
complex with GlcNAc6 (Schimpl et al., 2012). The structure of this protein comprised 
a (β/α)8 TIM barrel domain with a small insertion domain similar to the YKL-40 
structure. In the Schimpl et al. structure, the electron density map of the GlcNAc6 
chitooligosaccharide was well-defined only for four sugars in the -2 to +2 subsites 
(Figure 1.14A). The binding groove of YKL-39 was lined by a few aromatic residues 
that are conserved in the GH-18 chitinases, except that a Tyr at position 104 in    
YKL-39 was found in place of Trp in other GH-18 members (Figure 1.14B). Binding 
of YKL-39 with the chitooligosaccharide was achieved through a combination of 
hydrophobic stacking interactions between the sugar rings and aromatic amino acids 
and hydrogen-bonding, in a similar fashion to that found in chitinase-oligosaccharide 
complexes (Figure 1.14C). The 3D structure of YKL-39 confirmed that the essential 
catalytic Glu residue at the conserved sequence motif DxxDxDxE was substituted 
with Ile145, making it lack chitinase activity, as mentioned earlier (Figure 1.14B). 
Shimpl’s YKL-39 sequence also presented the substitutions of D143 and E145 within 
the D138xxD141xD143xE145 conserved sequence motif to Ser143 and Ile145. However, 
reverse mutations of these two residues to aspartate and glutamate, generating the 
S143D/I145E double mutant that revealed significant chitinase activity with 
nanomolar range (kcat/Km = 2 s-1 nM-1) that was lower than human chitinase CHIT1 
(kcat/Km = 296 s-1 nM-1).  These results indicated that the active chitinase activity of 
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YKL-39 was recovered by returning the substitutions of essential catalytic acid 
residues in the binding site to the residues present in the active enzymes, suggesting 
that YKL-39 is a pseudo-chitinase with reservation of the chitin-binding function 
(Schimpl et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13  Structure of the YKL-39 in complex with chitohexaose. 
(A) Stereo image of a cartoon representation of the structure of YKL-39 in complex 
with GlcNAc6, showing four N-acetylglucosamine units of the ligand as cyan carbon 
atoms with electron density map of the chitinsugar contoured at 2.25 σ that shown as 
green color. (B) Surface representation of the YKL-39 in complex with 
chitooligosaccharide, with the conserved with chitotriosidase (PDB code 1LQ0) 
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colored by light grey, and identical residues colored by grey. The side chains of 
aromatic residues that are important to binding activity are shown as sticks with pink 
carbon atoms. The ligand GlcNAc6 is shown as a stick model with cyan carbon atoms. 
(C) Stereo images of the ligand binding site of YKL-39 and the active site of 
chitotriosidase. The substitutions of catalytic residues in YKL-39 and catalytic 
residues in chitotriosidase are displayed with dark grey carbon atoms. The side chains 
of aromatic residues that are involved in binding property are presented as sticks with 
pink carbon atoms. 
 
1.5 Research objectives 
       To address the functional and structural roles of YKL-39, this thesis has been 
divided into two parts. The first part involves cloning, and expression of YKL-39 for 
production of anti-YKL39 antibodies. In the second part, the structures of YKL-39 
and its ligand complexes were solved using protein X-ray crystallization technique. 
The binding kineteics of YKL-39 against various chitoologosaccharides were 
investigated by Isothermal titration calorimetry (ITC) and fluorescence spectroscopy. 
 
The objectives of this research are 
1. To clone, express and purify human chitinase-like protein YKL-39 in E. coli   
BL21(DE3) cells. 
2. To produce polyclonal and monoclonal antibodies specific for human YKL-39. 
3. To solve the X-ray structures of YKL-39 protein alone and in the presence of 
various chitooligosaccharides. 
4. To determine binding affinities of YKL-39 towards its specific sugar ligands. 
 
 
 
 
 
 
 
 
 
 
CHAPTER II  
MATERIALS AND METHODS 
 
2.1  Materials 
2.1.1  Bacterial strains and plasmids 
Escherichia coli strain DH5α was used for routine cloning and plasmid 
preparation. The expression vector pET32a(+), which is a thioredoxin fusion system, 
was used for cloning and expression of the full-length YKL-39 cDNA. E. coli type 
strain BL21(DE3) cells were used for high-level expression of recombinant 
thioredoxin-His6/YKL-39 fusion protein. 
 
2.1.2  Molecular cloning and plasmid purification 
Chemicals and reagents used for molecular cloning were of molecular 
biology grade. All oligonucleotide primers (Table 2.1) used for amplification and 
DNA sequencing of YKL-39 gene were ordered from BioDesign (Bangkok, Thailand). 
Human cDNA was purchased from GenScript Corporation (Piscataway, NJ, USA). 
Pfu DNA polymerase, Pfu polymerase 10x buffer, dNTP mix, BamH1 and XhoI 
restriction enzymes, T4 DNA ligase, ligase 10x buffer and pGEM-T easy vector 
system were purchased from Promega (Madison, WI, USA). High-Speed Plasmid 
Mini Kit was product of Geneid (Taipei, Taiwan) and QIAquick Gel Extraction Kit of 
QIAGEN (QIAGEN GmbH, Hilden, Germany). HyperLadderTm I DNA marker was 
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bought from Bioline (Tacerton MA, USA) and SYBRÒ Green I nucleic acid gel stain 
from Sigma-Aldrich (St. Louis, MO, USA). 
 
2.1.3  Protein expression and purification 
Chemicals and reagents used for protein expression and purification 
were of analytical grade. Acrylamide, ammonium sulfate, ammonium persulfate, 
bromophenol blue, bis-N, N"-methylenebisacrylamide, calcium chloride, coomassie 
blue R250, coomassie blue G250, ethylenediamine tetra-acetic acid (EDTA), 
isopropyl β-D-thiogalactoside (IPTG), 2-mercaptoethanol, magnesium chloride, 
glycerol, glycine, sodium azide, sodium dodecyl sulfate (SDS) and Tris 
(hydroxymethylamine), N, N', N", N"'-tetramethylethylenediamine (TEMED) were 
products of Sigma-Aldrich. Ammonium hydroxide, glacial acetic acid, hydrochloric 
acid, methanol, n-butanol, phosphoric acid, potassium chloride, potassium hydroxide, 
sodium acetate, sodium bicarbonate, sodium chloride, sodium hydroxide, sodium 
dihydrogen phosphate and sodium hydrogen phosphate were obtained from Carlo 
ERBA (Rodano, Milano, Italy). Ampicillin, phenyl methylsulfonyl fluoride (PMSF), 
imidazole, isopropyl β-D-thiogalactoside (IPTG), hen egg white lysozyme, Triton    
X-100, Bacto tryptone, yeast extract, bacto agar and Luria-Bertani broth (LB) were 
product of USB Corporation (Cleaveland, OH, USA). Enterokinase was purchased 
from GenScript. Vivaspin-20 ultrafiltration membrane concentrators (10 kDa 
molecular-weight cut-off) were product of Vivascience (Hanover, Germany). 0.2 μm 
pore size filter membrane was bought from Nalgene (Rochester NY, USA). MF-
Millipore Membrane Filters (0.22 μm and 0.45 μm pore size) were purchased from 
Millipore Corporation (Beverly, MA, USA). Ni-nitrilotriacetic acid (Ni-NTA) agarose 
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resin was a product of QIAGEN. Chromatographic media and pre-packed columns for 
automated protein purification were products of Amersham Pharmacia (Amersham 
Biosciences Biotech, Piscataway, NJ, USA). These pre-packed columns included 
HisTrap HP 1-mL, HisTrap HP 5-mL, Hiprep 26/10 Desalting column, HiTrap Q FF 
5-mL, and HiLoad 16/60 Superdex 200 prep grade (1.6×60 cm) gel filtration columns. 
 
 2.1.4  Polyclonal antibody and monoclonal antibody production 
 Chemicals and reagents used for polyclonal and monoclonal antibody 
production were of analytical grade. Freund’s complete adjuvant, polyethylene glycol 
(PEG), IsoQuick™ Kits for Mouse Monoclonal Isotyping, Hypoxanthine 
Aminopetrin Thymidine (HAT), and Hypoxanthine-Thymidine (HT) were purchased 
from Sigma-Aldrich. Horseradish peroxidase-conjugated goat anti-rabbit 
immunoglobulins (goat-anti-Igs-HRP) were purchased from Merck Millipore 
(Billerica, MA, USA). Horseradish peroxidase-conjugated rabbit anti-mouse 
immunoglobulins (Rab-anti-mIgs-HRP) were purchased from Dako (Glostrup, 
Denmark). Skimmed milk powder was product of Himedia (Himedia Laboratories 
Pvt. Ltd., Mumbai, India), 3, 3’, 5, 5’-Tetramethylbenzidine substrate (TMB) was 
obtained from Invitrogen (Carlsbad, CA, USA).  Protein A agarose column was a 
product of GenScript Corporation (CA, USA). BM condimed H1 (10x Hybridoma 
cloning supplement) was purchased from Roche (Roche Diagnostics GmbH, 
Mannheim, Germany). Fetal Calf Serum (FCS), Hybridoma-Serum free media, 
Iscove’s Modified Dulbeco’s Medium (IMDM) medium, and Dulbecco’s Modified 
Eagle’s Medium (DMEM) were obtained from Gibco® (Grand Island, NY, USA). 
 
 
 
 
 
 
 
 
 
32 
 
2.1.5  Protein crystallization 
Crystallization screening kits used for finding crystallization conditions 
included JB Screen HTS I and HTS II that were purchased from Jena Bioscience 
GmbH (Jena, Germany), Wizard I and II were purchased Emerald (Emerald 
BioSystems, Bainbridge Island, WA, USA), and Crystal Screen High Throughput, 
HR2-110, HR2-112 and HR2-130 from Hampton Research (Aliso Viejo, CA, USA). 
Microbatch sitting drop 60 well plates and hanging drop vapor diffusion 24 well 
plates were purchased from Hampton Research or Nunc (Nunc GmbH, Wiesbaden, 
Germany). Al’s oil, Nylon loop 0.05-0.5 mm, 20 mm Siliconized glass cover, Crystal 
Clear sealing tape were purchased from Hampton Research. High vacuum grease was 
purchased from Dow Corning Corporation (Midland, MI, USA). PEG3350 was a 
product of USB Corporation. 2, 2-bis (hydroxymethyl)-2, 2', 2''-nitrilotriethanol (Bis-
Tris) were purchased from Sigma-Aldrich.  
N-acetyl-chitooligosaccharides used for protein crystallization and binding 
studies, including di-N-acetyl-chitobiose, tri-N-acetylchitotriose, tetra-N-acetyl-
chitotetraose, penta-N-acetyl-chitopentaose, and hexa-N-acetylchitohexaose, were 
purchased from Megazyme (Megazyme International Ireland Co., Ltd., Wicklow, 
Ireland). 
 
2.2  Analytical programs 
An amino acid sequence alignment of human chitinase and chitinase-like proteins 
was constructed using the “CLUSTALWW” algorithm in a GCG package 
(Thompson, Higgins, and Gibson, 1994) and displayed in Genedoc 
(http://www.psc.edu/biomed/genedoc/) and the DNASTAR package (DNASTAR, 
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Inc., Madison, WI, USA). The crystallographic were as follows. The HKL-2000 
program (Otwinowski and Minor, 1997) was used for data indexing, refinement, and 
scaling. The MOLREP program (Vagin and Teplyakov, 1997) was used for molecular 
replacement method, the Coot program (Emsley and Cowtan, 2004) for model 
building, REFMAC5 in the CCP4 suit (Murshudov, Vagin, Lebedev, Wilson, and 
Dodson, 1999) for refinement, and PROCHECK (Laskowski, MacArthur, Moss, and 
Thornton, 1993) for validation of the stereochemistry of the final model. 
 
2.3  Gene isolation and cloning of human YKL-39 
A set of specific oligonucleotides was designed to amplify the full-length 
CHI3L2 gene encoding YKL-39 (Genbank accession number NM_004000) by PCR 
technique using human uterus cDNA (GenScript Corporation) as DNA template. The 
forward oligonucleotide included a BamHI cloning site and the reverse 
oligonucleotide included an XhoI cloning site. The sequences of both primers are 
shown in Table 2.1. 
 
Table 2.1 Primers for synthesis of human YKL-39 cDNA. Underlined sequences 
indicate the restriction sites. 
      YKL-39                                                       Primers 
YKL-39BamHI Forward  5’‐GCGGATCCTACAAACTGGTTTGCTAC‐3’ 
YKL-39XhoI Reverse   5’‐ACTCGAGTTACAGGGAGCCAAGGCTTCT‐3’ 
 
The construct was designed to include six histidine residues tagged to the        
C-terminus of thioredoxin connected with the full-length human YKL-39 at the        
 
 
 
 
 
 
 
 
34 
 
C-terminus. The DNA fragment encoding YKL-39 was amplified by PCR performed 
under the following conditions: 35 cycles, denaturation at 97°C for 30 sec, annealing 
at 60°C for 1 min and extension at 72°C for 1 min, except for the final cycle where 
extension proceeded for 4 min. The amplified PCR product was then examined by 1% 
agarose gel electrophoresis that contained SyberGreen for detection of PCR products. 
After separating on agarose gel, the PCR product was observed under UV light using 
The Gel Doc 2000 system (Bio-Rad, USA).  The PCR product of expected size (1.1 
kb) was cut to further purify using the QIAquick Gel Extraction Kit (QIAGEN), 
following the manufacture’s instructions. The purified DNA fragment encoding YKL-
39 was cloned into the digested pET32a(+) vector, to generate the recombinant 
plasmid, called pET32a(+)/CHI3L2.In order to identify the presence of the insert 
CHI3L2 gene in successfully constructed pET32a(+)/CHI3L2, colony PCR, restriction 
digestion analysis and DNA sequencing were carried out. Both sense and anti-sense 
strands of the CHI3L2 gene were confirmed by automated DNA sequencing (First 
Base Laboratories, Selangor, Malaysia). 
 
2.4  Recombinant expression and purification 
2.4.1  Transformation of recombinant plasmid into E. coli BL21 (DE3) 
host cells 
 The recombinant pET32a(+)/CHI3L2 was transformed into E. coli 
BL21(DE3) expression host cells as described by Sambrook et al. (1989). The 
competent cells of E. coli BL21(DE3) host were prepared as described in Appendix 
A. One microliter (50-100 ng) of plasmid was added to 100 μL of thawed E. coli stain 
BL21(DE3) competent cells was mixed gently by swirling and continued to store the 
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tube on ice for 30 min. The mixed cells were heat shocked at 42°C for 45 s, and then 
rapidly transferred to ice for 10 min. The transformed cells were added with 900 μL 
of LB broth, and then grown at 37°C for 45 min. Afterwards, 200 μL of the cell 
suspension was spread on LB agar plates, containing 100 μg/mL of ampicillin, and 
incubated overnight at 37°C. 
 
2.4.2  Expression of fusion Trx-His6/YKL-39 
Single colonies of the E. coli BL21 (DE3) cells harboring the 
recombinant plasmid pET32a(+)/CHI3L2 were grown overnight in LB medium 
containing 100 mg/mL ampicillin (LB/Amp) at 37°C with gentle shaking at 200 rpm. 
After overnight incubation, the bacterial culture was diluted to a ratio of 1:100 with 
LB/Amp broth, and further grown at 37°C until OD600 reached 0.6-0.8. The culture 
was cooled down to 25°C for 30 min, then IPTG was added to a final concentration of 
0.5 mM, and the culture was shaken at 200 rpm at 25°C for an additional 18 h. The 
induced YKL-39 expression cells were harvested by centrifugation at 4,500 rpm at 
4°C for 30 min, and the cell pellet kept at -30°C until use. To obtain highest level of 
protein expression, different conditions for YKL-39 induction were optimized, 
including IPTG concentration, temperature, and induction time. The concentrations of 
IPTG were varied from 0-1.0 mM. Three induced temperatures, including at 15°C, 
25°C and 37°C were tried with induction times of 2, 4, 8, 12 and 18 h. The condition, 
which gave highest level of protein expression, was chosen for further studies. To 
examine protein expression level, total protein profiles of E. coli BL21(DE3) cells, 
containing the recombinant pET32a(+)/CHI3L2 plasmid with and without DNA insert 
were compared. After IPTG induction, one milliliter of the induced cells was 
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harvested by centrifugation, and then the cell pellets were resuspended in 100 µL of 
1×SDS sample buffer (50 mM Tris, pH 6.8, 0.03% bromophenol blue, 2% SDS, 10% 
glycerol and 1.6% of 2-mercaptoethanol). The cell suspension was boiled for 5 min, 
then centrifuged at 10,000 rpm for 5 min and 5 μL of supernatant was analyzed on 
12% SDS-PAGE. To obtain crude supernatant, containing soluble fusion protein, the 
induced cell pellet was re-suspended in 30 mL of lysis buffer (50 mM Tris-HCl, pH 
8.0 containing 50 mM NaCl, 1 mM PMSF, 1 mg/mL lysozyme and 1% (v/v) triton  
X-100), and lysed on ice using a Sonopuls Ultrasonic homogenizer with a 6-mm-
diameter probe (Sigma-Aldrich, St Louis, MO, USA). Sonication was carried out 15 
times on ice with 30% power output, for 15 s, and with 1 min for cooling interval. 
Crude supernatant was transferred to a new vial after centrifugation at 12,000 rpm for 
45 min. 
 
2.4.3  Purification of recombinant YKL-39 
2.4.3.1  Purification of YKL-39 for antibody production 
Crude supernatant containing soluble fusion Trx-His6/YKL-39 
protein that obtained from Section 2.5.2 was applied onto a Ni-NTA agarose (1x1 mL, 
QIAGEN) column that was pre-equilibrated with five column volumes (CV) of 
equilibration buffer (50 mM NaCl, 50 mM Tris-HCl, pH 8.0). The column was 
operated manually under gravity flow. After sample loading, the column was washed 
thoroughly with 10 CV of 5 mM imidazole, followed by 10 CV of 20 mM imidazole 
in the equilibration buffer to remove unbound proteins. Subsequently, the bound 
fractions were eluted with 5 CV of 250 mM imidazole in equilibration buffer. These 
bound fractions that contained mainly the Trx-His6/YKL-39 fusion protein were 
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pooled, and then thoroughly dialyzed against 50 mM NaCl in 50 mM Tris-HCl, pH 
8.0, for a complete removal of imidazole. The protein solution was concentrated using 
Vivaspin-20 membrane concentrator (Mr cut-off 10,000, Vivascience AG). Further 
purification was performed by anion exchange chromatography on a 5x1 cm2 HiTrap 
Q FF pre-packed column connected to an ÄKTAprimeTM plus system (GE 
Healthcare).  The column was equilibrated with 5 CV of 20 mM Tris-HCl, pH 8.0, at 
a flow rate of 2.50 mL/min. One milliliter of concentrated protein was filtered through 
0.45 μm pore size membrane filter (Millipore) before applying to the column, and 
then 1.0 mL fractions were collected. Unbound proteins were removed with 2 CV of 
20 mM Tris-HCl, pH 8.0. Afterward, bound proteins were eluted with 10 CV of a 
linear gradient of 0-1 M NaCl in the same buffer. The containing Trx-His6/YKL-39 
fractions were pooled and concentrated, then were further cleaved by enterokinase for 
removal of the fusion tag thioredoxin. The cleavage reaction was carried out by 
incubating 0.2 unit of enterokinase per 100 µg of the fusion protein at 15°C for 18 h.  
Afterwards, the thioredoxin segment, which still connects with the His6 at the           
C-terminus, was separated from the YKL-39 protein by a Ni-NTA agarose affinity 
column as described in the first step. Unbound fractions containing purified YKL-39 
were pooled, exchanged into 20 mM Tris-HCl (pH 8.0), and concentrated to 10-20 
mg/mL using the Vivaspin membrane concentrator. The purity of YKL-39 was 
verified by SDS-PAGE. Protein concentration was determined by the Pierce BCA 
assay (Novagen, Darmtadt, Germany). Aliquots of the purified YKL-39 were stored at 
-30°C until use. 
 
 
 
 
 
 
 
 
 
 
38 
 
2.4.3.2  Purification for crystallization and protein-ligand binding 
study 
Crude supernatant containing soluble fusion Trx-His6/YKL-39 
obtained from section 2.5.2 was centrifuged at 19,000 rpm for 1 h, then filtered 
through a 0.45 μm pore size membrane filter (Millipore). Further purification was 
performed using two HisTrap HP (1x5 mL) pre-packed columns connected in series 
with Hiprep 26/10 Desalting column (Amersham Pharmacia), which was operated by 
an ÄKTAprimeTM plus FPLC system. The columns were equilibrated with 10 CV of 
equilibration buffer (50 mM NaCl, 50 mM Tris-HCl, pH 8.0), a constant flow rate of 
1 mL/min was maintained and protein fractions of 2 mL were collected. After sample 
loading, the bound protein resin was washed with 25 CV of equilibration buffer to 
remove unbound proteins. Finally, the bound protein was eluted with 10 CV of 250 
mM imidazole in equilibration buffer, then passed through a Hiprep 26/10 Desalting 
column (Amersham Pharmacia) to completely remove imidazole. The Trx-His6/YKL-
39 containing fractions were pooled and concentrated, then further cleaved by 
enterokinase to eliminate the Trx-His6 fragment. The cleavage reaction was carried 
out by incubating with 0.2 unit of enterokinase per 100 µg of the fusion protein at 
15°C for 18 h.  Afterwards, the Trx-His6 segment was separated from the YKL-39 
protein by adsorption to a (1x1 mL) pre-packed HisTrap HP column (Amersham 
Pharmacia), connected to an ÄKTAprimeTM plus system. Unbound fractions 
containing purified YKL-39 were pooled, concentrated, and then further purified 
through a HiLoad 16/60 Superdex 200 prep grade gel filtration (Amersham 
Biosciences) to obtain the homogeneous protein solution. The column was 
equilibrated and eluted with 50 mM NaCl, 50 mM Tris-HCl (pH 8.0) with a flow rate 
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of 0.50 mL/min. The protein sample was filtered through 0.45 μm pore size 
membrane filter (Millipore), then 1.0 mL was injected to the system, and 1.0 mL 
fractions were collected. YKL-39-containing fractions were combined, exchanged 
into 20 mM Tris–HCl (pH 8.0), and concentrated to 10-20 mg/mL in the Vivaspin 
membrane concentrator. All purification steps were carried out at 4°C. The purity and 
protein concentration were determined as described in Section 2.4.3.1.  
 
2.5  Polyclonal antibody production 
2.5.1  Immunization 
Two male New Zealand rabbits (eight week old) were immunized 
subcutaneously with the purified antigen YKL-39 emulsified in PBS with 50% 
Freund’s complete adjuvant (Sigma-Aldrich). Immunizations were repeated twice 
every second week with the same antigen. Immunization and bleeding were scheduled 
as follows: 
Week 0  Collection of pre-immune serum (10 mL)    
1st immunization with 500 μg YKL-39 
Week 2  2nd immunization with 200 μg YKL-39 
Week 4  3rd immunization with 200 μg YKL-39 
Week 5  Collection of immunized serum (10-20 mL) and verification of anti-
YKL39 production by Western blot technique 
  4th immunization with 200 μg YKL-39 
Week 6  3rd bleed 10 mL  
Week 7  4th bleed 10 mL 
Week 8  5th bleed 10 mL 
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Five days after the final boost, the immunized serum was collected from the 
central ear artery using a 19-gauge needle. The immunized serum was allowed to clot 
and retract at 4°C overnight, and then retrieved by centrifugation at 4,500 rpm for 15 
min. The titer of anti-YKL39 antibodies in the serum was determined by indirect 
ELISA and Western blotting.  
 
2.5.2   Purification of anti-YKL39 polyclonal antibodies 
The immunized rabbit serum was further purified by affinity 
chromatography on a protein A agarose (1x1 mL) column (GenScript Corporation, 
USA). Serum sample was diluted with binding buffer (0.15 M NaCl, 20 mM sodium 
phosphate, pH 8.0) at a ratio of 1:1 to ensure that proper ionic strength and pH were 
maintained for optimal binding. The diluted serum sample was filtered through a 0.45 
μm filter, and then applied onto protein A resin column, which was equilibrated with 
10 CV of binding buffer. Bound IgG resin was washed with 30 CV of binding buffer. 
Bound IgG resin was washed with 30 CV of binding buffer. The bound antibodies 
were eluted with 10 CV of elution buffer (0.1 M glycine, pH 2.5), and were 
immediately neutralized to pH 7.4 with neutralization buffer (1 M Tris-HCl, pH 8.5) 
at a ratio of 1:10 volume of total eluted volume. The eluted fraction was then applied 
onto Hiprep 26/10 Desalting column (Amersham Pharmacia) connected with an 
ÄKTAprimeTM plus system for the exchanging buffer to PBS. The purity of the 
purified antibodies was verified by SDS-PAGE. Antibody concentration was 
determined by the Pierce BCA assay. Aliquots of the purified pAbs were flash-frozen 
in liquid N2, followed by storage at -30°C until use. 
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2.5.3  Characterization of anti-YKL-39 antisera  
2.5.3.1  Determination of the antibody titers and specificity by 
Western blotting 
To determine the sensitivity of the raised antibodies, titers and 
cross-reactivity of the purified pAbs was evaluated by Western blotting. The purified 
YKL-39 (5 μg) was resolved on 12% polyacrylamide gel, and then electrophoretically 
transferred onto a nitrocellulose membrane (Amersham Pharmacia) by the semi-dry 
transferring technique at 15 volts for 1 h. After blotting, non-specific bindings were 
blocked by incubation with 5% (w/v) skimmed milk in 1x PBS for 1 h at room 
temperature. The blocked membrane was rinsed once with 1x PBS, then incubated for 
additional 1 h with anti-YKL39 antisera at various concentrations of the purified 
pAbs. Then, the membrane was washed five times with 0.1% Tween 20 in PBS, pH 
7.2 (washing buffer, PBS-T) for 5 min of each washing, followed by incubation with 
horseradish peroxidase-conjugated goat anti-rabbit immunoglobulins (goat-anti-Igs-
HRP) at a dilution of 1:10,000. After 1 h of incubation, followed by three more 
washes, signals representing antibody-antigen interactions were detected by the 
chemiluminescence using enhanced chemiluminescence reagent (Amersham 
Pharmacia), and then the membrane was exposed to X-ray film (Kodak, Belgium). 
Cross-reactivity of the purified pAbs (10 ng) was tested against three different     
YKL-39 homologues, including human YKL-40, human acidic mammalian chitinase 
(AMCase), and bacterial chitinase. 
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2.5.3.2  Determination of the antibody titers and specificity by 
indirect ELISA 
Each well of the ELISA plate was coated with 50 µL of 10 
µg/mL YKL-39 protein in carbonate/bicarbonate buffer, pH 9.6, at 4°C for 18 h. The 
coated plate was blocked with 2% (w/v) skim milk in PBS, pH 7.2 (blocking buffer) 
by incubation for 1 h at room temperature. Then, the plate was washed four times 
with 0.05% Tween 20 in PBS, pH 7.2 (washing buffer, PBS-T). Fifty microliters of 
various 2-fold serial dilutions of antiserum (1:10-1:20,480) or purified pAbs in the 
blocking buffer were added to the plates in triplicate. For specificity determination of 
pAbs, 96-well of ELISA plates were coated with varying protein concentrations with 
each protein concentration added to each well of the ELISA plate in triplicate. After 1 
h of incubation at room temperature, the plate was washed for additional four times 
with the washing buffer, followed by adding 50 µL horseradish peroxidase-
conjugated goat anti-rabbit immunoglobulins (goat-anti-Igs-HRP) at dilution of 
1:2,000. After 1 h of incubation, and then three more washes, 100 µL of 3, 3’, 5, 5’-
tetramethylbenzidine substrate (TMB) (Invitrogen) was added and incubated at room 
temperature in the dark. The reactions were stopped by adding 100 µL of 1 N HCl. 
The intensity of the developed signals was determined spectrophotometrically with a 
Biochrom Anthos MultiRead Microplate Reader (Biochrome Ltd.) at a wavelength of 
450 nm (A450). The antibody-antigen binding curve was evaluated by a nonlinear 
regression function available in Prism version 5.0 (GraphPad Software, La Jolla, CA, 
USA) using the following single-site binding model. 
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2.6 Monoclonal antibody production 
 2.6.1  Immunization 
Three eight-weeks-old female BALB/c mice were immunized 
intraperitoneally with 70 µg of the purified YKL-39 protein in sterile PBS at two 
weeks intervals. Serum was collected a week before each injection. The immunization 
and bleeding schedule was as follows: 
Week 0   Collection of pre-immune serum, 1 mL     
1st Immunization with 70 μg of YKL39 
Week 1  Collection of immunized bleed, 1 mL  
Week 2   2nd Immunization with 70 μg of YKL39 
Week 3  Collection of immunized bleed, 1 mL 
Week 4   3rd Immunization with 70 μg of YKL39 
Week 5   Verification of monoclonal antibody by indirect ELISA  
Indirect ELISA was employed to determine the immune response of the mice 
prior to their use for cell fusion. Three days prior to cell fusion, mouse was boosted 
with 70 μg of YKL-39 protein in PBS. 
 
2.6.2  Determination of antibody response in the immunized mice by 
indirect ELISA  
To determine the antibody response in the immunized mice, indirect 
ELISA was employed. Each well of the ELISA plate was coated with 50 µL of 10 
µg/mL YKL-39 in carbonate/bicarbonate buffer, pH 9.6, at 4°C for 18 h. The coated 
plate was blocked with 2% (w/v) skim milk in PBS, pH 7.2 (blocking buffer) by 
incubation for 1 h at room temperature. Then, the plate was washed four times with 
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0.05% (v/v) Tween 20 in PBS, pH 7.2 (washing buffer). Fifty microliters of 5 fold 
serial dilutions (1:5-1:10x106) of mice antiserum in the blocking buffer were added in 
triplicate. For determination of the specificity of the mAb, 96-well of ELISA plates 
were coated with varying protein concentrations with each protein concentration 
added to each well of the ELISA plate in triplicate. After 1 h of incubation at room 
temperature, the plate was washed an additional four times with the washing buffer, 
followed by adding 50 µL horseradish peroxidase-conjugated rabbit anti-mouse 
immunoglobulins (Rab-anti-mIgs-HRP) at dilution of 1:2,000. After 1 h of incubation 
and then three more washes, 100 µL of TMB substrate was added and incubated at 
room temperature in the dark. The reactions were stopped by adding 100 µL of 1 N 
HCl. The intensity of the developed signal was determined by measuring the 
absorbance in an ELISA plate reader at the wavelength 450 nm. 
 
 2.6.3  Hybridoma production 
  2.6.3.1  Preparation of splenocytes 
    The immunized mouse was sacrificed and its spleen was 
removed and placed in tissue culture dish containing 5 mL of Iscove’s Modified 
Dulbeco’s Medium (IMDM) medium (Gibco®). After rinsing, the spleen was 
transferred to a new tissue culture dish containing 5 mL of IMDM medium. 
Splenocytes were collected by crushing the spleen in IMDM medium. The cell 
suspension was transferred to a 50 mL falcon tube and then allowed to settle for 10 
min. The cells were collected by centrifugation at 2000 rpm, 4°C for 5 min, while 
supernatant was discarded. Red blood cells (RBC) were lysed in 0.83% (w/v) NH4Cl 
hypotonic solution. The RBC cell suspension was diluted by adding 20 mL of the 
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IMDM medium. Then, the splenocytes were washed two times with serum-free 
IMDM. The number and viability of the cells were counted in 0.2% (v/v) tryphan blue 
on a hemacytometer. 
 
2.6.3.2  Preparation of mouse myeloma cell lines 
Approximately two weeks prior to the fusion, the P3X63-
Ag8.653 mouse myeloma cell line was thaw and cultured in a petri-dish plate 
containing complete IMDM media. They were subcultured daily at the splitting ratio 
1:2 in order to maintain log phase of growth before the fusion process. It is crucial 
that the myeloma cells should be in log phase and healthy in order for the fusion 
process be successful. On the day of fusion, the myeloma cells were collected, and 
then washed two times with serum-free IMDM by centrifugation at 1,500 rpm, 4°C 
for 5 min. The number and viability of the cells were counted in 0.2% (v/v) tryphan 
blue on a hemacytometer. 
 
2.6.3.3  Cells fusion  
 Splenocytes and mouse myeloma cells were mixed together at a 
ratio of 2:1, and then centrifuged at 1,500 rpm for 10 min. Cell pellets were incubated 
at 37°C for 5 min before being fused together by a standard hybridoma technique 
(Kohler and Milstein, 1975) using polyethylene glycol (PEG). Addition of reagents is 
as follows: 1.5 mL of 50% (v/v) PEG 1450, which was incubated at 37°C for 5 min 
before being used, was added in a drop wise fashion with gentle shaking for over 1 
min, followed by continuously shaking for another minute. One milliliter of warm 
IMDM was added within 1 min. Then, 3 mL of warm IMDM was added into the tube 
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for over 1 min. Finally, 16 mL of the IMDM was added into the tube within 2 min. 
After centrifugation at 400 g for 10 minutes, cell pellets were incubated at 37°C for 5 
min in a water bath before removing the supernatant. Then, the fused cells were re-
suspended in 100 mL of Hypoxanthine Aminopetrin Thymidine (HAT) medium. One 
hundred microliters of the cell suspension were added in each well of a 96-well plate 
and cultivated at 37°C in a 5% CO2 incubator. After five days of cultivation, 150 µL 
of Hypoxanthine-Thymidine (HT) medium was added into each well. The plates were 
incubated at 37°C in a 5% CO2 incubator to allow the hybridoma cells to proliferate. 
 
2.6.3.4  Hybridoma screening by ELISA 
Supernatants taken from the culture medium, which contained 
hybridoma cells, were used to determine the production of monoclonal antibody 
against YKL-39 antigen by indirect ELISA, as described in Section 2.8.2.  
 
2.6.3.5  Limiting dilutions 
To obtain a single hybridoma clone, limiting dilutions were 
carried out. The hybridomas from the positive wells were counted and cell 
concentrations were adjusted to 4, 2 and 1 cell per 150 µL of the IMDM 
supplemented with 10% (v/v) BM condimed H1 and 10% (v/v) fetal calf serum (FCS) 
(Gibco®). Then, the cells were expanded by cultivation at 37°C in a 5% CO2 
incubator. After 7-10 days of cultivation, wells which contained single hybridoma 
clones were marked. Supernatant from the single clones was collected and checked by 
indirect ELISA for the presence of monoclonal antibodies capable of binding 
specifically to YKL-39. The single clones obtained from the limiting dilution 
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procedure that produced the highest levels of anti-YKL39 antibody were selected 
and further expanded. 
 
2.6.4  Isotype determination of monoclonal antibodies 
The isotypes of the newly-generated monoclonal antibodies (mAb) were 
determined by captured ELISA technique using IsoQuick™ Kits for Mouse 
Monoclonal Isotyping (Sigma-Aldrich). Each well of ELISA plate was coated with 50 
µL of different goat anti-mouse immunoglobulin isotypes in carbonate/bicarbonate 
buffer, pH 9.6, at 4°C for 18 h. The coated plate was blocked with 2% (w/v) skim 
milk in PBS, pH 7.2, (blocking buffer) by incubation for 1 h at room temperature. 
Then the plate was washed four times with 0.05% (v/v) Tween 20 in PBS, pH 7.2 
(washing buffer). Fifty microliters of 10 µg/mL of the produced mAb were added. 
After 1 hour of incubation at room temperature, the plate was washed four times with 
the washing buffer, followed by addition of 50 µL of rabbit-anti-mouse Igs-
conjugated with HRP at dilution 1:2,000. After 1 h of incubation, following three 
washes, 100 µL of TMB substrate was added, and the plate was incubated at room 
temperature in the dark. The reactions were stopped by addition of 100 µL of 1 N 
HCl. The intensity of the developed color was determined by measuring the 
absorbance on an ELISA plate reader at the wavelength 450 nm. 
 
2.6.5  Monoclonal production in serum free media 
A hybridoma cell line capable of producing monoclonal antibody against 
human YKL-39 with IgM isotype was cultured in IMDM supplemented with 10% 
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(w/v) heat inactivated FCS, 40 μg/mL gentamycin and 2.5 μg/mL amphotericin B 
(Biolab, Smutprakarn, Thailand) in a humidified atmosphere of 5% (v/v) CO2 at 37°C 
and was further subcultured in serum free media IMDM, containing 1% (w/v) 
penicillin/streptomycin. The antibody-containing culture media was collected, sterile 
filtered and stored at -30°C until use. 
 
2.6.6  Monoclonal antibody purification 
The culture media were collected and the presence of anti-YKL39 mAb 
was checked by indirect ELISA. The mAb was then purified by Hitrap IgM 
purification HP (Amersham Biosciences) connected to an ÄKTA purifier system. The 
culture media containing anti-YKL39 mAb was adjusted to the same concentration of 
ammonium sulfate as in the binding buffer. Small amounts of solid ammonium sulfate 
were added to the sample until the final concentration was 1.0 M, while stirring 
slowly and continuously during this procedure. Crude antibody was filtered through a 
0.45 μm membrane filter immediately before loading on the column. Sample was 
applied to a Hitrap IgM column which was pre-equilibrated with 5 CV of binding 
buffer (20 mM sodium phosphate, 1.0 M (NH4)2SO4, pH 7.5). Unbound materials 
were washed with 15 CV of the binding buffer, while bound IgM antibody was eluted 
with 12 CV of elution buffer (20 mM sodium phosphate, pH 7.5). The purity of the 
purified antibody was verified by SDS-PAGE. Antibody concentration was 
determined by the Pierce BCA assay. Aliquots of the purified mAb were stored at       
-30°C until use. 
 
 
 
 
 
 
 
 
 
 
49 
 
2.6.7  Characterization of anti-YKL39 monoclonal antibody 
2.6.7.1  Specificity of anti-YKL39 mAb  
To assess cross-reactivity of the purified mAb, Western blotting 
was carried out against three different YKL-39 homologues. These proteins included 
human YKL-40, human acidic mammalian chitinase (AMCase), and bacterial 
chitinase at various concentrations, as described in the polyclonal antibody production 
Section 2.6.3.1. The ability of the mAb to bind to the native form of human YKL-39 
expressed by various human cell lines was also evaluated by immunoblotting. 
  
2.6.7.2  Sensitivity of anti-YKL39 mAb 
The sensitivity of generated anti-YKL39 mAb was also examined 
by Western blot analysis. Two-fold serial dilutions of anti-YKL-39 antibody were 
used, ranging from 0.65-10 µg, and YKL-39 was fixed at 2.5 µg. Detail is as 
described in the polyclonal antibody production section (2.6.3.1).   
 
2.6.7.3  Cell culture 
All human cell lines were obtained from the American Cell 
Culture Collection. Human T cell lines (Jurkat) and myeloid cell lines (U937 and 
THP-1) were cultured in Roswell Park Memorial Institute (RPMI-1640) medium, 
supplemented with 10% (w/v) heat inactivated FCS, 40 μg/mL gentamycin and 2.5 
μg/mL amphotericin B in a humidified atmosphere of 5% (v/v) CO2 at 37°C. Hela and 
COS-7 (monkey, kidney cell line) cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) under the conditions mentioned earlier. After cell passages of three 
times a week, the cells were collected, and then washed three times with PBS by 
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centrifugation at 1,500 rpm for 5 min. Then, 1x107 cells were lysed on ice for 30 min 
in 1 mL of lysis buffer (50 mM Tris-HCl (pH 8.2), 100 mM NaCl, 2 mM EDTA, 
0.02% (w/v) NaN3) containing 1% (v/v) Triton X-100, 1 mM 
phenylmethylsulphonylfluoride (PMSF), 5 mM iodoacetamide, and 10 μg/mL 
aprotinin) at 4°C for 30 min. Clear lysate was collected by centrifugation at 13,000 
rpm, 4°C for 30 min, and used for functional assays. 
 
2.6.7.4  Dot blot analysis 
The purified YKL-39 or whole cell lysate prepared from various 
cell lines was spotted onto a nitrocellulose membrane, and then allowed to dry. 
Nonspecific binding was blocked by 5% (w/v) skim milk in 1% (v/v) Tween 20 in 
PBS (PBS-T) for 1 h at 28°C. The membrane was incubated for further 1 h with the 
mAb from clone 6H11. The membrane was washed five times in PBS-T, 5 min each, 
and incubated with rabbit-anti-mouse Igs-conjugated with HRP at a dilution of 
1:5,000 for 1 h. After thoroughly washing, the signals were detected by the enhanced 
chemiluminescence method. 
 
2.7 Protein crystallization 
  2.7.1  Initial screening by microbatch screening crystallization 
  2.7.1.1  Protein sample preparation 
The freshly purified YKL-39 was concentrated in a Vivaspin-20 
membrane concentrator (Mr cut-off 10,000) at 4,500 rpm, to 20 mg/mL stock 
concentration in 20 mM Tris-HCl, pH 8.0, and the protein was kept at 4°C until 
crystallization set up. To eliminate microbial contamination, dust, and aggregation, 
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the protein solution was filtered through a 0.2 μm centrifugal filter at 8,000 rpm for 5 
min before crystallization setup. For initial screening, the microbatch under oil and 
sitting drop vapor diffusion methods were employed to obtain suitable conditions for 
reproducible single crystals for X-ray diffraction experiments. 
 
 2.7.1.2 Initial screening by microbatch under oil screening 
crystallization 
Initial crystallization experiments were performed manually by 
the microbatch under oil method (Chayen, 1999). The initial screening was performed 
in 60 well plates (Nunc, Wiesbaden, Germany). Firstly, each well of the 
crystallization plate was filled with 10 μL of 100% paraffin oil to prevent evaporation 
of the aqueous drops. For each crystallization drop, 1 μL of each aqueous precipitant 
cocktail solution from Jena screen HTS I and HTS II (Jena Bioscience), Crystals 
Screen High Throughput HR2-110, or HR2-112 kit (Hampton Research) were added 
under oil into each well, followed by 1 μL of 10 mg/mL YKL-39 solution (Figure 
2.1). To complete a single crystallization drop, each well was carefully examined 
under a Stemi 2000-C stereo microscope (Zeiss Corp, NJ, USA). The crystallization 
plate was covered with a plate cover to prevent dust from outside. The evaporation 
rate of water in the crystallization drop through the oil was minimized by placing it on 
a moist sponge in a plastic box, followed by incubation at 15°C or 25°C to allow 
protein crystals to grow. The crystal growth was examined daily for one week, and 
then continued once a week afterwards.  
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Figure 2.1  Schematic representation of Microbatch under oil crystallization 
technique. 
 
2.7.1.3  Initial screening by robotic screening crystallization 
From this section, crystallization experiments and protein-ligand 
binding by ITC technique were performed at the Institute of Molecular and Cell 
Biology (IMCB), Singapore, under advising by Prof. Dr. Robert C. Robinson, 
collaboration. Initial crystallization of YKL-39 was further set up using a 
Screenmaker 96+8TM Robot (Innovadyne Technologies, Inc., Santa Rosa, CA, USA) 
with sitting drop vapor diffusion technique in CrystalQuickTM plates (Greiner bio-
one). The appropriate protein concentration was determined, and crystallization 
screening was performed by hanging drop technique using Pre-Crystallization Test 
(PCT, Hampton) as precipitant. Initially, 1 µL of the purified protein was mixed with 
1 µL of the PCT reagents on a 20 mm siliconized cover slip, then the cover slip, 
containing the mixing drop was inverted and put on to the top of the sealed grease 
well of a 24 well plate containing 0.5 mL of PCT reagent.  After incubation for 30 
min at 25°C, the drop was carefully examined under a Stemi 2000-C stereo 
microscope. If the protein concentration for crystallization screening was appropriate, 
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microcrystallines or light granular precipitates would be observed throughout the 
drop. The protein concentration, which gave light granular precipitates, was then 
chosen for further optimization. For screening with the sitting drop vapor diffusion 
technique, the crystallization drop included 20 nL of the freshly prepared YKL-39 
(12.75 mg/mL in 20 mM Tris–HCl, pH 8.0) and 20 nL of each precipitating agent 
from the screening kits, including JCSG-plus HT96 (Molecular Dimensions), Wizard 
I and II (Emerald) and Crystal Screen High Throughput HR2-130 (Hampton). Then, 
170 nL of the same precipitant was applied into the well as reservoir (Figure 2.2). The 
crystallization plates were incubated at two different temperatures of 15°C and 25°C 
to allow crystal growth. The protein drops that were equilibrated over the reservoir of 
the precipitating agent were examined under a stereomicroscope periodically, as 
mentioned for the Microbatch under oil method. 
 
 
 
 
 
 
Figure 2.2  Schematic representation of Sitting Drop Vapor Diffusion technique. 
 
2.7.2  Optimization of crystallization conditions 
The initial screening conditions that yielded small crystals were 
further optimized by Hanging Drop Vapor Diffusion technique (Weber, 1997) to 
obtain high quality crystals. Factor variables, including concentrations of PEG and 
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salts, were adjusted at fixed pH and protein concentration during optimization. A 
grid of 24 conditions was set up as shown in the Figure 2.3. The crystallization 
droplet contained equal volumes of protein and mother liquor, for which 1 µL of 
YKL-39 (12.75 mg/mL) was pipetted onto the center of a 22 mm siliconizd cover 
slip, followed by an equal volume of the reservoir solution. The prepared cover 
slip, containing the crystaliization drop, was subsequently inverted and placed on 
the top edge of the wells, containing 0.5 mL of the reservoir (Figure 2.4), along 
the top edge of the well containing reservoir was firstly sealed with high vacuum 
grease. The prepared crystallization plates were subsequently incubated at 15°C 
and 25°C. 
 
 
 
 
 
 
 
Figure 2.3  Grid screen of variable concentrations of PEG and salts. 
 
 
 
 
 
Figure 2.4  Schematic representation of Hanging Drop Vapor Diffusion technique.  
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2.7.3  Crystallization of protein/ligand complexes  
To determine the crystal structures of YKL-39 in complex with its 
ligands, the YKL-39 crystals were grown under condition 27% (w/v) PEG 3350, 0.2 
M Li2SO4, 0.1 M Bis Tris, pH 5.5 by the hanging drop vapor diffusion method. The 
YKL-39 crystals were soaked with various chitooligosaccharides (GlcNAc2 to 
GlcNAc6). Initially, a single X-ray quality crystal of YKL-39 was transferred to a new 
drop of precipitant containing each chitooligosaccharide at a specified concentration: 
0.1 mM for GlcNAc5 or GlcNAc6, 5 mM for GlcNAc4, and 10 mM for GlcNAc3 or 
GlcNAc2. The prepared glass cover slip, containing the soaked crystals, was 
subsequently inverted and placed on the top edge of the wells containing 0.5 mL of 
that precipitant as described for the hanging drop vapor diffusion method (Section 
2.8.2). The crystal plates were then incubated at 25°C for 16 h. The survival of the 
crystals was observed every 4 h by stereomicroscope.  The soaked crystals were 
mounted in a nylon loop, and flash-cooled in liquid nitrogen for X-ray diffraction.  
 
2.7.4  Data collection and processing 
2.7.4.1  Crystal transportation by dry shipper 
The crystals were fished from the drop by a nylon loop connected 
with the wand plug into the bottom of the caps, then rapidly immersed into liquid 
nitrogen in a dewar. Afterwards, the loop containing a crystal was capped into the 
associated cryo vial (Hampton Research) immersed and kept in liquid nitrogen for the 
entire shipping time.  
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2.7.4.2   In-house X-ray diffraction 
Initial X-ray diffraction data sets were collected in-house X-ray 
generator located at the Institute of Molecular and Cell Biology, Proteos, Singapore 
using the X-ray source from an RU-H3R rotating anode. The X-ray generator 
(Rigaku/MSC) was operated at 50 kV and 100 mA, with an incident wavelength 
setting at 1.54 Å. During diffraction, the crystals were maintained at 100K with a 
nitrogen cold stream that was generated by an X-Stream 2000 low temperature 
system. The X-ray diffraction was recorded on an R-AXIS IV++ image plate area 
detector (Rigaku/MSC). The crystal in its nylon-loop was placed onto the goniometer 
head, which allowed it to be positioned accurately within the X-ray beam and rotated 
between the X-ray beam and the detector, and the position of the mounted crystal was 
adjusted to center with assistance by a digital camera. The distance between the 
crystal and detector was varied from 60 to 70 mm in order to maximize the resolution 
of diffracted spots. The exposure time was set at 1 min. Once an X-ray diffraction 
image was observed, the first image was preliminarily analyzed by indexing to check 
crystal quality. Initial space group, lattice type, and unit cell parameters were then 
determined by a single oscillation image in the HKL-2000 program (Otwinowski and 
Minor, 1997). For data collection, X-ray diffraction data were collected with 0.50° 
oscillations for 180° rotation or until the data were complete. All the diffraction 
images were also indexed, integrated, and scaled with the same program. 
 
2.7.4.3  Synchrotron X-ray diffraction 
All diffraction data of the ligand-free YKL-39 and the crystal 
complexes were collected on beamline BL13B1 at the National Synchrotron 
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Radiation Research Center (NSRRC, Hsinchu, Taiwan). The mounted crystal was 
kept with a nitrogen cold stream at 105K during the diffraction process. X-ray 
diffractions were recorded on the ADSC Quantum 315 CCD detector. The wavelength 
was set at 1.00 Å. The distance between the crystal and detector was varied from 200 
mm to 350 mm in order to maximize the resolution of diffracted spots. The exposure 
time was set between 4 to 10 s and collected for 180° rotations with 0.50-1.00º 
oscillations per frame around the omega axis until the data were complete. All the 
diffraction images were also indexed, integrated and scaled with program HKL-2000. 
The maximum resolution for each data set was determined based on the criteria that 
the average ratio of measured intensity to its standard deviation (I/σ(I)) was more than 
2-fold in the outer shell. The most widely used global quality indicator is the Rmerge 
(Rhodes, 2000). It measures the spread of individual intensity measurements around 
the average value for the group of equivalent reflections. It has the formula 
Rmerge = [ΣhklΣi |Ii(hkl) - 〈I(hkl)〉|]/[ ΣhklΣiIi(hkl)]               (2.1) 
Where Ii is the intensity for the ith measurement of an equivalent reflection 
with indices hkl.  
Rmerge at the highest resolution shell that strongly depends on redundancy was 
considered for evaluating the quality of data set, and was kept at lower than 40%. 
Moreover, the completeness was more than 90%, and redundancy was at least 4-fold 
in all shells. After the X-ray data collections were completed, the merged data of each 
data set were then converted into an mtz format using the program Scalepack2mtz 
from the CCP4 suite (CCP4, 1994). Scaling, merging and statistical analysis of all the 
data sets were further examined with programs from the CCP4 suite (CCP4, 1994). 
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2.7.5  Phase determination by molecular replacement method 
To determine the orientation and position of the molecules within the 
unit cell, molecular replacement method (Navaza, 1994) was used to solve the phase 
problem. In this study, all the YKL-39 structures were solved by the molecular 
replacement using the program MOLREP from the CCP4 suite (Vagin and Teplyakov, 
1997). The first data set to be processed was that of the YKL-39/GlcNAc2 complex, 
which was processed to highest of resolution of 1.53 Å using the previously known 
structure of YKL-39 in complex with GlcNAc6 (PDB code 4AY1) as a search model 
(Schimpl et al., 2012). The rotation and translation function solutions were solved for 
one protein molecule per asymmetric unit with correlation coefficient of 71.0% and 
Rfactor of 46.7% in resolution range of 19.60-1.74 Å. The other data sets, including the 
ligand-free YKL-39, in complex YKL-39/GlcNAc4 and YKL-39/GlcNAc6 crystals 
were solved by using the final model of the YKL-39/GlcNAc2 complex as a search 
model.    
 
2.7.6  Model building and refinement 
After obtaining initial phases from the search model, an initial model 
was manually rebuilt in Coot (Emsley and Cowtan, 2004). The electron density map 
of |Fobs|-|Fcal| and 2|Fobs|-|Fcal| was calculated from the observed structure factor 
amplitudes and the calculated structure factor amplitudes. A new model was then fit 
to the new electron density map and further rounds of structural refinement were 
performed with Refmac5 in the CCP4 suit (Murshudov et al., 1999) and Phenix 
(Adams et al., 2002). The resultant electron density map showed the regions of 
disagreement between the search model and the new structure, which was further 
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determined through rebuilding and refinement processes. These processes were 
continued until the correlation between the diffraction data and the model were 
maximized. The agreement was measured by an Rfactor defined as 
                                 Σall reflections |Fobs - Fcal| 
R = _______________________________________                (2.2) 
                                Σall reflections |Fobs| 
 
A similar quality criterion was Rfree, which was calculated from a subset (~5%) 
of reflections that were not included in the structure refinement. The water molecule 
positions were added into the model in the refinement stages by inspecting the     
||2Fobs|-|Fcal|| electron density map for peaks at 1.0σ.  
 
2.7.7  Validation of model quality 
The quality of geometry of the final model was validated by 
PROCHECK (Laskowski et al., 1993). The Ramachandran plot (Ramachandran and 
Sasisekharan, 1968) of each model was calculated by PROCHECK. The number of 
Ramachandran outliers was found to be less than 0.2%. In addition, the root-mean-
square (R.M.S.) deviations from ideality of bond length and angles were also 
determined with PROCHECK. The criteria of a well-refined model exhibits R.M.S. 
deviations were less than 0.014 Å for bond lengths and 3° for bond angles. All the 
structures and electron density maps were created and displayed with Pymol 
(www.pymol.org). 
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2.8  Protein-ligand interaction 
2.8.1 Isothermal titration calorimetry (ITC) 
ITC experiments were carried out using the ITC-200 system (Microcal 
Inc.). All solutions were degassed to avoid air bubbles in the calorimeter. All of 
measurements were carried out at 25°C with stirring speed of 260 rpm after the 
baseline was set with distilled water. Protein and chitooligosaccharide were prepared 
in 20 mM potassium phosphate buffer, pH 8.0. For the titration with GlcNAc6 and 
GlcNAc5, 10 µM of YKL-39 was placed in the reaction cell with a volume of 0.4 mL, 
and 0.25 mM ligand was placed in the syringe. Aliquots of 4 µL of ligands were 
injected into the reaction cell. The injections were repeated 20 times over 140 s 
intervals. The background was measured by injecting the ligand into the cell 
containing only buffer. ITC experiments with GlcNAc4, GlcNAc3 and GlcNAc2 were 
performed as described for GlcNAc6 but with higher concentrations of the reaction 
components. For the experiment with GlcNAc4, 30 µM YKL-39 in 20 potassium 
phosphate buffer, pH 8.0, was added in the reaction cells and 0.45 µM GlcNAc4 was 
placed in the syringe. For experiments with GlcNAc3 and GlcNAc2, 15 µM YKL-39 
was added in the reaction cells and 3 µM GlcNAc3 and 4 µM GlcNAc2, respectively, 
were added into the syringe. The ITC data were collected by using the Microcal 
Origin v.7.0 software. All data were subtracted from the heat releasing profile 
obtained by injections of the corresponding ligand into the reaction cell after the 
saturated binding reaction. The data were fitted by a nonlinear least-squares algorithm 
fitted to a single-site binding model. After background subtraction, all data were fit to 
yield the stoichiometry (n), the equilibrium binding association constant (Ka), and the 
enthalpy change (∆H) of the reaction. The Gibb’s free energy (∆G) and the entropy 
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change (∆S) were calculated from the enthalpy change (∆H) and binding constant 
with the following equation. 
ΔG = ΔH - TΔS = -RTln(Ka)                                 (2.3) 
Where R represents the gas constant (1.98 cal K−1 mol−1) and T the absolute 
temperature in Kelvin (K). The enthalpic term represents the change in heat that is 
produced by breaking and forming noncovalent bonded interactions, whereas the 
entropic term reflects changes in order. In these experiments, all data from the binding 
reactions fitted well to a single-site binding model with a calculated n (stoichiometry) 
of 0.9-1.1. The shape of the ITC binding curve is dependent on the association 
constant (Ka) and the molar concentration of macromolecule [M] being titrated which 
can be determined by the so-called Wiseman c-value (Wiseman, Williston, Brandts, 
and Lin, 1989). The relation is shown as:  
c = nKa[M]                                      (2.4) 
 Where n is the stoichiometry of the reaction, Ka is the equilibrium binding 
association constant, and [M] is the molar protein concentration. For the binding 
of GlcNAc4, GlcNAc5, and GlcNAc6, they could be optimized to give a c-value to 
be in the range of 10 < c < 1000. This ensures that Ka can be determined from the 
Wiseman binding isotherm. For the binding of GlcNAc2 and GlcNAc3 to YKL-39 
yielded a c-value of 0.1. Binding thermodynamics can be obtained by ITC even if 
c is in the range of 0.01 < c < 10 if a sufficient portion of the binding isotherm is 
used for analysis (Turnbull and Daranas, 2003).  
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 2.8.2  Intrinsic fluorescence studies of protein-ligand binding 
          The purified YKL-39 was titrated with different concentrations of the 
chitooligosaccharides in 20 mM Tris-HCl, pH 8.0 at 25°C. Changes in intrinsic 
tryptophan fluorescence were monitored directly in a LS-50 fluorescence 
spectrometer (Perkin-Elmer Limited). The excitation wavelength was 295 nm and 
emission intensities were collected over 300-450 nm with the excitation and emission 
slit widths being kept at 5 nm. Each protein spectrum was corrected for the buffer 
spectrum. Binding curves of the ligands, which were detected as  increasing 
fluorescence intensities after adding the ligand, were evaluated by a nonlinear 
regression function available in Prism version 5.0 (GraphPad Software, California, 
USA) via the following single-site binding model:  
 F-F0= 
(Fmax – F0) × (L0)
Kd+(L0)
                                  (2.5) 
F and F0 refer to the fluorescence intensity in the presence and absence of 
ligand, respectively; Fmax refers to the maximum fluorescence signal of the protein-
ligand complex; L0 is the initial ligand concentration (µM) and Kd is the equilibrium 
dissociation constant (µM).  
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
RESULTS 
 
3.1 Molecular Cloning, Expression, and Purification of YKL-39 
3.1.1  Molecular cloning 
A database search showed that the CHI3L2 gene encoding YKL-39 is 
located in human chromosome 1 at locus 1p13.3. In this study, the nucleotide 
sequence of CHI3L2 cDNA in the GenBank database 
(www.ncbi.nlm.nih.gov/genbank) was used as the template to design a set of 
oligonucleotides, which was designed to generate in-frame protein expression. The 
full-length CHI3L2 gene encoding YKL-39 (Genbank accession number 
NM_004000) was successfully amplified by PCR technique with human uterus cDNA 
(GeneScript) as the DNA template. The pairs of oligonucleotide primers could 
produce the expected PCR products (∼1.1 kb), which were analyzed by agarose gel 
electrophoresis (Figure 3.1.1). 
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Figure 3.1.1  Identification of the amplified PCR product of the CHI3L2 gene. 
The PCR products of CHI3L2 gene were analyzed on 1% (w/v) agarose containing 
syber green. Lane M: 1 Kb DNA marker; lanes 1 and 2: ∼1,100 bp of the expected 
PCR products (arrow). 
 
The PCR product of the expected size (∼1.1 kb) was purified and directly 
cloned into the  pET32a(+) expression vector, generating the recombinant plasmid, so 
called pET32a(+)/CHI3L2. The fusion protein expressed from the designed construct 
(Figure 3.1.2) consisted of five components of functional importance to this study: a 
thioredoxin fusion tag, a sixhistidine tag (His6), S-tag, an enterokinase cleavage site, 
and a YKL-39 polypeptide. The Trx tag was fused to the protein to enhance protein 
solubility, while the His6 tag was induced to aid protein purification. Enterokinase 
cleavage site is used for fusion tag removal that contains a five amino acid sequence, 
DDDDK.  
 
 
 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
 
 
Figure 3.1.2  The gene organization of the pET32a(+)/CHI3L2 construct. 
 
The recombinant plasmid pET32a(+)/CHI3L2 clones were examined by colony 
PCR, restriction enzyme digestion, and DNA sequencing to ensure the success of this 
construction. The recombinant plasmids were isolated from the positive E. coli 
colonies, which were grown on LB/Amp medium, and were subsequently determined 
for the CHI3L2 gene insertion by the colony PCR technique with specific 
oligonucleotide primers for the CHI3L2 gene. Agarose gel revealed the PCR product 
of expected size (1.1 kbp) from clones 1 and 2 (Figure 3.1.3A). The restriction 
endonuclease digestion assay was also performed to confirm the presence of the 
CHI3L2 gene in the pET32a(+)/CHI3L2 construct. After digestion the isolated 
plasmid obtained from positive colonies with BamHI and XhoI, two DNA bands were 
seen on agarose gel to the smaller size DNA fragment of about 1.1 kbp corresponded 
to the size of the CHI3L2 gene obtained from PCR amplification, whereas the bigger 
DNA band of about 6.0 kbp was corresponded to the pET32a(+) expression vector 
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(Figure 3.1.3B). Therefore, both colony PCR and restriction enzyme digestion 
suggested that the pET32a(+)/CHI3L2 constructed was generated successfully. 
 
                                    
  
 
 
 
 
 
 
 
 
 
 
 
 
                                            (A)                                                    (B) 
 
Figure 3.1.3  Confirmation of recombinant plasmid pET32a(+)/CHI3L2 by colony 
PCR and restriction enzyme digestion. 
(A) Colony PCR, The PCR products of the selected E. coli colonies were analyzed on 
1% agarose gel electrophoresis. Lane M: 1 kb DNA marker; lanes 1-2: PCR products 
obtained from clones 1 and 2; lane 3: negative control; lane 4: positive control.  (B) 
Restriction enzyme digestion: the restriction fragment of the pET32a(+) expression 
vector and the CHI3L2 gene obtained from restriction endonuclease digestion with 
BamHI and XhoI. Lane M: 1 kb DNA marker; lane 1: 1.1 kb band of the CHI3L2 gene 
and 6.0 kbp band of pET32a(+) vector after the recombinant plasmid 
pET32a(+)/CHI3L2 was digested with BamHI and XhoI.  
 
Furthermore, both sense and anti-sense strands of the CHI3L2 gene were 
confirmed by automated DNA sequencing. The DNA sequencing results indicated 
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that the recombinant plasmid pET32a(+)/CHI3L2 had an open reading frame (ORF) 
that encoded the N-terminal thioredoxin, followed by the His6 tag connected with the 
N-terminus of the mature YKL-39. Overall, this recombinant plasmid 
pET32a(+)/CHI3L2 encoded 364 amino acids of the mature YKL-39 lacking a 26-aa 
signal sequence. Figure 3.1.4 represents an open reading frame of the construct, which 
expressed as a fusion protein that contains a thioredoxin fragment, followed by the 
His6 residues (purple color) attached at the N-terminus of the YKL-39 polypeptide, 
via an enterokinase cleavage site (orange color) for removal of the N-terminus fusion 
tag. In this construct, there are an extra seven amino acids A-M-A-D-I-G-S flanking 
between the enterokinase recognition site and the first three residues: Y (Tyrosine), K 
(Lysine) and L (Leucine) as shown in blue color of the YKL-39 polypeptide. The 
deduced amino acid sequence of YKL-39 was found to be identical to the 390-aa 
sequence of CHI3L2 isoform 1 (identifier: Q15782-4) reported in the 
UniProtKB/Swiss-Prot database. The exception is that a single amino acid residue in 
our sequence at position 318 had Trp instead of Arg as show in red color with arrow 
(Figure 3.1.4). The discrepancy of this amino acid has been suggested previously to 
be a natural variation that occurs due to a single nucleotide polymorphism (The MGC 
Project Team, 2004).  
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Figure 3.1.4  The deduced amino acid sequences of the constructed recombinant 
plasmid pET32a(+)/CHI3L2. 
The constructed recombinant plasmid contained the thioredoxin fusion tag, followed 
by the His6 (purple) connected with the enterokinase cleavage site (orange), attached 
at the N-terminus of the mature YKL-39 polypeptide. The single amino acid residue 
exception to the sequence in the UniProtKB/Swiss-Prot database (identifier: Q15782-
4), Arg318 substituted with Trp, is shown in red with an arrow. 
   
The amino acid sequence of human YKL-39 was highly homologous to many of 
the recently identified members of the human chitinase and chitinase-like protein 
family. Sequence alignment of the human YKL-39 with these proteins, including 
YKL-40 (CHI3L1, P36222), acidic mammalian chitinase (AMCase, Q9BZP6-1), 
human chitotriosidase (CHIT1, Q13231), human oviduction (oviduction, Q86YN0), 
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and stabilin-1 isoform 1(SI-CLP, Q9NY15) by CLUSTAL W is shown in Figure. 
3.1.5. The YKL-39 sequence is closest to CHIT1 (55.2% identity), followed by YKL-
40 (51.3%). On the other hand, YKL-39 had lowest identity to SI-CLP (17.5%). The 
amino acid residues S143 and I145 located at the ends of the DxxDxSxE motif 
(Figure 3.1.5, black asterisks) are reported to suppress chitinase activity. In true 
chitinases like AMCase and CHIT1, these two residues are found as Asp and Glu 
instead. Double mutations of S143 to D143 and I145 to E145 in YKL-39 created 
pseudo-chitinase activity for this protein (Schimpl et al., 2012). 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.5  Structure-based alignments of human YKL-39 and its homologues.  
The sequence alignment was generated by CLUSTAL W. The YKL-39 sequence 
(SwissProt: Q15782) was aligned with the amino acid sequence of AMCase (Swiss-
Prot: Q9BZP6), chitotriosidase (Swiss-Prot: Q13231), and (SwissProt: P36222). The 
secondary structural components of AMCase (pdb 3FXY), Chitotriosidase (pdb 
1GUV), and YKL-40 (pdb 1HJW) were identified, edited, and displayed as a 
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PostScript output in the ESPript v. 2.2 program (Gouet, Courcelle, Stuart, and Metoz, 
1999). The amino acid residues that are important for binding to GlcNAc units are 
indicated as pink triangles. The last three acidic residues in the DxxDxDxE motif 
(yellow letters) that are important for chitinase activity of AMCase and 
Chitotriosidase are marked with black asterisks. 
 
3.1.2  Expression and purification 
3.1.2.1  Expression and solubility of YKL-39 
A major effort of the protein studies is improvement of 
techniques for molecular cloning, protein expression, and purification to obtain 
soluble, functional proteins. In this study, we tried to express the soluble form of 
human YKL-39 in E. coli system by various expression vectors and E. coli host 
strains. Finally, YKL-39 was successfully expressed in E. coli BL21(DE3) cells from 
the pET32a(+) expression vector as a fusion protein as described in Section 3.3.1. The 
total molecular weight of the fusion protein was estimated to be 55 kDa. The 
pET32a(+)/CHI3L2 construct was made to be suitable to be expressed in E. coli 
BL21(DE3) expression host cells. After the constructed pET32a(+)/CHI3L2 construct 
proved successful, protein expression and solubility of the E. coli expressed YKL-39 
recombinant protein were evaluated. The recombinant Trx-His6/YKL-39 protein was 
successfully expressed at high levels in the IPTG induced group, but not in the control 
group as seen in Figure 3.1.6A. The 55 kDa protein corresponding to the expected 
size of recombinant Trx-His6/YKL-39 protein was detected (lanes 2 and 3), while no 
uninduced band was seen in the cell lysate fraction (lane 1). Subsequently, the 
solubility of the expressed protein was determined. The results shown in Figure 
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3.1.6B revealed that the majority of the soluble protein was found primarily in the 
supernatant after centrifugation to remove insoluble material. SDS-PAGE analysis of 
the induced cells in the soluble and insoluble fractions exhibited the expected protein 
band of Trx-His6/YKL-39 at 55 kDa, however, the protein band was mainly seen in 
the soluble fraction (lane 3), as compared to the protein band in the insoluble fraction 
(lane 2) and the control cells (lane 1). The results showed that YKL-39 was expressed 
in E. coli in soluble form.  
 
 
 
 
 
 
 
 
Figure 3.1.6  SDS-PAGE of the expression of the Trx-His6/YKL-39 fusion protein.  
(A) Protein expression analysis: Lane M: protein molecular weight marker; lane 1: 
whole cell lysate of un-induced BL21(DE3) host containing pET32a(+)/YKL-39;  
lanes 2-3: whole cell lysate of induced BL21(DE3) host containing pET32a(+)/YKL-
39 with IPTG. (B) Solubility determination. Lane M: protein molecular weight 
marker; lane 1: total proteins of induced BL21(DE3) host containing 
pET32a(+)/YKL-39 with IPTG; lane 2: pellet of cell lysate after induction with 0.5 
mM IPTG for 16 h; lane 3: supernatant of cell lysate after induction.  
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3.1.2.2  Optimization of recombinant YKL-39 expression from E. coli  
BL21(DE3) cells 
In this study, expression trials were carried out in order to obtain 
optimal conditions that gave highest yield, with highest solubility of human YKL-39. 
Different factors, including IPTG concentration, temperature, and time of induction, 
that generally affect yield and solubility of the recombinant expression were 
investigated.  Initially, IPTG concentration was analyzed. SDS-PAGE analysis 
showed that the concentration of 0.5 mM IPTG yielded the highest level of soluble 
protein. Further optimization was carried out at a fixed concentration of 0.5 mM IPTG 
for 16 h with various temperatures (15°C, 25°C, 30°C and 37°C). SDS-PAGE 
analysis of total proteins obtained in the cell pellet and crude supernatant revealed 
high expression level of the soluble YKL-39 was observed when induced at 15°C and 
25°C. Thus, all the following experiments were performed under the induction 
temperature at 25°C. For further optimization, the expression of Trx-His6/YKL-39 in 
E. coli BL21(DE3) was examined at different times of induction (0, 4, 6, 9, 12, and 16 
h). As shown in Figure 3.1.7, SDS-PAGE gel analysis revealed no protein band of 55 
kDa at 0 h of induction. The soluble form of Trx-His6/YKL-39 fusion protein was 
clearly observed even at 4 h. However, protein expression reached highest level after 
6 h of IPTG induction and maintained a similar level up to 16 h. Thus, all the 
following experiments were performed at the induction time of over 6 h. For the 
convenience of experimental handling, an overnight induction was preferred for 
YKL-39 expression. In conclusion, the expression level of the soluble YKL-39 was 
dependent on IPTG concentration, temperature and time of induction, with the 
optimal conditions set as 0.5 mM IPTG concentration at 25°C for 16 h. This condition 
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was further utilized for high expression level of YKL-39 functional and structural 
characterization.  
 
 
 
 
 
 
 
 
Figure 3.1.7  SDS-PAGE of Trx-His6/YKL-39 fusion protein at different induction 
times with 0.5 mM IPTG, and 25°C.  
Lane M: protein molecular weight marker; lanes 1-5: supernatant of whole cell lysate 
of induced BL21(DE3) host containing pET32a(+)/CHI3L2 with IPTG for 4, 6, 9, 12, 
and 16 h, respectively.  
 
3.1.2.3  Protein purification for polyclonal and monoclonal antibody 
production  
Recombinant Trx-His6/YKL-39 was expressed as an N-terminal 
thioredoxin and His6 tag fusion protein in the E. coli BL21(DE3) under the optimized 
condition as described in Section 3.1.2.2. The presence of the His6 tag facilitated the 
protein purification by Ni-NTA resin affinity chromatography. The Trx-His6/YKL-39 
fusion protein contained the cleavage site for entorokinase at the N-terminus of the 
mature YKL-39 protein. Initially, the recombinant fusion protein containing His6 tag 
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was purified by gravity Ni-NTA resin affinity column. To minimize nonspecific 
binding and reduce the amount of contaminating proteins, a two-step wash (5 mM, 
followed by 20 mM imidazole) was carried out before the column was eluted with 
250 mM imidazole. SDS-PAGE analysis showed the majority of the 55 kDa protein 
band, corresponding to the Trx-His6/YKL-39 fusion protein in the Elute I and Elute II 
fractions, as showed in Figure 3.1.8. However, several contamination proteins were 
also observed in the elution I fraction. Approximately 80-90% purity of the YKL-39 
protein was obtained by first Ni-NTA resin affinity chromatography atep, with the 
overall yield of about 6.8 mg protein per liter of E. coli culture. After elution, the 
buffer of the eluted sample was immediately changed to 50 mM Tris-HCl, pH 8.0, 
containing 50 mM NaCl to remove imidazole. 
 
 
 
 
 
 
 
 
Figure 3.1.8  SDS-PAGE of the Trx-His6/YKL-39 fusion protein purified by gravity 
Ni-NTA resin affinity chromatography.  
Lane M: molecular weight protein marker; lane 1: flow-through fraction; lanes 2-3: 
wash fraction with 5 mM imidazole; lane 4: wash fraction with 20 mM imidazole; 
lanes 5-6: eluted fractions with 250 mM imidazole. 
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For further purification, Sepharose Q HP anion exchange chromatography was 
applied to eliminate the contaminating proteins, so as to obtain highly purified fusion 
protein. The protein purified from gravity Ni-NTA resin was filtered, and then applied 
onto a Sepharose Q HP column. SDS-PAGE analysis displayed the majority of the 
fusion protein band in fractions 39-41 (Figure 3.1.9). However, several low molecular 
weight contaminated proteins were still observed. These eluted fractions were then 
pooled and concentrated. After this purification step, approximately 5.1 mg purified 
protein was obtained from 1 liter of E. coli culture.  
 
 
 
 
 
 
 
 
 
Figure 3.1.9  An elution profile of the fusion Trx-His6/YKL-39 purified from an 
ÄKTA purifier system with a Sepharose Q HP anion exchange chromatography. 
The E. coli expressed YKL-39 fusion protein was applied onto a Ni-NTA resin 
column, followed by a Sepharose Q HP pre-packed column. The bound protein was 
eluted with a linear gradient of 1 M NaCl in 10 mM Tris-HCl, pH 8.0. The inset 
displays SDS-PAGE analysis of the eluted fractions containing the Trx-His6/YKL-39 
fusion protein in fractions 39-41. 
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To remove the Trx-His6 fusion tag, the purified protein obtained from 
Sepharose Q HP anion exchange chromatography was cleaved with enterokinase to 
generate the fusion tag free YKL-39. After digestion overnight, the Trx-His6 fusion 
tag was completely removed from the protein solution by the second gravity Ni-NTA 
resin
 
step. The purification profile of the free fusion-tag YKL-39 protein obtained 
from the second Ni-NTA resin was evaluated by SDS-PAGE, as shown in Figure 
3.1.10. 
 
 
 
 
 
 
 
 
Figure 3.1.10  SDS-PAGE of the free-tag YKL-39 protein purified by second          
Ni-NTA agarose. 
Lane M: molecular weight protein marker; lane 1: digested fusion Trx-His6/YKL-39 
solution before purification; lane 2: flow-through fraction contained the tag-free 
YKL-39 protein; lanes 3: fraction of wash with 5 mM imidazole; lane 4: 20 mM 
imidazole wash fraction; lanes 5-7: fractions of uncleav Trx-His6/YKL-39 and Trx-
His6 tag fragment eluted with 250 mM imidazole. 
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The flow-through fractions containing nonfusion YKL-39 protein were detected 
at approximately 39 kDa, which corresponds to the theoretically expected molecular 
weight of YKL-39. The uncleav Trx-His6/YKL-39 and Trx-His6 tag fragment were 
observed in the Wash II and elute fractions as expected. After the second Ni-NTA 
resin step exchange of the buffer and concentration, the purity of YKL-39 was 
evaluated to be >95%, with a yield of about 3.4 mg per liter of culture (Table 3.1). 
The protein from the second Ni-NTA resin was used for polyclonal and monoclonal 
antibody production. Improvement of the purity of YKL-39 after purification is 
displayed in Figure 3.1.11. 
 
 
 
 
 
 
 
 
Figure 3.1.11 SDS-PAGE analysis of the purified YKL-39 after each purification 
step.  
Lane M: protein molecular weight marker; lane 1: cell lysate of un-induced 
BL21(DE3) host containing pET32a(+)/CHI3L2; lane 2: cell lysate of induced with 
IPTG; lane 3: elution of Trx-His6/YKL-39 from Ni-NTA affinity column and anion 
exchange chromatography, lane 4: the purified YKL-39 after thioredoxin removal and 
further purification by the second Ni-NTA affinity column. 
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Table 3.1.1 Complete purification of human YKL-39. 
 
Purification step Total volume 
(mL) 
Total 
protein (mg) 
Yield  
(%) 
    Protein form 
Crude extract 30 105 100 Trx-His6/YKL-39 
First Ni-NTA 
affinity column 
15 6.8 6.5 Trx-His6/YKL-39 
Anion exchange 
column 
5 5.1 4.8 Trx-His6/YKL-39 
Second Ni-NTA 
affinity column 
5 3.4 3.3 YKL-39 
 
Table 3.1.1 shows that the purification of the recombinant Trx-His6/YKL-39 
yielded approximately 80-90% purified YKL-39 after first Ni-NTA resin affinity 
chromatography step. After enterokinase cleavage, followed by second Ni-NTA 
affinity chromatography, 3.4 mg of the purified YKL-39 was obtained from one liter 
of bacterial culture.  
 
3.1.2.4  Protein purification for crystallization  
To obtain high quality and quantity of YKL-39, the purification 
protocol was further developed using His Trap HP (1-mL). As shown in the elution 
profile in Figure 3.1.12 present the elution profile of the protein purification by His 
Trap HP, which showed that most contaminating proteins were washed out in the 
unbound and wash fractions. Bound proteins were found in fractions eluted with 5 to 
250 mM imidazole. This result indicated that fusion protein was not strongly bound to 
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the Ni2+ resin. After removal of the Trx-His6 tag by enterokinase cleavage overnight 
and further purification by a second His trap column, SDS-PAGE showed the 39 kDa 
free-tag YKL-39 in flow-through fractions, while noncleav Trx-His6/YKL-39 and 
Trx-His6 tag fragments were observed in the eluent (Figure 3.1.13).  As shown in 
Figure 3.1.14, SDS-PAGE analysis of eluted fractions showed a single band of the 39 
kDa protein. The purity of homogeneous protein of >95% was obtained after final 
purification step. Therefore, it was used for crystallization and protein-ligand binding 
studies.  
 
 
 
 
 
 
 
 
 
Figure 3.1.12  An elution profile of the recombinant Trx-His6/YKL-39 recombinant 
obtained from an ÄKTA purifier system with a His trap column. 
Crude supernatant was applied onto a His trap (1-mL) column. Bound proteins were 
eluted with a linear gradient of 0-250 mM imidazole in 50 mM Tris-HCl, pH 8.0. 
Inset displays SDS-PAGE gel of the eluted fractions containing the Trx-His6/YKL-39 
fusion protein in fractions 35-44. 
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Figure 3.1.13  Elution profile of the HisTrap HP column of Trx-His6/YKL-39 fusion 
protein after cleavage with enterokinase.   
Inset represents SDS-PAGE gel of the eluted fractions. Lane M: low molecular 
weight protein marker; lane R: the overnight digestion of fusion protein Trx-
His6/YKL-39 by enterokinase; lane FT: the free-tag YKL-39 eluted in the flow-
through; lanes 26-30: the un-cut fusion protein and N-terminus Trx-His6 tag fractions 
eluted with 250 mM imidazole. 
 
 
 
Figure 3.1.14  SDS-PAGE analysis of the purified YKL-39 obtained after 
purification with a Hiload 16/60 Superdex 200 prep grade gel filtration column.  
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The protein sample obtained from the second Ni-NTA affinity step was applied onto a 
Hiload 16/60 Superdex 200 prep grade gel filtration column under the conditions 
given in Section 2.5.3.2. Lane M: molecular weight protein maker; lanes 1-10: eluted 
fractions with 50 mM NaCl and 50 mM Tris buffer, pH 8.0. 
 
3.2  Production of polyclonal and monoclonal antibodies  
YKL-39 is recently known as an osteoarthritis marker, since expression of 
YKL-39 was highly up-regulated at both mRNA and protein levels in cartilage from 
patients with osteoarthritis (Steak et al., 2002 and Knorr et al., 2003). Therefore, the 
availability of in-house polyclonal and monoclonal antibodies will open up an 
opportunity for the development of immunological tools (i.e., specific YKL-39 
ELISA kit and YKL-39 immunosensor) for a sensitive detection of the disease 
progression. In this study, we describe the production of anti-YKL-39 polyclonal and 
monoclonal antibodies for investigation of protein-protein or protein-ligand 
interactions, as well as for development of a sensitive enzyme-linked immunoassay 
that requires specific, well characterized, and uniform antibodies against YKL-39. 
 
3.2.1  Polyclonal antibody production 
3.2.1.1 Determination of immune response to produce anti-YKL39 
antibodies  
The purified YKL-39 protein was used as immunogen for 
production of anti-YKL-39 polyclonal antibodies (pAbs). After the final 
immunization, an average of 5-10 mL of anti-serum was obtained after each bleeding. 
To determine the antibody response in the immunized rabbit, antibody titers were 
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determined by indirect ELISA assay. Figure 3.2.1A, shows the Ag:Ab binding curve, 
presenting concentration dependence of anti-YKL39 antisera towards the recombinant 
YKL-39. The hyperbolic feature, mimicking the Michaelis-Menten plot, between the 
interaction signals versus YKL-39 concentrations indicated that YKL-39 protein was 
able to stimulate a specific immune response in rabbits to produce high-specific pAbs. 
The binding curve demonstrated saturated and specific binding of the anti-YKL39 
antiserum to the YKL-39 antigen (10 µg/mL) within a range of 1:10-1:327,680 
dilutions of the antisera used. Pre-immune serum gave no reactivity to YKL-39 at the 
given ratios of Ag:Ab concentrations. Secondary antibody treatment alone (1:2,000 
dilution) also demonstrated no reactivity (data not shown). These results showed that 
the anti-YKL39 antisera were specifically reactive to the purified YKL-39 protein. 
The polyclonal antibodies reacted strongly with the YKL-39 at dilution up to 
1:40,000. In addition, the signals, representing specific interactions was seen with the 
linear range of detection from 1:2,560 to 1:20,480 of anti-serum dilutions (R2 = 
0.9934), as shown in Figure 3.2.1B.  
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Figure 3.2.1  Antibody titers after final immunization were determined by Indirect 
ELISA assay. 
(A) The binding curve of Ag:Ab. 96 well plates were coated with 10 µg/mL YKL-39 
and 2-fold serial dilutions of the antisera from 1:10 to 1:327,680 were added in to the 
wells in triplicate (closed-circle), while the pre-immune rabbit serum was coated as a 
negative control (closed-triangle). A HRP-conjugated goat anti-rabbit antibody was 
used to detect protein-antibody complex and the absorbance measured at 450 nm with 
TMB as substrate. The binding curve representing antigen-antibody interactions were 
obtained from a nonlinear regression fit available in Prism v5.0 (GraphPad Software) 
using the following single-site binding model. (B) The linear range of detection was 
found to be from 1:2,560 to 1:20,480 of anti-serum dilutions.  
 
3.2.1.2  Affinity purification of anti-YKL39 polyclonal antibodies 
The antisera were further purified by affinity chromatography on 
a protein A agarose column (GenScript Corporation, USA). Immunized serum was 
diluted with binding buffer (0.15 M NaCl, 20 mM Na2HPO4, pH 8.0) at a ratio of 1:1 
to ensure that proper ionic strength and pH are maintained for optimal binding, as 
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described in Section 2.7.2. Bound antibodies were eluted with 10 CV of elution buffer 
(0.1 M glycine, pH 2.5), and were immediately neutralized to pH 7.4 with 
neutralization buffer.  Figure 3.2.2 is SDS-PAGE analysis of the anti-YKL39 antisera 
purification. Panel A represents the elution profile of each purification step. To 
evaluate the quality of the purified antibodies, the eluted fractions were further 
analyzed by SDS-PAGE. Under non-reducing conditions, the immunoglobulin 
migrated behind the 97 kDa marker (panel B, lanes 1-2). Under reducing conditions, 
two protein bands from the eluted fractions were observed, one of which had a 
molecular weight of 50 kDa and the other one a molecular weight of 25 kDa that 
belonged to heavy and light chains, respectively (panel B, lanes 3-4). The antibodies 
bound with protein A column, indicating that it was a protein A-specific 
immunoglobulin G (IgG) isotype. 
 
 
 
Figure 3.2.2 Purification of anti-YKL39 polyclonal antibodies by protein A-agarose 
chromatography. 
(A) SDS-PAGE of purified anti-YKL39 under reducing conditions: Lane M, 
molecular weight protein marker. Lane 1, crude antiserum. Lane 2, flow-through 
fraction. Lane 3, wash fraction with binding buffer. Lanes 4-5, eluted fractions with 
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elution buffer (0.1 M glycine, pH 2.5). (B) SDS-PAGE of eluted fractions. Lane M, 
molecular weight protein marker. Lanes 1-2, eluted fractions under non-reducing 
condition, while Lanes 3-4 eluted fractions under reducing condition.  
 
3.2.1.3  Characterization of purified anti-YKL39 polyclonal 
antibodies 
3.2.1.3.1  Specificity of purified anti-YKL39 polyclonal 
antibodies 
  Indirect ELISA and Western blot immunoassay were 
carried out to determine specificity and sensitivity to YKL-39. Titers of the purified 
antibodies were further determined by indirect ELISA. Our raised antibodies were 
found to be highly sensitive, reacting strongly with the YKL-39 protein even when 
only 5 ng of the purified anti-YKL39 pAbs was used. For further biochemical 
characterization, 10 ng of anti-YKL39 pAbs was selected as the optimum 
concentration. Figure 3.2.3A displays the Ag:Ab binding curves, showing the 
concentration dependence of anti-YKL39 antiserum towards the recombinant YKL-39 
and other chitinase and CLP homologs. The hyperbolic feature between the 
interaction signals versus YKL-39 concentrations indicated specific interactions 
between the anti-YKL39 pAbs and antigen (Figure 3.2.3A, blue curve). When YKL-
40 (purple), AMCase (pink), and bacterial chitinase A (orange) were used as 
immunogens in range of 0.24-500 ng, no significant increase in the signal was 
observed. In addition, the pre-immune serum, which was used as control did not react 
with protein even at the maximum amount of YKL-39 used (yellow line). The results 
indicate that the raised antibodies were highly specific to the YKL-39 antigen. The 
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binding intensity of each antigen was further tested at a fixed concentration of 500 
ng/well and the anti-YKL39 antibodies of 10 ng/well (Figure 3.2.3A). The absorbance 
obtained for YKL-39 was 15–19 folds greater than that for human YKL-40, AMCase, 
and bacterial chitinase. This further confirmed a high specificity of the purified 
antibodies towards YKL-39. To ensure the specificity of purified pAbs to YKL-39, 
Western blot analysis was carried out with various GH-18 homologs. As shown in 
Figure 3.2.3C, the antibodies recognized both fused (lanes 2 and 3) and bare (lane 4) 
forms of human YKL-39, but did not recognize YKL-40 (lane 5), AMCase (lane 6), 
and bacterial chitinase (lane 7). The antibodies also did not cross-react with proteins 
in human serum (lane 8). The results suggested that the purified pAbs were highly 
specific for YKL-39. 
 
Figure 3.2.3  Specificity of purified anti-YKL39 antisera by indirect ELISA and 
Western blot analysis.  
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(A) Anti-YKL39 antiserum was raised against the purified YKL-39. Specificity of the 
purified anti-YKL39 antibodies (10 ng/well) was tested towards different 
concentrations (0–500 ng/well) of the CLPs by indirect ELISA assay. Blue, YKL-39; 
purple, YKL-40; pink, AMCase; orange, bacterial chitinase. Pre-immune serum 
against YKL-39 was used as control (yellow line). (B) Bar chart showing 
immunological interaction between a fixed concentration (500 ng/well) of YKL-39 
homologs and purified YKL-39 antisera (10 ng/well). Values are averaged from the 
data of triplicate trials. (C) Cross-reactivity of anti-YKL39 pAbs with other human 
chitinases and CLPs proteins was analyzed by SDS-PAGE (left panel) in comparison 
with Western blot analysis (right panel). Lane M, protein molecular weight marker; 
lane 1, cell lysate of uninduced E. coli BL21(DE3) host containing 
pET32a(+)/CHI3L2; lane 2, cell lysate of cells induced with IPTG; lane 3, elution of 
Trx-His6/YKL-39 from first Ni-NTA affinity column; lane 4, purified YKL-39 after 
ion exchange chromatography, after removal of the Trx-His6 tag, and further purified 
by second Ni-NTA affinity column; lane 5, YKL-40; lane 6, AMCase; lane 7, 
chitinaseA; lane 8, healthy human serum. 
 
 3.2.1.3.2  Sensitivity of purified anti-YKL39 polyclonal 
antibodies 
  The sensitivity of the raised antibodies was carried out 
by indirect ELISA and Western blot analysis as described in Section 2.7.3.2 and 
2.7.3.1. Indirect ELISA assay was performed to determine the optimal coating 
concentration of YKL-39. Concentrations of YKL-39 antigen coated on each well of 
ELISA plate were varied from 0.05 to 10 µg/mL, followed by the addition of 10 ng of 
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the purified anti-YKL39 pAbs. Figure 3.2.3A is the binding curve, showing saturation 
of the purified anti-YKL39 to the YKL-39 antigen above 10 µg/mL (left panel). The 
binding affinity (Ka) of YKL-39 protein for the detection by anti-YKL39 antibody 
was estimated to be 2.4x107 M-1. In addition, the signal of interaction with the linear 
range of detection was found to be from 0.16 to 1.25 µg/mL of YKL-39 with R2 = 
0.9999, as shown in Figure 3.2.3A (right panel). The limit of detection, which was 
estimated as the concentration of YKL-39 giving 10% of the maximum A450, for the 
assay was found to be 0.04 µg/mL of YKL-39. The optimal YKL-39 concentration, 
which gave half the maximum value of A450 or Bmax of the binding curve, was 
determined to be 1.7 µg/mL. In addition, the titer of the optimal YKL-39 
concentration determination was also carried out by Western blot analysis. Different 
concentrations of YKL-39 were used in a range of 0.08-10 µg while the anti-YKL39 
pAbs were fixed at 10 ng. After the membrane was exposed to an X-ray film, it was 
observed that at 10 ng of anti-YKL39 antibody generated a strong signal at 10 µg, and 
became fainted when the amount of YKL-39 was decreased down to 0.31 µg of YKL-
39 (Figure 3.2.3B). At amounts of YKL-39 antigen lower than 0.16 µg, no signal of 
Ag:Ab reaction was observed. 
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Figure 3.2.4  Sensitivity of the purified anti-YKL39 pAbs by indirect ELISA and 
Western blot analysis. 
(A) Assessment of the binding affinity of the purified anti-YKL39 antibodies by 
indirect ELISA. The left panel is the binding curve of the Ag:Ab interaction. The 
purified anti-YKL39 antibodies (10 ng/well) were tested with different concentrations 
(0–10 µg.mL-1/well) of YKL-39. Binding affinity was analyzed by nonlinear 
regression of data to a specific one-site binding function (Prism5). The right panel 
shows a linear response range at 0.16-1.25 µg/mL of YKL-39. (B) Sensitivity of the 
purified anti-YKL39 pAbs with YKL-39 protein was analyzed by Western blot 
analysis. YKL-39 amount was varied from 0.08-10 µg was used and the purified pAbs 
were fixed at 10 ng.  
 
The optimal concentrations of anti-YKL39 antibodies used for indirect ELISA 
and Western blot assays were further investigated.  Firstly, an indirect ELISA was 
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carried out. Different concentrations of anti-YKL39 antibodies in a range of 0.05 to 
10 µg/mL were tested against 2.5 µg/mL of YKL-39. Signals representing antibody-
protein interactions were detected with the HRP-conjugated IgG by the enhanced 
chemiluminescence method. The interaction of Ag:Ab gave the binding curve, which 
demonstrated saturation of the purified anti-YKL39 at above 2.5 µg/mL of the    
YKL-39 antigen as shown in Figure 3.2.3.4A (left panel). The binding affinity (Ka) of 
anti-YKL39 antibody for YKL-39 protein was estimated to be 1.3 x 107 M-1. The right 
panel represents the linear range of detection, which was found to be from 0.4 to 1.25 
µg/mL of anti-YKL39 (R2 = 0.978). The limit of detection, which was calculated as 
the concentration of anti-YKL39 giving a 10% of the maximum A450, was found to be 
0.8 µg/mL. Moreover, the titer of the optimal anti-YKL39 concentration 
determination was also carried out by Western blot analysis. Two-fold serial dilutions 
of anti-YKL39 ranging from 0.04 to 10 µg were used to estimate the immunoactivity 
toward 2.5 µg of YKL-39. After the membrane exposed to the X-ray film, it was 
observed that at 10 ng of anti-YKL39 antibody generates a strong signal while 0.31 
µg of anti-YKL39 that was able to give the weakest of signal.  
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Figure 3.2.5  Titer of the anti-YKL39 by indirect ELISA and Western blot analysis. 
(A) Assessment of the binding affinity of the purified anti-YKL39 antibody to YKL-
39 protein by indirect ELISA. The left panel is binding curve of the Ag:Ab 
interaction. The purified anti-YKL39 antibody concentrations were varied from 0.5-
100 µg/mL at fixed 2.5 µg/mL YKL-39. Binding affinity was analyzed by nonlinear 
regression, specific   one-site binding (Prism5). The right panel show linear range at 
0.4-12.5 µg/mL of anti-YKL39 antibody. (B) Sensitivity of purified anti-YKL39 pAbs 
for YKL-39 protein was analyzed by Western blot analysis. Anti-YKL39 antibody 
was used ranging from 0.005-10 µg and YKL-39 was fixed at 2.5 µg.  
 
3.2.2  Monoclonal antibody production 
 3.2.2.1 Determination of immune response to YKL-39  
To produce monoclonal antibody (mAb) specific for YKL-39, 
three female BALB/c mice were immunized intraperitoneally with 70 µg of the 
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purified YKL-39 protein in sterile PBS at two week intervals. Immunized mice sera 
were collected after 7 days of each injection as described in Section 2.8.1. The 
immune responses against YKL-39 antigen were determined by indirect ELISA using 
YKL-39. As shown in Figure 3.2.5, high titers of antibody response in the immunized 
mice serum were observed, whereas no signal was observed in the pre-immunized 
sample. Titer of raised antibody in immunized mice serum was high at dilutions of 
1/390,625.  The results indicated the success of induction of antibody production 
against YKL-39 protein.  
 
 
 
Figure 3.2.6  Determination of immune response against YKL-39 in immunized 
mice by indirect ELISA.  
The binding curve of Ag:Ab, the 96 well plates were coated with a 10 µg/mL of 
YKL-39 and 5-fold serial dilutions of the immunized mice serum from 1/5 to 
1/1,953,125 were performed in triplicate. The HRP-conjugated rabbit anti-mouse Igs 
antibody was used to detect the protein-antibody complex. Mouse 1, box; mouse 2, 
closed-triangle, mouse 3, open-triangle; pre-immunized mouse, closed-circle. Protein-
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antibody binding curves were evaluated by a nonlinear regression function available 
in Prism version 5.0 fit to the single-site binding model. 
 
3.2.2.2  Monoclonal antibody production by standard hybridoma 
technique 
   Spleen cells were further fused with P3X63-Ag8.653 myeloma 
cells by standard hybridoma technique using 50% (v/v) polyethylene glycol (PEG) as 
described in Section 2.8.3. After ten days of cultivation, cell growth was monitored 
under a microscope. Numbers and sizes of hybridoma containing wells were recorded. 
It was found that 477 wells contained healthy hybridomas, which was approximately 
50% of the 960 wells observed. The presence of antibodies in positive wells was 
determined by indirect ELISA. The results showed 71 hybridomas containing wells 
(7.4%) were obtained that were strongly reacted with YKL-39. In order to obtain 
single hybridoma clones, ten positive wells that gave high responses to YKL-39 
antigen were further chosen for dilution by limiting dilution as described in Section 
2.8.4. After 7-10 days of cultivation, wells that contained single clones were marked 
and screened by indirect ELISA to determine the level of anti-YKL39 mAb 
production. From our data, five clones that gave highest signals were selected, and 
subsequently re-cloned by the 2nd round of limiting dilution until the stable single 
clone were obtained. As tested by indirect ELISA assay, two single clones gave high 
positive reactivity to YKL-39 protein were obtained. These clones were referred to as 
8H3 and 6H11. The 8H3 monoclone was originated from the well of plate no. 8, row 
H, column 3 of the fusion step. For the 6H11clone, 94% of the wells from 192 wells 
in 1st limiting dilution showed strong reactivity with YKL-39 by indirect ELISA 
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screening. To confirm that these two clones were not the same, a 2nd limiting dilution 
was carried out. It was found that most positive wells still reacted strongly with  
YKL-39, indicating that 6H11 was originally derived from the same clone in the 
fusion experiment, prior to cloning by limiting dilution. Finally, they were further 
expanded, purified and characterized as described in the next section. Figure 3.2.6 
represented the summarization of the anti-YKL39 mAb production. 
 
 
Figure 3.2.7  Summarization of the anti-YKL39 mAb production. 
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3.2.2.3  Determination of monoclonal antibody isotyping 
The specific isotype of monoclones 6H11 and 8H3 was 
determined by captured ELISA technique using IsoQuick_Kits for Mouse 
Monoclonal Isotyping (Sigma-Aldrich) as described in Section 2.8.5. As shown in 
Figure 3.2.7, the isotype mapping identified two hybridoma clones, 6H11 and 8H3, to 
be IgM isotype. Because the 6H11 clone exhibited greater immunoactivity, this clone 
was selected for further purification and characterization. 
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Figure 3.2.8  Determination of the isotype of the generated mAb of clones 6H11 and 
8H3 clone by capture ELISA. 
The culture supernatant was added into each well of a 96-well plate with isotype 
antibodies (goat anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA), and antigen-
antibody reaction was visualized by use of HRP-conjugated anti-mouse 
immunoglobulin and TMB was used as substrate. Absorbance was read at 450 nm. 
For conjugate reaction, the culture supernatant of a single clone is absent. 
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3.2.2.4  Large scale production of anti-YKL39 monoclonal antibody  
The 6H11 monoclone was expanded in scale up. The reactivity of 
the stable 6H11 cell line was determined by indirect ELISA. The anti-YKL39 mAb-
containing culture supernatant was collected, and then the titer of mAb was 
determined by indirect ELISA. Figure 3.2.11 shows the titer of anti-YKL-39 mAb 
from culture supernatant of the 6H11 hybridoma cell line. The mAb from culture 
supernatant strongly reacted with YKL-39 by giving A450 signal of more than 1.0 unit 
above A450 of the conjugate control. These results showed that crude anti-YKL39 
medium strongly reacted with the purified YKL-39 protein. 
 
 
Figure 3.2.9  Determination of anti-YKL39 mAb titer of the 6H11 hybridoma cell 
line by indirect ELISA.  
A 96-well plate was coated with 10 µg/mL YKL-39 and 10-fold serial dilutions of     
anti-YKL39 mAb-containing culture supernatant ranging from 1 to 1x10-5 were added 
in to the wells in triplicate. HRP-conjugated rabbit anti-mouse Igs antibody was used 
to detect protein-antibody complex and the absorbance measured at 450 nm with 
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TMB as substrate. Protein-antibody binding curve were evaluated by a nonlinear 
regression function available in Prism version 5.0 (GraphPad Software) fit to the 
single-site binding model. 
 
3.2.2.5  Purification of anti-YKL39 mAb 
The antibody-containing culture media were collected and 
checked for reactivity by indirect ELISA, as described in Section 3.2.2.4. Crude anti-
YKL39 mAb was purified with a HiTrap IgM HP column (GE HealthCare) connected 
to an ÄKTA purifier system. The culture medium containing mAb was applied on a 
Hitrap IgM column, and unbound medium were washed with binding buffer, while 
bound IgM antibodies were eluted with elution buffer (20 mM sodium phosphate, pH 
7.5). The purity of the mAb against YKL-39 was verified by SDS-PAGE. Figure 
3.2.10 presents an elution profile of the purification, which showed a large peak in 
unbound fraction. Heavy and light chains of the antibody showed two bands 
migrating to approximately 92 kDa and 25 kDa. These protein bands corresponded to 
the molecular mass of IgM isotype that was seen in both unbound and eluted fractions 
as shown in Figure 3.2.11A. For Figure 3.2.11B, each purified fraction was also 
analyzed on a 8% PAGE gel under both reducing and non-reducing conditions. Under 
non-reducing condition, both unbound and eluted fractions were observed to contain a 
band on the top of the gel which corresponded to the high molecular weight of IgM, 
which consists of five subunit of approximately 180 kDa each (MW approximately 
900 kDa). These results indicated that most of the monoclonal IgM did not bind to the 
column. However, it was found that there was no detectable contaminant in the eluted 
antibody, indicating that the mAb was successfully purified. 
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Figure 3.2.10  An elution profile of anti-YKL39 mAb purified by affinity 
chromatography on a HiTrap IgM HP column. 
Crude supernatant containing anti-YKL39 mAb was adjusted to high salt 
concentration, in order to improve the binding ability. The sample was loaded onto a 
1-mL Hitrap IgM column. Unbound samples were washed with binding buffer, while 
bound IgM antibodies were eluted with 20 mM sodium phosphate, pH 7.5. The purity 
of the purified mAb against YKL-39 was verified by SDS-PAGE. 
 
 
 
Figure 3.2.11 SDS-PAGE analysis of the purification of anti-YKL39 mAb using a 
HiTrap IgM HP column. 
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(A) 12% SDS-PAGE electrophoresis of purified anti-YKL39 mAb under reducing 
conditions: Lane M, molecular weight protein marker. Lane 1, unbound fraction. 
Lanes 2, eluted fraction. Lane 3, washed fraction with binding buffer. Lanes 4-5, the 
eluted fraction of IgG with elution buffer (0.1 M glycine, pH 2.5). (B) 8% PAGE of 
the eluted fractions: Lane M, molecular weight protein marker. Lane 1, unbound 
fraction. Lane 2, eluted fraction. Lane 3, washed fraction, while lanes 4-5, unbound 
and eluted fractions under non-reducing condition.   
 
3.2.2.6  Characterization of anti-YKL39 monoclonal antibodies  
To ensure the ability of anti-YKL39 mAb, the characterization of 
anti-YKL39 monoclonal antibody was characterized for specificity, sensitivity, and 
the ability of the monoclonal antibodies to bind to native human YKL-39 from 
various human cell lines.  
  
 3.2.2.6.1  Determination for specificity and sensitivity of       
anti-YKL39 mAb 
  To assess the specificity of the newly raised mAb against 
various GH-18 homologs, including YKL-40, acidic mammalian chitinase (AMCase) 
and bacterial chitinase, western blotting was carried out as described in polyclonal 
antibody production. As shown in Figure 3.2.12A, the antibody recognized both fused 
(Lanes 2 and 3) and bare (Lane 4) forms of human YKL-39, but did not recognize 
YKL-40 (Lane 5), AMCase (Lane 6), and bacterial chitinase (Lane 7). The antibody 
also did not cross-react with proteins in human serum (Lane 8). The results suggested 
that the mAb was highly specific for YKL-39. The sensitivity of generated anti-
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YKL39 mAb was also examined by western blot analysis. Two-fold serial dilution of 
anti-YKL39 antibody was used ranging from 0.65-10 µg and YKL-39 was fixed at 2.5 
µg. As seen in Figure 3.2.12B, the strongest titer was seen at a ratio of 10:5 (µg/µg) of 
mAb:Ag, while the slightest titer of the antibody that recognized the YKL-39 Ag was 
2.5:5(µg/µg). 
 
 
 
Figure 3.2.12  Cross-reactivity of anti-YKL39 mAb. 
(A) Chitinases and chitinase-like proteins were analyzed by SDS-PAGE (left panel) 
in comparison with Western blot analysis (right panel). Lane M, protein molecular 
weight marker; Lane 1, cell lysate of uninduced E. coli BL21(DE3) host containing 
pET32a(+)/YKL-39; Lane 2, cell lysate of the cells induced with IPTG; Lane 3, 
elution of Trx-His6/YKL-39 fusion protein from the first Ni-NTA affinity column; 
Lane 4, purified YKL-39 after anion exchange chromatography, followed by 
thioredoxin removal, and further purified by the second Ni-NTA affinity column; 
Lane 5, YKL-40; Lane 6, AMCase; Lane 7, bacterial V. harveyi chitinase A; Lane 8, 
human serum. (B) Sensitivity of purified anti-YKL39 mAb for YKL-39 protein was 
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analyzed by Western blot analysis. Two-fold serial dilution of the amount of anti-
YKL39 antibody was used ranging from 0.65-10 µg and YKL-39 were fixed at 2.5 
µg. Lane 1, 10 µg of anti-YKL39 mAb: Lane 2, 3, 4, and 5 are 5, 2.5, 1.25 and 0.62 
µg of anti-YKL39 mAb, respectively. 
 
3.2.2.6.2  Determination for reactivity of anti-YKL39 mAb 
against native YKL-39 in human cell lines and osteoarthritis sample  
The ability of the monoclonal antibodies to bind to the 
native human YKL-39 form in various human cell lines, including Jurkat, U937, Hela, 
COS-7, and THP-1 and synovial fluid of osteoarthritic patients was also determined 
by immunoblotting. Purified YKL-39 or whole cell lysate prepared from various cell 
lines was spotted onto a nitrocellulose (NC) membrane, followed by incubation with 
the mAb from clone 6H11. The signals were detected by enhanced 
chemiluminescence using rabbit anti-mouse IgG antibody conjugated with 
horseradish peroxidase at 1:5000 dilution. Figure 3.2.13A (SDS-PAGE) and 3.2.13B 
(immunoblot) show that anti-YKL39 mAb reacted strongly with a protein band in the 
whole cell lysate of Jurkat cells (Lane 2). This protein migrated to the same position 
of recombinant YKL-39 (Lane 1) on SDS-PAGE. Jurkat cells have been reported 
previously to express SI-CLP, but not other CLPs (Kzhyshkowska et al., 2007). 
However, Santa Cruz Biotechnology (Santa Cruz, CA) used the whole cell lysate of 
Jurkat cells to determine the specificity of their commercially available anti-YKL-39 
polyclonal antibody (H-80) (Santa Cruz Biotechnology Inc.). Figure 3.2.13C is a dot 
blot assay showing strong cross-reactivity of anti-YKL39 mAb with YKL-39, the 
synovial fluid of a volunteer with osteoarthritis, and the whole cell lysate of U937 
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cells. However, the mAb did not recognize all proteins in the whole cell lysates of 
Hela cells, COS-7 cells, and THP-1 cells. The negative control, in which IgG 
secondary antibody was added in the absence anti-YKL39 mAb, did not produce a 
positive signal.  
 
 
 
Figure 3.2.13  Detection of YKL-39 expression using anti-YKL39 mAb in human 
cell line and synovial fluid of osteoarthritic patients by dot blot analysis.  
(A) SDS-PAGE analysis. (B) Western blot analysis. Lane 1, YKL-39; Lane 2, whole 
cell lysate of Jurkat cells. (C) Dot blot analysis showing antigen-antibody interactions 
with human sample or human cell lines. Purified YKL-39 or whole cell lysate was 
spotted onto nitrocellulose membrane, and then the membrane was allowed to dry. 
After blocking with 5% (w/v) skim milk, the membrane was incubated for 1 h with 
6H11 mAb. The signals were detected by enhanced chemiluminescence using rabbit 
anti-mouse IgG antibody conjugated with horseradish peroxidase at 1:5000 dilution. 
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3.3  Determination of crystal structures of YKL-39 
This section described determination of crystal structures of YKL-39 in the 
absence and presence chitooligosaccharide and details of sugar-protein interactions 
from data obtained from protein crystallization.   
 
3.3.1  Crystallization of human YKL-39 
3.3.1.1  Initial screening of crystallization of YKL-39 
Initial crystallization experiments were firstly performed 
manually by the microbatch under oil method (Chayen et al., 1992). Equal volumes of 
protein and mother liquor were mixed under oil. After monitoring crystal growth for 
two months, YKL-39 crystals were not yet observed. The crystallized drops were 
mostly observed as clear drops and precipitates.   
To solve the crystallization problem, the appropriate protein concentration for 
crystallization screening was firstly determined with the Pre-Crystallization Test 
(PCT ™, Hampton), using hanging drop vapor diffusion technique as described in 
Section 2.9.1.1. After incubation for 30 min, the reaction drops were carefully 
examined under a stereo microscope. The results revealed that the appropriate protein 
concentration for crystallization screening, which generated microcrystalline or light 
granular precipitate throughout the drop, was 12.75 mg/mL. So this protein 
concentration was chosen for further studies. Subsequently, initial crystallization of 
YKL-39 was performed by sitting drop vapor diffusion technique. After mixing equal 
volumes of each precipitating agent and YKL-39 solution, the crystal growth was 
monitored. The crystals with various sizes and needle clusters were observed under 
different conditions in the crystallization trials at both 15°C and 25°C. As listed in 
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Table 3.3.1, the YKL-39 crystals were obtained under conditions, including 25% 
(w/v) PEG 3350, 0.2 M Li2SO4, 0.1 M Bis Tris, pH 5.5, at 25°C on day 21 (Figure 
3.3.1A); 30% (w/v) PEG 1500 at 15°C on day 5 (Figure 3.3.1B) and 20% (w/v) PEG 
3000, 0.1 M citrate, pH 5.5 at 15°C on day 14 (Figure 3.3.1C). In addition, needle 
clusters were also observed under the condition containing 10% (w/v) PEG 8000, 0.2 
M Ca(OAc)2, 0.1 imidazole, pH 8.0, at 15°C on day 30 (Figure 3.3.1D). The 
precipitant, which was found to be appropriate for further crystallization of this 
protein, was PEG in a wide range of the molecular weights from 1,500 to 8,000. 
YKL-39 crystallization was successful under the mono-valent salt, Li2SO4, and di-
valent salts, Ca(OAc)2, while the buffers were Bis Tris, citrate and imidazole at pH 
5.5 and 8.0.  
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Figure 3.3.1  Crystals and needle clusters of ligand-free YKL-39 from initial 
screenings using sitting drop technique.  
The conditions included (A) 25% (w/v) PEG 3350, 0.2 M Li2SO4, 0.1 M Bis Tris, pH 
5.5 at 25°C; (B) 30% (w/v) PEG 1500 at 15°C; (C) 20% (w/v) PEG 3000, 0.1 M 
Citrate, pH 5.5 at 15°C; and (D) 10% (w/v) PEG 8000, 0.2 M Ca(OAc)2, 0.1 M 
imidazole, pH 8.0 at 15°C. 
 
 
 
 
 
 
 
 
 
 
Table 3.3.1  Crystallization conditions of ligand-freeYKL-39 from screening kits that yielded small crystals and needle clusters in  
sitting drop technique. 
Condition no. Precipitant Salt Buffer Temperature 
(ºC) 
Days of 
observation 
Crystal 
morphology 
H9 
(JCSG-plus HT96) 
25% (w/v) PEG 3350 0.2 M Li2SO4 0.1 M Bis Tris, 
pH 5.5 
25 21 Crystals 
D7 
(HR2-130) 
30% (w/v) PEG 1500 - - 15 5 Small crystals 
No. 6 
(Wizard I) 
20% (w/v) PEG 3000 - 0.1 M citrate, 
pH 5.5 
15 14 Crystals 
No. 46 
(Wizard I) 
10% (w/v) PEG 8000 0.2 M Ca(OAc)2 0.1 imidazole, 
pH 8.0 
15 30 Needle clusters 
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3.3.1.2  Optimization of YKL-39 crystallization 
 From all the positive screening conditions, the condition H9 from 
JCSG-plus HT96 gave the good quality hexagonal crystals under condition 25% (w/v) 
PEG 3350, 0.2 M Li2SO4, 0.1 M Bis Tris, pH 5.5. Thus, it was then selected for 
further optimization by the hanging drop method. The concentrations of PEG 3350 
were varied in range of 21-31% (w/v) and lithium sulfate was varied ranging in 0.1-
0.4 M in two dimension grid screening as shown in Figure 3.3.2. The high quality 
crystals of ligand-free YKL-39 were observed within one days at 25°C in the 
condition 27% (w/v) PEG 3350, 0.2 M lithium sulfate in 0.1 M Bis Tris, pH 8.0 and 
another condition of 31% (w/v) PEG 3350, 0.3 M lithium sulfate in 0.1 M Bis Tris, 
pH 8.0, while the condition of 29 and 31% (w/v) PEG 3350, 0.2 M lithium sulfate in 
0.1 M Bis Tris, pH 8.0 generated single crystals, but smaller sizes with the cracked 
surface as shown in Figure 3.3.3. These crystals were used to perform preliminary   
X-ray diffraction by an in-house X-ray diffraction system. All crystals were 
diffracted, and gave diffraction patterns similar to a protein diffraction pattern (the 
data are not shown). However, they diffracted to low resolution at about 3.0-6.0 Å, 
which is not enough for collection and processing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2  Grid screen with variation of % PEG 3350 and lithium sulfate. 
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Figure 3.3.3  Photographs of YKL-39 crystals obtained from the crystal optimization 
using a variation of PEG 3350 and lithium sulfate concentrations.  
The positive conditions, which yielded the crystals of YKL-39, are:  
(A) 27% PEG 3350, 0.2 M Li2SO4 in 0.1 M Bis Tris, pH 8.0 
(B) 29% PEG 3350, 0.2 M Li2SO4 in 0.1 M Bis Tris, pH 8.0  
(C) 31% PEG 3350, 0.2 M Li2SO4 in 0.1 M Bis Tris, pH 8.0  
(D) 31% PEG 3350, 0.3 M Li2SO4 in 0.1 M Bis Tris, pH 8.0  
 
Subsequently, a refined grid screening optimization was performed by 
increasing concentrations of PEG 3350 from 27 to 37% (w/v) and lithium sulfate from 
0.20 to 0.35 M, as shown in Figure 3.3.4. Big sizes of single crystals were observed 
within one day under the conditions: 27% PEG 3350, 0.2 M Li2SO4 in 0.1 M Bis Tris, 
pH 8.0, and 31% PEG 3350, 0.3 M Li2SO4 in 0.1 M Bis Tris, pH 8.0, (Figure 3.3.5). 
Under these two conditions, the fully-grown crystals were observed within seven days 
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after their first appearance. Thus, these conditions were chosen for crystallization of 
the ligand-free YKL-39 and for soaking with chitooligosaccharides in order to study 
protein-ligand binding. Many small crystals with cracked surface were observed 
under other conditions with highly percentages of PEG as seen in Figure 3.3.4.  The 
result indicated that high concentrations of precipitant resulted in a decrease in crystal 
size.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4  The refined grid screen with a variation of lithium sulfate and PEG 3350. 
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Figure 3.3.5  The positive conditions that gave large crystals within 1 day are: 
(A) 27% PEG 3350, 0.2 M Li2SO4 in 0.1 M Bis Tris, pH 8.0 
(B)  31% PEG 3350, 0.3 M Li2SO4 in 0.1 M Bis Tris, pH 8.0  
 
3.3.1.3  Crystallizations of YKL-39 in complex with 
chitooligosaccharides 
The suitable conditions for crystallization of ligand-free YKL-39 
were used to produce high quality diffraction crystals as described in Section 3.3.2. 
Single crystals were allowed to fully grow for a week, and then soaked with various 
chains of chitin oligosaccharides, including GlcNAc2 to GlcNac6. The concentration 
of ligands was also optimized. It was found that the chitinsugar concentrations, which 
gave the X-ray quality crystals without being cracked or damaged, were 0.1 M 
GlcNAc5 and GlcNAc6, 5 M GlcNAc4, 10 M GlcNAc3 and GlcNAc2.  
 
3.3.2  X-ray diffraction analysis of ligand-free YKL-39 and its complex 
crystals.  
     Four X-ray data sets of ligand-free YKL-39 and its complexes with 
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GlcNAc2, GlcNAc4 and GlcNAc6 crystals were successfully collected. They were 
diffracted at 100 K in a nitrogen stream from an Oxford Cryosystems Cryo-stream 
and data collected on an ADSC Quantum 315 CCD detector with the wavelength 
at 1.00 Å.  All the diffraction data were indexed, integrated and scaled with the 
HKL-2000 program (Otwinowski and Minor, 1997). The ligand-free YKL-39 and 
YKL-39 soaked with GlcNAc2, GlcNAc4 and GlcNAc6 crystals diffracted X-ray to 
2.40 Å, 1.53 Å, 1.87 Å and 2.48 Å resolutions, respectively. 
 
Figure 3.3.6  Diffraction images of ligand-free YKL-39 and YKL-39 complexed 
with GlcNAc2.  
The ligand-free YKL-39 (A) and YKL-39 complexed with GlcNAc2 (B), crystals 
diffracted to 2.40 and 1.53 Å resolutions, respectively. 
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Table 3.3.2  Statistics of X-ray diffraction data collection of YKL-39.  
 
 
 
YKL-39 YKL39/ 
GlcNAc2 
YKL39/ 
GlcNAc4 
YKL39/ 
GlcNAc6 
Data collection statistics     
Beamline BL13B1 BL13B1 BL13B1 BL13B1 
Wavelength (Å) 1.00 1.00 1.00 1.00 
Space group P41212 P41212 P41212 P41212 
Unit-cell parameter (Å) a = 71.62 a = 70.68 a = 71.35 a = 71.21 
 b = 71.62 b = 70.68 b = 71.35 b = 71.21 
 c = 140.66 c = 140.26 c = 140.53 c = 141.02 
Resolution range (Å) 26.27- 2.40 19.61 -1.53 19.8 - 1.87 24.5 - 2.48 
Resolution outer shell (Å) 2.44 - 2.40 1.56 -1.53 1.97 - 1.90 2.54 - 2.50 
No. unique reflections 11748 50934 26230 12681 
No. observed reflections 181110 617279 225642 90749 
Completeness (%) 99.9 (100.0) 99.3 (99.3) 99.0 (87.8) 99.6 (94.6) 
Average redundancy per 
shell 
15.3 (15.8) 11.5 (8.6) 7.4 (5.8) 6.8 (5.3) 
I/σ(I) 101.0 (6.4) 26.3 (2.8) 45.1 (2.8) 11.0 (3.1) 
R(merge) (%) 3.0 (46.9) 7.5 (75.3) 4.3 (45.5) 15.2 (34.7) 
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3.3.3  Phase determination by molecular replacement  
The first data set belonging to YKL-39/GlcNAc2 complex that was 
processed to 1.53 Å was solved by the molecular replacement with MOLREP (Vagin 
and Teplyakov, 1997, 2010) using the known structure of YKL-39 in complex with 
GlcNAc6 (PDB access number 4AY1) as a model (Schimpl et al., 2012). The rotation, 
translation and subsequent fitting functions were performed by the same software. In 
the final fitting solution was performed in the P41212 space group, and gave an R-
factor of 47.25%. 
 
3.3.4  Refinements and Structural determination of YKL-39 structures  
3.3.4.1  The model quality of the YKL-39 structures 
 The other data sets of ligand-free YKL-39 and in complex   
YKL-39/GlcNAc4 and YKL-39/GlcNAc6 crystals were solved by using the final 
model structure of complex YKL-39/GlcNAc2 as the starting model.  The analysis of 
the Fo - Fc and 2Fo - Fc electron density map and model building was carried out in the 
COOT program (Emsley and Cowtan, 2004), restrained refinement in REFMAC5 
from the CCP4 suite ("Collaborative Computing Project Number 4", 1994), and 
Phenix (Adams et al., 2002; Afonine et al., 2010). The geometry of each final model 
was validated by PROCHECK (Laskowski et al., 1993). All four diffraction data sets 
were determined to have tetragonal P412121 space group symmetry with similar unit 
cell parameters, as summarized in the Table 3.3.2. All data sets were collected to 
99.3-99.9% completeness over in the resolution range of 2.48-1.53 Å. These crystals 
contained one monomer per asymmetric unit, which corresponded to the same 
Matthew’s coefficient (VM) of 2.2 Å3/Da. A solvent content was calculated to be 
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42.5% to 43.0%.  The final model of the YKL-39/GlcNAc2 complex, which was used 
as a model of the other data sets, was refined at 1.53 Å resolution with an Rfactor of 
17.4%, Rfree of 20.7% with the R.M.S. deviations of bond length of 0.010 Å and bond 
angle of 1.48°. The 2,952 protein atoms (365 amino acid residues for one molecule in 
the asymmetric unit) exhibited a good fit with the electron density map with an 
average B-factor of 12.35 Å2. The final 2Fo-Fc  map, contoured at 1.0 σ, showed a 
clear electron density map for GlcNAc2 (29 ligand atoms) in subsites -2 to -1, with an 
average B-factor of 14.61 Å2, while the 780 water molecules were refined with an 
average B-factor of 36.10 Å2. In a good agreement with data, no residue was found in 
the outlier regions of the Ramachandran plots as summarized in Table 3.3.3. The 
ligand-free YKL-39 structure was refined at 2.40 Å resolution to an Rfactor of 21.6% 
and Rfree of 24.3% for 2,894 protein atoms (365 amino acid residues for a molecules 
in the asymmetric unit) and 168 water molecules with an average B-factor of 66.6 Å2 
and 79.4 Å2, respectively. The final model of the YKL-39/GlcNAc4 complex was 
refined to 1.87 Å with an Rfactor of 18.6%, and an Rfree of 23.6% with the R.M.S. 
deviations of bond length of 0.010 Å and bond angle of 1.37°. The 2,919 protein 
atoms (364 amino acid residues) showed good fit with the electron density map with 
an average B-factor of 23.7 Å2. The final 2Fo - Fc  map, contoured at 1.0 σ, shows an 
electron density map for GlcNAc4 (57 ligand atoms) covering subsites -3 to +1 with 
an average B-factor of 31.46 Å2, while 428 water molecules were refined with an 
average B-factor of 39.04 Å2. The crystal structure of the YKL-39/GlcNAc6 complex 
was refined at 2.48 Å with an Rfactor of 18.7% and Rfree of 23.5% with the R.M.S. 
deviations of bond length of 0.008 Å and bond angle of 1.28°. The 2,894 protein 
atoms (365 amino acid residues) exhibited a good fit with the electron density map 
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(an average B-factor of 48.6 Å2). The final 2Fo - Fc map, contoured at 1.0 σ, showed 
clearly electron density map for GlcNAc6, which appeared to cover subsites -3 to +3. 
The average B-factor was found to be of 53.1 Å2 (85 ligand atoms), while 263 water 
molecules were refined with an average B-factor of 49.8 Å2. In summary, the fitted 
model was in a good agreement with the calculated model, with no residue in the 
outlier regions of the Ramachandran plots, as shown in Table 3.3.3. Atomic 
coordinates and structure factors of the final models of YKL-39 have been deposited 
in the Protein Data Bank with PDB accession numbers: 4P8U for apo YKL-39, 4P8V 
for the YKL-39/GlcNAc2 complex, 4P8W for the YKL-39/GlcNAc4 complex, and 
4P8X for the YKL-39/GlcNAc6 complex. 
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Table 3.3.3 Statistics of structural refinement. 
 YKL-39 YKL39/ 
GlcNAc2 
YKL39/ 
GlcNAc4 
YKL39/ 
GlcNAc6 
PDB access code 4P8U 4P8V 4P8W 4P8X 
Refinement statistics     
Resolution range (Å) 26.27-2.40 19.61-1.53 19.8- 1.87 24.5-2.48 
aRfactor (%)           21.6   17.4   18.6  18.7 
bRfree (%) 24.3 20.7 23.6 23.5 
No. of residue in protein 365 365 364 365 
No. protein atoms 2896 2952 2919 2894 
No. ligand atoms  - 29 57 85 
No. waters 168 780 428 263 
Mean B-factor     
Protein 66.64 16.35 23.72 48.55 
Ligand  - 14.61 28.81 53.11 
Water 79.45 36.10 34.63 49.85 
R.M.S. deviations     
Bond length 0.013 0.010 0.010 0.008 
Bond angle 1.39 1.48 1.37 1.28 
Ramanchandan plot     
Residue in favoured region (%) 96.1 98.6 97.8 97.8 
Residue in allowed region (%) 3.9 1.4 2.2 2.2 
Residue in outlier (%) 0.0 0.0 0.0 0.0 
Numbers in parentheses are outer shell parameters. 
aRfactor = (Σ|Fobs|−|Fcal|/Σ|Fobs|). 
bBased on 5% of the data. 
cCalulated with PROCHECK (version 1.00.0) 
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3.3.4.2  The overall structure of YKL-39 in the presence and absence 
chitin fragments 
The overall structure of YKL-39 contains two conserved domains 
(Figure 3.3.7A) that are found in all GH-18 chitinases and chitinase-like proteins. The 
major (β/α)8 TIM barrel domain (Domain I) comprises eight parallel strands B1-B8 
(purple), which run in alternation with eight helices A1-A8 (cyan) as shown in Figure 
3.3.7B. It is noticeable that helices A1, A3, and A6 are broken and contain short 
helices: G1-1 in helix A1, G3-1 and G3-2 in helix A3, and G6-1 and G6-2 in helix 
A6. The TIM barrel domains of GH-18 glycosyl hydrolases are known to interact 
specifically with chitin oligosaccharides (Aalten et al., 2001, Fusetti et al., 2002, 
Fusetti et al., 2003, Meng et al., 2010, Songsiriritthigul et al., 2008, and Schimpl et 
al., 2012,). The second domain is termed the small α+β insertion domain (Domain II) 
(Figure 3.3.7A). This domain is inserted between the tail of strand B7 and the start of 
helix A7. It is made up of six anti-parallel strands connected by a short helix that 
forms a typical Greek key motif. The exact function of this domain is unknown, but 
certain amino acid residues in this domain help to stabilize the sugar-protein complex. 
The substituted catalytic residue Glu145 to Ile and Asp143 to Ser in the loop of strand 
β4, which is part of a DxxDxDxE conserved sequence motif, makes it lack chitinase 
hydrolytic activity. In contrast to this subfamily, YKL-39 is without a chitin binding 
domain. Detailed structural analysis revealed that YKL-39 contains two disulfide 
bonds, the first bond links Cys31 and Cys56 that are located within the TIM barrel 
domain. The second bond forms between Cys308 of the TIM barrel domain and 
Cys372 of the small insertion domain. Both bonds help maintain the structural 
integrity of the protein. In addition, six cis peptide bonds are observed, including 
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Glu42-Pro43, Ser62-Phe63, His112-Pro113, Ile145-Tyr146, Lys220-Pro221, and 
Trp360-Ser361, two of which (Ile145-Tyr146 and Trp360-Ser361) directly participate 
in ligand binding. The structures of YKL-39 in the presence of chitin fragments detail 
the binding surface of the TIM barrel domain, consisting a long, deep groove with 
approximate dimensions of 35 Å (long) x 17 Å (wide) x 7 Å (deep). This groove has 
been reported to interact with chitin fragments in other GH-18 homologues (Fusetti et 
al., 2003; Fusetti et al., 2002; Meng et al., 2010; Songsiriritthigul et al., 2008; van 
Aalten et al., 2001).. The shape of this groove is a crevice in which both ends are 
open, permitting chitooligosaccharides of different sizes to be accommodated and 
extended out from the groove in either direction. The narrowest part of the crevice 
points towards the center of the TIM barrel domain, a feature that favors a bent sugar 
chain.   
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Figure 3.3.7  The overall structure of YKL-39. 
(A) The cartoon model of YKL-39 in complex with GlcNAc6. The chitin-binding cleft 
is located on the surface of the (β/α)8 TIM-barrel domain (domain I), which is 
presented in cyan for helices and purple for strands, while the α+β insertion domain 
(domain II) flanked by the strand B7 and the helix A7 is shown in gray. The 
chitooligosaccharide GlcNAc6 is shown as ball and sticks and colored by atoms with 
yellow for carbons, blue for nitrogen, and red for oxygen atoms. RE and NRE denote 
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the “reducing” and “non-reducing” ends of the sugar chain. (B) Structural topology of 
YKL-39. The eight strands are designated as B1 to B8, loops as L, and eight α-helices 
connected between β-strands as A1 to A8. The helices are often segmented. Short 
helices are referred to by the letter G, for instance, G1-1 indicates the short helix 
within the region of the A1 helix. 
 
 The structures of YKL-39 in the presence of GlcNAc2, GlcNAc4, and GlcNAc6 
were successfully determined. The overall structures of YKL-39 in the presence chitin 
fragment were considered. The longest chitin fragment, GlcNAc6, complex was found 
within the long deep groove through the central of protein molecule covering subsites     
(-3)(-2)(-1)(+1)(+2)(+3) as seen in Figure 3.3.8. From the subsite definition as 
assigned by Davies and Henrissat (1995), the non-reducing end is designated as 
subsite -3, followed by the subsites located towards the reducing end are designated as 
subsites -2, -1, +1, +2 and +3, respectively. The binding site was lined with a few 
invariant aromatic acid residues. Three of them, Trp36, Trp360 and Trp218 were 
found in suitable positions to form stacking interactions with the bound chitin 
fragment. A conserved residue, Asp213, which was observed in GH-18 chitinases and 
CLPs, was in the position to form H-bond with the subsite -1GlcNAc (Figure 3.3.8A). 
Figure 3.3.8B represents the electrostatic analysis, which revealed the surface of 
binding cleft of YKL-39. A negatively charged region was observed in the deep, 
central part of binding sites. 
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Figure 3.3.8  Electrostatic surface of YKL-39 in complex with GlcNAc6. 
(A) The important amino acids interacting with GlcNAc6 by hydrophobic interaction 
are shown in blue and H-bonds in red. The sugar chain is represented as sticks, carbon 
in yellow, oxygen in red and nitrogen in blue. (B) Electrostatic surface representation 
of YKL-39 in complex with GlcNAc6. The positively charged regions are shown in 
blue, the neutral regions in white, and the negatively charged regions in red. The 
figures were created by Pymol (DeLano, 2002). 
 
3.3.4.3  Chitooligosaccharide binding induces structural movements  
Superimposition of the apo YKL-39 structure with structures in 
complex with GlcNAc2, GlcNAc4, and GlcNAc6 gives Cα RMSDs for 326 residues of 
0.46, 0.38, and 0.39 Å, respectively, as shown in Table 3.3.4.  These values reflect 
some structural non-identity and that may be induced upon sugar binding. Figure 
3.3.9A presents the (β/α)8 TIM barrel domains of the ligand-free YKL-39 and the 
sugar-bound YKL-39, showing the small structural differences that were observed in 
the loop regions surrounding the surface of the chitin binding cleft. Close inspection 
of the GlcNAc-binding subsites of the apo protein (Figure 3.3.9A, blue) in 
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comparison with that of the protein in complex with the longest chitooligosaccharide 
GlcNAc6 (Figure 3.3.9, cyan) reveals considerable movements of loop L1 on the 
surface of subsite -3, loops L3 and LM’ (see Figure 3.3.7B for loop assignment) near 
subsites -2 and -1, and L6 near subsites +2 and +3 in the structure with GlcNAc6. As 
compared to the exterior of the native protein (Figure 3.3.9B), four key residues: 
Tyr104 and Leu105 (part of the bottom loop L3), and Met364 and Phe301 (part of the 
top loop LM’) were found to shift significantly towards the center of the chitin-binding 
cleft. This narrows the cleft of the sugar bound protein around subsites -2/-1 by 1.3 Å 
(Figure 3.3.9C).  Such local movements engender close contacts between the GlcNAc 
rings and the binding residues around the corresponding subsites. In contrast, Tyr243 
(part of loop L6) rotates away from its original position, making the cleft at this 
particular subsite (+3) to widen by 1.9 Å in comparison to that of the non-ligand-
bound structure (Figure 3.3.9D). This orientation of Tyr243 increases the access to 
subsite +2 from the subsite +3 direction, suggesting that longer sugars may be 
accommodated in this conformation. Taken together, these structural differences 
provide evidence that the binding of chitooligosaccharides induces local structural 
changes that help strengthen the interactions between the YKL-39 and the 
chitosugars.  
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
Table 3.3.4 Root-mean-square deviations between the structures of ligand-free   
YKL-39 and YKL-39 in complex with chitooligosaccharides. 
 
The complex crystal structures RMSD The number of Cα 
YKL-39/GlcNAc2 0.46 327 
YKL-39/GlcNAc4 0.38 321 
YKL-39/GlcNAc6 0.39 334 
 
 
Figure 3.3.9  Structural comparison of the YKL-39 structures in the absence and 
presence of GlcNAc6.  
(A) The structure of ligand-free YKL-39 (royal blue) was superimposed with the 
structure of YKL-39 in complex with GlcNAc6 (cyan and grey). (B) A close up of the 
GlcNAc6 binding pocket from (A). The binding residues around the chitin binding 
cleft that have different conformations in the two structures are included (Leu105, 
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Tyr104, Met364, Tyr243 and Phe30), which are displayed as sticks. (C) Surface 
representation of the sugar-binding groove of the apo form of YKL-39. (D) Surface 
representation of the sugar binding groove of the YKL-39/GlcNAc6 complex, 
showing local changes causing the closure of the surface area around subsites -2 and -
1, and the widening of the area beyond subsite +2 as compared to the binding groove 
of the apo protein. 
 
3.3.4.4  Specific interactions of YKL-39 with chitooligosaccharides 
  Like all GH-18 members, the sugar binding cleft of YKL-39 
comprises multiple subsites for GlcNAc units. The critical binding features of these 
subsites are aromatic residues, which interact with the GlcNAc rings mainly through 
hydrophobic interactions, and charged or polar side chain residues, which form 
hydrogen bonding interactions with the saccharide chain. Inspection of the substrate 
binding cleft of YKL-39 in apo form (Figure 3.3.10A) and YKL-39 in complexes 
with GlcNAc2 (Figure 3.3.10B), GlcNAc4 (Figure 3.3.10C), and GlcNAc6 (Figure 
3.3.10D) reveals the binding behaviors of individual chitooligosaccharides. GlcNAc2 
was found at the center of the binding cleft between subsites -2 and -1 (Figure 
3.3.10B). As summarized in Table 3.3.5 (H-bonding interaction) and Table 3.3.6 
(binding residues), subsites -2 and -1 comprise a large number of binding residues. 
Residues Phe63, Leu105, Phe301, Trp360, Met364 interact with the GlcNAc ring at 
subsite -2, while  Tyr32, Ser143, Tyr104, Ile145, Asp213, Tyr269, and Trp360 are 
found at subsite -1. The contacts around the center of the binding cleft make highly 
ordered interactions, which suggest that an arriving chitin chain would initially and 
preferentially interact at the center of the binding groove. For a longer chain 
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chitooligosaccharide, the interaction may become extended through occupation of the 
neighboring weaker-affinity subsites, where the four sugar rings GlcNAc4 were 
extended from subsites -3 to +1 (Figure 3.3.10C), and by the complex with GlcNAc6 
from subsites -3 to +3 (Figure 3.3.10D). This affinity gradient is well supported by 
lowest B-factor for the subsite -2GlcNAc (43.63 Å2), indicating high rigidity due to 
tight interactions at the internal site. Increases in B-factor for bound sugar at the 
extended subsites (-1GlcNAc, 44.76, +1GlcNAc, 44.75, +2GlcNAc, 52.48, 
+3GlcNAc, 81.64, and -3GlcNAc, 64.28 Å2) apparently reveal high flexibility of the 
sugar rings forming weak interactions with the binding residues at such subsites. 
Comparing the three complex structures, they displayed essentially identical. The 
superimposition of all the structures with the ligand gave an RMSD value of 0.12 Å 
for the 325 Cα residues. Taken together, these results demonstrated that only 
GlcNAc2 is sufficient to induce the local conformation change at the binding site. 
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Figure 3.3.10  The residues involved in chitooligosaccharide/YKL-39 binding. 
The residues contributing hydrogen bonding and hydrophobic interactions are 
displayed as sticks. (A) the unliganded form of YKL-39; (B) YKL-39 in complex 
with GlcNAc2; (C) YKL-39 in complex with GlcNAc4; (D) YKL39 in complex with 
GlcNAc6. The sugar residues are shown as sticks and colored by atom, with yellow 
for carbon, blue for nitrogen and red for oxygen. Hydrogen bonds are shown as red 
dashed lines. The 2Fo-Fc is contoured at 1σ.  
 
Hydrophobic interactions between chitohexaose (GlcNAc6) and 
aromatic/hydrophobic residues surroundings subsites -3 to +3 of the YKL-39 binding 
groove are analyzed and shown in Figure 3.3.11A. Three key residues, Trp36 at 
subsite -3, Trp360 at subsite -1, and Trp218 at +2, are found to stack directly against 
the plane of the pyranose rings of the GlcNAc units. These interactions are expected 
to contribute significantly to binding at these subsites. The first two residues (Trp36 
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and Trp360) are completely conserved in other GH-18 homologues and act as key 
binding residues (Fusetti et al., 2003; Fusetti et al., 2002; Meng et al., 2010; 
Songsiriritthigul et al., 2008; van Aalten et al., 2001). The conserved aromatic Trp36, 
located at the edges of the binding cleft, marks the non-reducing end of the long chain 
chitin fragment by stack interaction to the planes of the bound sugar at subsite -
3GlcNAc, while Trp218 marks the reducing end of the chitin sugar, and is in the 
position suitable for binding with the subsite +2GlcNAc. For the subsite +3GlcNAc, 
no hydrophobic interaction was found, since the crucial binding residue equivalent to 
W212, which is seen in the YKL-40 homologues, is missing in YKL-39. It is 
presumed that there is a weak binding at this subsite.  
In spite of lacking chtinase activity in YKL-39, chitooligasaccharides still bind 
to YKL-39 in a fashion similar to that found in chitinase. A long chain sugar, such as 
GlcNAc6 was found in the chitin binding cleft of YKL-39 in a bent conformation, 
where the sugar ring at subsite -1 still adopting a boat conformation like the sugar 
chain in true chitinase (Songsiriritthigul et al., 2008; van Aalten et al., 2001). The 
electron density of YKL-39/GlcNAc6 complex suggested that the sugar units at the 
central subsites are held by a larger number of weak interactions, including salt 
bridges, H-bond, and hydrophobic interactions. Trp360 seem to play a particular role 
in ligand recognition by making hydrogen bonds with the C7-O of the subsite -
2GlcNAc. This residue is conserved in GH-18 chitinases and CLPs (Fusetti et al., 
2003; Fusetti et al., 2002; Meng et al., 2010; Schimpl et al., 2012; Songsiriritthigul et 
al., 2008; van Aalten et al., 2001). The binding of -2GlcNAc was stabilized by a 
hydrogen-bonding network, involving Trp360, and Leu105, while the conserved 
Asp213 and Tyr104 residues formed hydrogen bonds with C6-O and C3-O of the 
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subsite -1GlcNAc, respectively. Figure 3.3.11B displays a number of hydrogen bonds 
that help to stabilize the sugar/protein complexes. Such hydrogen bonds are formed 
either directly between the sugar rings and the binding residues or mediated by water 
molecules. As summarized in Tables 3.3.5 and 3.3.6, high densities of interactions are 
seen at subsites -2, -1, and +1, which are likely to determine the preferential binding 
at these sites.  
 
Figure 3.3.11  Specific interactions within the chitin binding cleft of YKL-39. 
(A) The aromatic residues that are involved hydrophobic interactions with the sugar 
molecule at each subsite. (B) The amino acid residues and water molecules that 
 
 
 
 
 
 
 
 
131 
 
mediate the formation of the hydrogen bonding network. Water molecules are shown 
as blue diamonds and hydrogen bonds are shown as red dashed lines. 
 
Table 3.3.5  A summary of the H-bonding interactions between GlcNAc6 and the 
binding residues in the chitin binding cleft of YKL-39. 
 
GlcNAc subsite GlcNAc atom Binding 
residues/atom 
Distance (Å) 
+3 O6 Y243/OH 3.1 
+2 O3 
N2 
Y146/OH 
D213/O 
3.1 
3.3 
+1 O6 Y146/OH 2.5 
-1 O3 
O6 
Y104/N 
D213/OD2 
2.9 
2.7 
-2 O6 
O7 
L105/N 
W360/NE1 
3.3 
2.9 
-3  Not observed  
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Table 3.3.6 A summary of the interactions between GlcNAc6 with the binding 
residues in the chitin binding cleft of YKL-39. 
 
GlcNAc subsites Binding residues 
+3 Y243, E219 
+2 Y146,  S185, M190, D213, F214, W218 
+1 Y104, Y146, H271 
-1 Y32, Y104, S143, I145, L210, F212, D213 , Y269, W360 
-2 F63, F65, Y104, L105, M264, F301, W360 
-3 N35, R40, W36, Y269 
 
3.5.3  Structural comparison with other human GH-18 members 
Superimposition of the wild type YKL39/GlcNAc6 complex obtained in 
this study with the complex of YKL39/GlcNAc6 complex (4AY1) reported by 
Schimpl et al., 2013, is characterized by an RMSD of 0.22 for Cα positions over 334 
atoms (Figure 3.3.12). Thus the two complexes are essentially identical, even though 
they are derived from crystals of different space groups. The differences between the 
two protein sequences are at residues 35 and 318. In Schimpl’s structure Asn35 was 
mutated to Gln, generating N35Q mutant, to prevent glycosylation. In this study, 
YKL-39 was functionally expressed in E. coli system as a native, non-glycosylated 
protein. In our structure, Asn35 makes three salt bridges, two of which link with 
Tyr61 and Asp75 and the third one with a neighboring water molecule (Figure 
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3.3.12A, left panel and inset). Gln35 in Schimpl’s structure flips to a vertical direction 
and forms salt bridges with Tyr61, Lys74, and also a neighboring water molecule. 
Although the residue 35 in both structures lies in subsite -3, none makes contact with 
the GlcNAc ring at the corresponding subsite. Residue 318, which is seen as Trp in 
our structure, lies in a region of the protein distant to the chitin-binding groove. In the 
present structure, Trp318 forms hydrophobic interactions with Pro325 and the stalk of 
Lys340, while in structure 4AY1 Arg318 forms a salt bridge with Asp338 (Figure 
3.3.12A, right panel and inset). These interactions are standard residue:residue 
interactions, in line with the view that these substitutions arise from naturally 
occurring polymorphisms. In our structure, all six GlcNAc rings could be fitted into 
subsites -3 to +3 (Figure 3.3.12B, left panel), whereas only four GlcNAc rings of 
chitohexaose GlcNAc6 were fitted into subsites -2 to +2 in the 4AY1 structure (Figure 
3.3.12B, right panel). 
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Figure 3.3.12  Structural comparison of two YKL-39 structures. 
(A) Superposition of the currently-studied YKL-39 (PDB: 4P8X) and the previously-
reported YKL-39 (PDB: 4AY1, magenta) in complex with GlcNAc6. The differences 
between the two protein sequences at residues N35Q (left, inset) and W318R (right, 
inset) are displayed as ball and sticks. (B) GlcNAc6 with map in the binding cleft of 
the currently-studied YKL-39 (green), while GlcNAc6 with map in the binding cleft 
of the previously-reported YKL-39 (yellow). Color: carbon in the 4P8X structure is 
displayed in cyan, in the 4AY1 structure in magenta. For both structures, nitrogen 
atoms are in blue and oxygen atoms in red. Both 2Fo-Fc omit maps are contoured at 
1σ. 
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The superimposition of the YKL-39 structure to the available the crystal 
structure of human chitinase (CHIT1 and AMCase) and chitinase-like protein YKL-
40 gave RMSD of 0.59, 0.58 and 0.69 Å, respectively, as list in Table 3.3.7. Figure 
3.3.12 shows the structural superimposition of the structures of these proteins. Their 
overall the structures are high similarity in part of the (β/α)8 TIM barrel domain 
structures. Nevertheless, a few significant differences may explain divergent binding 
features between YKL-39 and the other two homologues. The most obvious variance 
is at subsite -4. In CHIT1 and YKL-40, this subsite has Tyr 34 as the key residue 
forming a hydrophobic stacking interaction against -4GlcNAc. This Tyr residue is 
missing in YKL-39, and the closest residue, Asp39, would be unlikely to make 
productive contact with a GlcNAc ring (Table 3.3.8). As a result, no affinity of 
binding at subsite -4 is likely for YKL-39. Another considerable difference is 
observed at subsite +3. In YKL-40, this subsite comprises Trp212 that directly stacks 
against the plane of the subsite +3GlcNAc. In contrast, Tyr243 in YKL-39 forms a 
hydrogen bond of a distance of 3.1 Å  with the equatorial C6-OH group of the subsite 
+3GlcNAc, suggesting that the interaction at this position is weaker than that in  
YKL-40. The subsite -3GlcNAc unit at the non-reducing end of the GlcNAc6 in YKL-
39 (Figure 3.3.13B) is well defined and interacts with Trp36, whereas the subsite 
+3GlcNAc unit is more flexible, adopting a more open position than the GlcNAc ring 
that forms stacking with Trp212 at subsite +3 in the YKL-40 structure (Figure 
3.3.13C). Weak affinity at the reducing end of the sugar chain is well characterized by 
high B-factor for the subsite +3GlcNAc (81.64 Å2), reflecting high flexibility due to 
loose fitting at this location. Within the YKL-40 structure, the chitosugar occupies 
two positions between subsites -4 to +2 (Figure 3.3.13C, green) and subsites -3 to +3 
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(Figure 3.3.13C, grey) due to its more extended binding cleft. The residue at the 
homologous position to the catalytic residue Glu140 in the human chitinase (CHIT1) 
at bottom of subsite -1 is substituted by Ile145 in YKL-39 and Leu140 in YKL-40 
(Figure 3.3.13A). Thus, neither YKL-39 nor YKL-40 have catalytic activity, although 
the overall feature of the bent conformation of the interacting sugar, suitable for being 
cleaved by normal chitinases, is maintained in the CLPs (Fusetti et al., 2003; Fusetti 
et al., 2002; Meng et al., 2010; Songsiriritthigul et al., 2008; van Aalten et al., 2001). 
 
Figure 3.3.13  Ribbon representation of YKL-39, superimposed with other GH-18 
human chitinases and CLPs  
The crystal structure of YKL-39 is colored in cyan, while human chitinase, CHIT1 
(PDB code: 1LG1) and AMCase (PDB code: 3FXY) are colored green and red, 
respectively. Chitinase-like protein YKL-40 (PDB code: 1HJW) is indicated by pink 
color.  
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Table 3.3.7  Root-mean-square deviation between the structures of complex       
YKL-39/GlcNAc6 and other human chitinases and chitinase-like proteins. 
 
Human chitinases and 
CLPs (PDB code) 
RMSD Sequence identity 
(%) 
Number of Cα 
CHIT1 (1LG1) 0.59 55.2 296 
AMCase (3FXY) 0.58 49 288 
YKL-40 (1HJW) 0.69 51.3 292 
 
YKL-39 and YKL-40 are closely related in size and sequence. Structural 
comparison also shows that the overall of the structures of both proteins are similar 
with a few significant differences in their chitin binding grooves (Figure 3.3.16A). 
For binding of GlcNAc4 to YKL-39, the 2Fo - Fc Fourier maps obtained from the 
refined model revealed the electron density map covering subsites -3 to +1. This is in 
contrast to binding features observed with YKL-40 and chitinase B (ChiB), where 
GlcNAc4 preferably occupies the central part of the binding cleft spanning from 
subsites -2 to +2 (Fusetti et al., 2003 and Gennady et al., 2004).  
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Figure 3.3.14  Superimposition of YKL-39 with its human GH-18 homologues. 
(A) The amino acid residues of YKL-39 (cyan), YKL-40 (margenta), and CHIT1 
(gray) that participate in sugar binding are shown. For the sake of clarity, only 
GlcNAc6 from the YKL-39 structure is presented (yellow). (B) Surface representation 
and of the sugar-binding cleft of YKL-39, showing chitohexaose occupying subsites -
3 to +3. However, the interaction at subsite +3 appears weak. Trp36 is highlighted in 
dark blue and Tyr234 is labeled. (C) Surface representation of the sugar-binding cleft 
of YKL-40, showing six GlcNAc units of the GlcNAc8 occupying subsites -3 to +3 
(PDB: 1NWU, green) or subsites -4 to +2 (PDB: 1HJW, gray). Tyr34 is highlighted in 
cyan and Trp212 in dark blue.  
 
 
 
 
 
 
 
 
 
 
Table 3.3.8  A summary of the interactions between GlcNAc6 and the binding residues in each subsites of YKL-39, YKL-40 and CHIT1. 
         Subsite 
Protein -4 -3 -2 -1 +1 +2 +3 
YKL-39 
(PDB: 4P8X) 
  W36  
 
R40 
 
W360  
L105 
F63, F301, M364 
W360 
D213,Y104 
Y32, S143, I145, 
Y269 
  
Y146 
Y104, L210, 
F212, H217 
W218 
Y146, D213 
F214 
   
Y243 
YKL-40 
(PDB:1HJW, 
1NWT) 
Y34 
E70 
 
W31 
N100, E290 
R35, W69 
W352  
N100, E290 
Y27, F58, T269 
W352 
D207, R263 
Y27,  A138, L140, 
Y206, F261 
W99 
Y141, R263 
 
  
Y141 
 
F208 
W212 
 
CHIT1 
(PDB: 1LG1) 
Y34 W31 
 
 
R35 
W358 
N100, E297 
 
Y27, F58, M300 
W358 
D138, E140 
D213, R269,Y212 
Y267 
W99 
Y141, R269 
 
 
W218 
 
 
F214 
 
Bold: stacking interaction residues 
Bold-and-underline: recognition residues 
Bold-and-italic: hydrogen bonding residues     139 
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3.4  Protein-ligand binding study 
Human YKL-39 is known as a member of GH-18 glycosyl hydrolases that acts as 
a chitooligosaccharide binding protein (Schimpl et al., 2012). A previous study by 
Schimpl et al. (Schimpl et al., 2012) showed the 3D structure of YKL-39 in complex 
with chitin fragment. However, there are no direct experimental data showing the free 
energy changes associated with chitooligosaccharide binding to this protein. This 
section described binding thermodynamics of YKL-39 with its sugar ligand 
determined by intrinsic tryptophan fluorescence titration assay and isothermal titration 
calorimetry (ITC). ITC particularly provides a direct measure of thermodynamics 
parameters, including the stoichiometry of the interaction (n), the association constant 
(Ka), the free energy change (∆G), the enthalpy change (∆H) and the entropy change 
(∆S). The data obtained from binding study and structural investigation provide the 
mechanistic ideas about how various chitooligosaccharides interacts at atomic levels 
with their protein partner and the energetic contributions to binding. 
 
3.4.1  Protein-ligand binding study by intrinsic tryptophan fluorescence 
spectroscopy 
Intrinsic fluorescence titration technique was used to evaluate the 
binding affinity of various chitin fragments in range of GlcNAc2 to GlcNAc6 towards 
the human YKL-39 protein. In agreement with the data obtained from the dose-
response curves, the titration of chitin oligosaccharides (GlcNAc2-GlcNAc6) using 
various concentrations to 10 µg of YKL-39 resulted in a progressive increases in the 
fluorescence intensity, with no shift in the λ max and present changes in fluorescence 
intensities over a range of emission wavelengths of 330-400 nm as shown in Figure 
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3.4.1 to 3.4.5. Such changes reflect interaction of tryptophan residues with 
chitooligosaccharides of various lengths: GlcNAc2 (Figure 3.4.1); GlcNAc3 (Figure 
3.4.2); GlcNAc4 (Figure 3.4.3); GlcNAc5 (Figure 3.4.4), and GlcNAc6 (Figure 3.4.5), 
respectively. As shown in an inset of the figures, transformation of the fluorescence 
data as described in Section 2.9.2, yielding a plot of relative intensities versus sugar 
concentrations gave a good fit with a single-site binding model. The relative 
intensities also reached saturation at certain concentrations of sugar used for titration, 
giving an idea that sugar reached specifically to the protein with a ratio of 1:1. From 
the plot, the dissociation constant (Kd) values for each corresponding sugar could be 
obtained from the concentration of ligand (µM) at half saturation and the change in 
the free energy (∆G, Kcal.mol-1) was estimated and both values are shown in Table 
3.4.1. The Kd values indicated that the long chains of chitooligosaccharides, including 
GlcNAc5 and GlcNAc6, reacted with YKL-39 with the highest affinity with Kd of 0.7 
and 0.4 µM, respectively, followed by GlcNAc4 (4.4 µM), GlcNAc3 (183 µM), and 
GlcNAc2 (216 µM), respectively. A decrease in Kd values with the increasing lengths 
of the chitin oligosaccharides suggest that the binding affinity depends on the length 
of the chitooligosaccharide. These results agree well with to the binding energy, 
which increased as the chain lengths of the chitosugar increased.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1  Binding of GlcNAc2 to YKL-39 as studies by intrinsic fluorescence spectroscopy.  
The purified YKL-39 (10 µg) was titrated with GlcNAc2. An aliquot of 2.5 µL of GlcNAc2 prepared as a 10 mM stock solution was 
added to the protein. The emission spectra were collected from 300-450 nm with an excitation wavelength of 295 nm. The dashed line 
indicates the protein solution without ligand added. An inset presents the relative fluorescence intensities (F-F0) plotted against sugar 
concentrations. The binding curve was fitted to a single-binding site model. 142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2  Binding of GlcNAc3 to YKL-39 as studies by intrinsic fluorescence spectroscopy.  
The purified YKL-39 (10 µg) was titrated with GlcNAc3. An aliquot of 1µL of GlcNAc3 prepared as a 10 mM stock solution was added 
to the protein. The emission spectra were collected from 300-450 nm with an excitation wavelength of 295 nm. The dashed line indicates 
the protein solution without ligand added. An inset presents the relative fluorescence intensities (F-F0) plotted against sugar 
concentrations. The binding curve was fitted to a single-binding site model. 143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.3  Binding of GlcNAc4 to YKL-39 as studies by intrinsic fluorescence spectroscopy.  
The purified YKL-39 (10 µg) was titrated with GlcNAc4. An aliquot of 1 µL of GlcNAc4 prepared as a 10 mM stock solution was added 
to the protein. The emission spectra were collected from 300-450 nm with an excitation wavelength of 295 nm. The dashed line indicates 
the protein solution without ligand added. An inset presents the relative fluorescence intensities (F-F0) plotted against sugar 
concentrations. The binding curve was fitted to a single-binding site model. 144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.4  Binding of GlcNAc5 to YKL-39 as studies by intrinsic fluorescence spectroscopy.  
The purified YKL-39 (10 µg) was titrated with GlcNAc5. An aliquot of 1 µL of GlcNAc5 prepared as a 0.1 mM stock solution was added 
to the protein. The emission spectra were collected from 300-450 nm with an excitation wavelength of 295 nm. The dashed line indicates 
the protein solution without ligand added. An inset presents the relative fluorescence intensities (F-F0) plotted against sugar 
concentrations. The binding curve was fitted to a single-binding site model. 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.5  Binding of GlcNAc6 to YKL-39 as studies by intrinsic fluorescence spectroscopy.  
The purified YKL-39 (10 µg) was titrated with GlcNAc6. An aliquot of 1 µL of GlcNAc6 prepared as a 0.1 mM stock solution was added 
to the protein. The emission spectra were collected from 300-450 nm with an excitation wavelength of 295 nm. The dashed line indicates 
the protein solution without ligand added. An inset presents the relative fluorescence intensities (F-F0) plotted against sugar 
concentrations. The binding curve was fitted to a single-binding site model. 146 
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Table 3.4.1  The equilibrium dissociation constant (Kd) and ∆G binding values derived 
from the binding curves obtained from intrinsic fluorescence study. 
 
 Chitooligosaccharides Kd (µM) ∆G binding (kcal/mol) 
GlcNAc2 216 ± 42 -5.0 
GlcNAc3 183 ± 47 -5.1 
GlcNAc4 4.4 ± 1.9 -7.3 
GlcNAc5 0.7 ± 0.3 -8.4 
GlcNAc6 0.4 ± 0.0 -8.8 
 
3.4.2 Thermodynamics of binding by Isothermal titration calorimetry 
(ITC) 
To gain an insight into the mechanism of binding, the binding kinetics of 
YKL-39 against various long chains of chitin oligosaccharides (GlcNAc2 to GlcNAc6) 
was investigated by ITC. This technique measures heat released or absorbed during 
binding events, providing information about binding in a single experiment 
(Agnieszka, 2011; Bissantz, Kuhn, and Stahl, 2010; Leavitt and Freire, 2001; 
Perozzo, Folkers, and Scapozza, 2004; Pierce, Raman, and Nall, 1999).  
 
3.4.2.1  Binding of GlcNAc2 to YKL-39 
  For ITC experiments to study binding of GlcNAc2 to YKL-39, 
the 4 µM stock solution of GlcNAc2 was added in discrete injections into 15 µM 
YKL-39 in 20 mM potassium phosphate buffer, pH 8.0, at 25°C. These conditions 
gave the ITC thermograms (Figure 3.4.6A, upper panels) and binding isotherms with 
theoretical single-site binding curve fit (Figure 3.4.6A, lower panels). These data were 
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further analyzed, which yielded ∆H of -13.1±4.4 kcal/mol, -T∆S of 7.6±3.8 kcal/mol, 
∆G of -5.0±0.01 kcal/mol, and Kd of 204±3 μM. These binding thermodynamic 
parameters are plotted against the number of sugar ring and presented in Figure 
3.4.7B. It shows that the overall binding of GlcNAc2 to YKL-39 protein is an 
exothermic and enthalpy driven reaction, due to the negative values of ∆H of 
−13.1±4.4 kcal/mol, and an unfavorable entropic term (-T∆S = 7.6±3.8 kcal/mol/K 
and ∆S = -27±14 cal/K.mol). 
  
3.4.2.2 Binding of GlcNAc3 to YKL-39 
   For binding of GlcNAc3 to YKL-39, 15 µM YKL-39 was titrated 
with GlcNAc3. Under the conditions given in the Material and Methods, the titration 
thermogram was obtained as shown in Figure 3.4.6B (upper panel), and the data fitted 
to a single-site binding model (Figure 3.4.6B, lower panel) yielded ∆H of -11.3±1.3 
kcal/mol, -T∆S of 6.1±1.3 kcal/mol, ∆G of -5.3±0.01 kcal/mol, and Kd of 142±8 μM. 
Figure 3.4.7B show that binding of GlcNAc3 to YKL-39 was also driven by enthalpy, 
with an unfavorable entropic term (-T∆S = 6.1±1.3 kcal/mol and ∆S = -20.4±4.5 
cal/K.mol. 
 
3.4.2.3  Binding of GlcNAc4 to YKL-39 
  For binding of GlcNAc4 to YKL-39, 30 µM YKL-39 was titrated 
with GlcNAc4. The titration thermogram was obtained as shown in Figure 3.4.6C 
(upper panel), and the data fitted to a single-site binding model (Figure 3.4.6C, lower 
panel) yielded ∆H of -17.0±2.0 kcal/mol, -T∆S of 9.1±1.8 kcal/mol, ∆G of -7.7±0.02 
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kcal/mol, and Kd of 1.7±0.7 μM. The binding of GlcNAc4 to YKL-39 was also driven 
by enthalpy, with an unfavorable entropic term (-T∆S = 9.1±1.8 kcal/mol and          
∆S = -30.5±5.9 cal/K.mol.  
 
3.4.2.4  Binding of GlcNAc5 to YKL-39 
  For binding of GlcNAc5 to YKL-39, 10 µM YKL-39 was titrated 
with GlcNAc5. The titration thermogram was obtained as shown in Figure 3.4.6D 
(upper panel), and the data fitted to a single-site binding model (Figure 3.4.6D, lower 
panel) yielded ∆H of -17.2±3.7 kcal/mol, -T∆S of 7.2±3.9 kcal/mol, ∆G of -10.0±0.4 
kcal/mol, and Kd of 0.06±0.04 μM. The binding of GlcNAc3 to YKL-39 was also 
driven by enthalpy, with an unfavorable entropic term (-T∆S = 6.1±1.3 kcal/mol and 
∆S = -24.3±13.3 cal/K.mol. 
 
3.4.2.5  Binding of GlcNAc6 to YKL-39 
For binding of GlcNAc6 to YKL-39, 10 µM YKL-39 was titrated 
with GlcNAc6. The titration thermogram was obtained as shown in Figure 3.4.6E 
(upper panel), and the data fitted to a single-site binding model (Figure 3.4.6E, lower 
panel) yielded ∆H of -12.2±1.5 kcal/mol, -T∆S of 2.0±1.5 kcal/mol, ∆G of -10.2±0.3 
kcal/mol, and Kd of 0.04±0.02 μM. The binding of GlcNAc6 to YKL-39 was also 
driven by enthalpy, with an unfavorable entropic term (-T∆S = 2.0±1.5 kcal/mol and 
∆S = -6.9±5.2 cal/K.mol. 
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Figure 3.4.6  YKL-39 binding to various chitooligosaccharides. 
Microcalorimetric titrations for the binding of chitooligosaccharide to YKL39 (upper 
panels), and binding isotherms with theoretical fittings (lower panels) obtained for the 
binding of GlcNAc2 (A), GlcNAc3 (B), GlcNAc4 (C), GlcNAc5 (D), and GlcNAc6 (E) 
to YKL-39. Each ligand was added to protein solution in 20 mM potassium phosphate 
buffer, pH 8.0, at 25°C.
 
 
 
 
 
 
 
 
 
 
Table 3.4.2  Thermodynamic parameters of chitooligosaccharides binding to YKL-39. 
 
 ITC 
Chitooligosaccharide Kda ∆Hb ∆Sc - T∆Sb ∆Gb n 
Wiseman 
c-value 
GlcNAc2 204 ± 3   -13.1 ± 4.4   -27.0 ± 14.8 8.0 ± 4.4 -5.1 ± 0.01 1.0±0 0.1 
GlcNAc3 142 ± 8 -11.3 ± 1.3 -20.4 ± 4.5 6.1 ± 1.3 -5.3 ± 0.01 1.0±0 0.1 
GlcNAc4     1.7 ± 0.7 -17.0 ± 2.0 -30.5 ± 5.9 9.1 ± 1.8    -7.8 ± 0.2    0.9±0.1 18 
GlcNAc5    0.06 ± 0.04 -17.2 ± 3.7    -24.3 ± 13.3 7.2 ± 3.9  -10.0 ± 0.4    0.9±0.1 167 
GlcNAc6    0.04 ± 0.02 -12.2 ± 1.5    -6.9 ± 5.2 2.0 ± 1.5  -10.2 ± 0.3    1.1±0.1 250 
 
a µM.  
b kcal/mol. 
c cal/K mol. 
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Figure 3.4.7  Thermodynamic parameters plot.  
(A) Free energy of binding of chitooligosaccharide to YKL-39 increased with the 
length. Free energy of binding of GlcNAc5 and GlcNAc6 are not significantly 
different, indicating that binding cleft of YKL-39 has five subsites. (B) The binding 
signature (free energy, binding enthalpy, and entropy factor) plotted for ligand 
binding events. 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4.3  Thermodynamic parameters of chitooligosaccharides binding to YKL-39. 
                                                    
 Intrinsic 
fluorescence 
  ITC   
Chitooligosaccharide Kda Kda ∆Hb ∆Sc - T∆Sb ∆Gb 
GlcNAc2 216 ± 42 204 ± 3 -13.1 ± 4.4 -27.0 ± 14.8 8.0 ± 4.4 -5.1 ± 0.0 
GlcNAc3 183 ± 47 142 ± 8 -11.3 ± 1.3 -20.4 ± 4.5 6.1 ± 1.3 -5.3 ± 0.01 
GlcNAc4 4.4 ± 1.9 1.7 ± 0.7 -17.0 ± 2.0 -30.5 ± 5.9 9.1 ± 1.8 -7.8 ± 0.2 
GlcNAc5 0.7 ± 0.3 0.06 ± 0.04 -17.2 ± 3.7 -24.3 ± 13.3 7.2 ± 3.9 -10.0 ± 0.4 
GlcNAc6 0.4 ± 0.0 0.04 ± 0.02 -12.2 ± 1.5 -6.9 ± 5.2 2.0 ± 1.5 -10.2 ± 0.3 
 
a µM. 
b kcal/mol. 
c cal/K mol. 
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CHAPTER IV 
DISCUSSION 
 
4.1  Molecular cloning, expression and purification of human YKL-39 
 The aim of the numerous protein characterization studies is improvement of 
techniques for molecular cloning, protein expression, purification, and protein 
functional and characterization methods. Generally, the most widely used expression 
host is E. coli due to it being a relatively simple and well characterized system 
capable of producing large quantities of soluble protein in a short period of time.  In 
this study, we employed the nucleotide sequence of CHI3L2 cDNA in the GenBank 
database (www.ncbi.nlm.nih.gov/genbank) to design a set of oligonucleotides, and 
then amplify the full-length CHI3L2 gene. The PCR fragment of the CHI3L2 gene 
was directly cloned into different expression vectors, and then expression from each 
vector was tested with the attempt to obtain a soluble YKL-39 in an E. coli system. 
Initially, the CHI3L2 gene encoding YKL-39 protein was successfully cloned into 
pGEX-6P-1 expression vector, generating a construct called pGEX-6P-1/CHI3L2. 
This vector was designed to express a fusion protein with Glutathione S-Transferase 
(GST) at the N-terminus, which contains a thrombin cleavage site for deletion of the 
fusion protein tag. Unfortunately, the fusion proteins were mainly expressed as 
inclusion bodies from all the conditions tested.  An alternative system was tried. 
Expression of YKL-39 as a thioredoxin fusion protein from the pET32a(+) vector was 
carried out. A construct called pET32a(+)/CHI3L2 was made suitable for protein 
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expression in E. coli BL21 (DE3) host cells.  The presence of a fusion tag at the 
upstream of the YKL-39 insert contains three desired characteristics: a thioredoxin 
(Trx) fusion tag, a hexahistidine tag, and an enterokinase cleavage site. The Trx 
fragment was fused to the protein to enhance protein solubility, whereas the 
hexahistidine residues facilitated protein purification, and the enterokinase cleavage 
site that contains a five amino acid recognition sequence, DDDDK, helped to remove 
the fusion tag. In this construct, there are an extra seven amino acids A-M-A-D-I-G-S 
between the Trx removal site and the mature YKL-39. Both sense and anti-sense 
strands of the CHI3L2 gene were confirmed by automated DNA sequencing. All of 
identification assay confirmed that the pET32a(+)/CHI3L2 construct had a correct 
structure, the insert CHI3L2 gene did not introduce any reading frame shifting. The 
deduced amino acid sequence of YKL-39 was found to be almost identical to the 390-
aa sequence of CHI3L2 isoform1 (identifier: Q15782-4) reported in the 
UniProtKB/Swiss-Prot database. The exception is that a single amino acid residue in 
our sequence at position 318 had Trp instead of Arg. The discrepancy of this amino 
acid has been suggested previously to be a natural variation that occurs due to a single 
nucleotide polymorphism (The MGC Project Team, 2004). The deduced amino acid 
sequence of human YKL-39 was compared with that of YKL-40 (CHI3L1, P36222), 
acidic mammalian chitinase (AMCase, Q9BZP6-1), human chitotriosidase (CHIT1, 
Q13231), human oviduction (oviduction, Q86YN0), and stabilin-1 isoform 1(SI-CLP, 
Q9NY15). The YKL-39 sequence is closest to CHIT1 (55.2% identity), followed by 
YKL-40 (51.3%). On the other hand, YKL-39 showed lowest identity to SI-CLP 
(17.5%). The amino acid residues S143 and I145 located at the end of DxxDxDxE 
motif are reported to suppress chitinase activity. In true chitinases like AMCase 
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(Olland et al., 2009) and CHIT1 (Fusetti et al., 2002), these two residues are found as 
Asp and Glu instead. Double mutations of S143 to D143 and I145 to E145 in YKL-39 
created pseudo-chitinase activity for this protein (Schimpl et al., 2012).  
Optimization for high level of YKL-39 expression was investigated. The effects 
of various IPTG concentrations, induction temperatures, and times were tested. High 
expression level of the soluble YKL-39 was found to be under the following 
conditions: 0.5 mM IPTG concentration, 25°C and 16 h of induction temperature and 
time. The fusion protein containing His6 tag was initially purified by Ni-NTA resin 
affinity column, followed by Sepharose Q HP anion exchange chromatography to 
eliminate the contaminating proteins. After digestion by enterokinase, the Trx-His6 
fusion tag was completely removed from the protein solution by the second Ni-NTA 
resin
 
step, followed by HiLoad 16/60 Superdex 200 prep grade gel filtration to 
improve the purity and homogeneous of protein solution. The high quality of 
homogeneous protein with >95% purity was obtained after purification and was 
appropriate to be used for production of polyclonal and monoclonal antibodies, and 
used for crystallization and protein-ligand binding studies.  
 
4.2  Production of anti-YKL39 polyclonal and monoclonal antibodies  
4.2.1  Production of anti-YKL39 polyclonal antibodies  
The Ag:Ab binding curves indicated concentration dependence of anti-
YKL39 antisera towards the recombinant YKL-39, whereas no signal was detected in 
the reaction of pre-immune serum. Secondary antibody treatment alone also 
demonstrated no reactivity to protein.  This indicated that YKL-39 protein was able to 
stimulate immune response in rabbits to produce highly specific and strongly reactive 
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polyclonal antibodies against the protein of interest. Subsequently, the immunized 
serum was further purified with protein-A column. SDS-PAGE analysis showed that 
the purified anti-YKL39 antisera migrated behind the 97 kDa protein marker under 
non-reducing condition, while two proteins of about 55 kDa and 25 kDa were 
observed under denaturing condition. Together with the achievement of antibody 
purification by Protein-A agarose, the results confirmed that anti-YKL39 pAbs had 
the specific IgG isotype. Indirect ELISA assay showed that the raised antibodies were 
highly sensitive, reacting strongly with the YKL-39 protein even when only 5 ng of 
the purified antibody was used. The Ag:Ab binding curves showed concentration 
dependence of anti-YKL39 pAbs towards the recombinant YKL-39, but not reaction 
with other GH-18 human chitinases and CLPs, human YKL-40, AMCase, and 
bacterial chitinaseA, indicating a high specificity of the purified antibodies towards 
YKL-39 antigen. Western blot analysis showed that the anti-YKL39 pAbs recognized 
both fusion Trx tag and native form of YKL39, but did not recognize other proteins 
even proteins in human serum. These results indicated that the purified pAbs were 
highly selective for YKL-39.  
The binding curve demonstrated hyperbolic saturation feature, yielding the 
binding affinity (Ka) of YKL-39 protein for the detected by anti-YKL39 antibody to 
be 2.4x107 M-1. In addition, the signal of interaction with the linear range was found 
to be from 0.16 to 1.25 µg/mL of YKL-39 with R2 = 0.9999. By Western blot analysis, 
the anti-YKL39 antibody generated a strong signal at 10 µg, and became faint when 
the amount of YKL-39 was decreased down to 0.31 µg of YKL-39. These results 
suggested that 10 ng of anti-YKL39 pAbs was able to detect YKL-39 antigen in range 
of 0.16 to 1.25 µg/mL by indirect ELISA and 0.3-10 µg by Western blot assay. 
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Optimization of the antigen coating and antibody concentration of these conditions 
can be used to develop a solid-phase immunoassay for the detection of YKL-39 in 
real sample of patients with progressive osteoarthritis. 
 
4.2.2  Production of anti-YKL39 monoclonal antibody 
Hybridoma technique is the most widely used to produce monoclonal 
antibodies. The myeloma tumor cells are fused with spleen cells that challenge to 
produce antibody against the specific antigen. The fusion cells, namely hybrinoma, 
can grow indefinitely and rapidly produce a large amount of antibodies in culture.  In 
this study, we further employed the hybridoma technique (Kohler and Milstein, 1975; 
Tomita and Tsumoto, 2011) to raise monoclonal antibody specific for the E. coli-
expressed YKL-39. The immunized mice with YKL-39 protein showed high titers of 
antibody response, indicating the success of induction of antibody production against 
YKL-39 protein. Spleen cells from the highest of immune response mouse were 
further fused with myeloma cells, following hybridoma technique, as described in 
Section 2.8.3. Hybrodomas were selected by cultivation fused cells in HAT medium 
(hypoxanthine-aminopterin-thymidine medium). This medium combined aminopterin, 
a drug that acts as a powerful block to the de novo nucleotide synthesis pathway, with 
hypoxanthine (a purine derivative) and thymidine (a deoxynucleoside), which are 
intermediates in DNA synthesis. Thus, unfused myeloma cells die, as they cannot 
produce nucleotides by the de novo or salvage pathways. Unfused spleen cells die as 
they have a short life span. In this way, only the hybridomas can survive (Holliday 
and Ho, 1998).  
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After ten days of cultivation, healthy hybridomas were observed in 477 wells. 
Screening for the positive hybridomas using indirect ELISA identified 71 hybridomas 
that strongly reacted with YKL-39. To obtain a single clone of hybrodomas, limiting 
dilution was investigated by separating hybridomas into the individual clones. 
Unfortunately, most of hybridomas lost their activity during cultivation. However, a 
positive single clones from the 1st limiting dilution were re-cloned by the 2nd round of 
limiting dilution until the stable single clone of hybridoma were obtained. Finally, two 
positive clones, namely 6H11 and 8H3, were obtained.  Isotyping mapping clearly 
suggested that both monoclones belong to the IgM isotype. Because the 6H11 clone 
exhibited greater immunoactivity, it was then selected for large scale production.  
Crude anti-YKL39 mAb was purified with a HiTrap IgM HP column (GE 
Health-Care). This column is made of 2-mercaptopyridine coupled to sepharose, 
thiophilic affinity medium, the binding affinity to ligand is promoted by water-
structuring salts. The antibody: coupled ligand column interaction has been suggested 
to result from a combined electron donating and accepting action of the                     
2-mercaptopyridine ligand (Hutchens and Porath, 1987; Lihme and Heegaard, 1991).  
Western blot analysis demonstrated that the antibody titer against recombinant 
YKL-39 had the strongest titer at a ratio of 10:5 (µg/µg) of mAb:Ag. Our newly 
raised mAb recognized both fused and bare forms of human YKL-39, but did not 
recognize other GH-18 homologs, suggesting that the anti-YKL39 mAb was highly 
specific for YKL-39. Detection of YKL-39 in Jurkat cells (a model for differentiation 
of T lymphocytes) and U937 cells (a model for the differentiation of monocytes and 
macrophages) by our mAb indicated that YKL-39 may be involved in both innate and 
adaptive immune systems in response to the likelihood of infection or tissue 
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inflammation. Dot blot assay showed that the monoclonal antibody was strongly 
active with the synovial fluid of an osteoarthritis patient, and human monocyte and T 
lymphocyte cell lines. Such results suggested that our monoclonal antibody was 
functionally active and exhibited cell type specificity. Taken together, both polyclonal 
and monoclonal antibodies were highly specific and active with various types of 
immunological assays, making them suitable for functional studies such as the 
identification of the YKl-39 regulated pathways involving cartilage tissue 
degeneration and development of an immunosensing tool for monitoring the progress 
of degenerative joint disease. 
 
4.3 The structural determination of YKL-39 in the absence and 
presence of chitin fragments 
4.3.1  The Crystallization of YKL-39 
The appropriate conditions to crystallize YKL-39 were found under 
conditions, containing 27 to 31% (w/v) PEG 3350 and 0.2 to 0.3 M lithium sulfate in 
0.1 M Bis Tris, pH 8.0, 25°C. The optimized conditions showed that high 
concentrations of precipitant resulted in a decrease in crystal size. To obtain structures 
in the presence chitin fragments, crystals of apo YKL-39 were soaked with the 
optimal concentration of each chitin fragment. Finally, four crystal structures of  
YKL-39 in the absence and presence of chitooligosaccharides, including ligand-free 
YKL-39 and in complex with GlcNAc2, GlcNAc4 and GlcNAc6 were solved to 
resolutions of 2.48-1.53 Å.  
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4.3.2  The overall structure of YKL-39 in the presence and absence chitin 
fragments 
 Like GH-18 chitinases and CLPs, the overall structure of YKL-39 
displayed two conserved domains, including the major (β/α)8 TIM barrel domain 
(Domain I) and a small insertion domain. The TIM barrel domains interact 
specifically with chitin oligosaccharides, while the exact function of the insertion 
domain is unknown (Fusetti et al., 2003; Fusetti et al., 2002; Meng et al., 2010; 
Schimpl et al., 2012; Songsiriritthigul et al., 2008; van Aalten et al., 2001). The 
structures of YKL-39 in the presence of chitin fragments revealed the binding surface 
of the TIM barrel domain to be a long, deep groove that is open at both ends to 
facilitate the accommodation of chitin fragments that extend out from the groove in 
both directions. 
 
4.3.3  Chitooligosaccharide binding induces structural movements 
Superimposition of the apo YKL-39 structure on the structures in 
complex with GlcNAc2, GlcNAc4, and GlcNAc6, showed that the presence of the 
saccharide chain in the chitin binding cleft induces local conformation changes that 
are mainly observed in the loop regions surrounding the surface of the chitin binding 
cleft. The most observations were found at the center of the chitin-binding cleft. The 
movement of key residues moved the binding cleft boundary residues of the sugar 
bound protein around subsites -2 and -1, closer by 1.3 Å, to close contact with the 
GlcNAc rings. In contrast, the rotation of Tyr243 widened the binding cleft at this 
particular subsite (+3) by 1.9 Å, resulting in the subsites to be extended from +2 to 
+3. Taken together, these structural differences provide evidence that the binding of 
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chitooligosaccharides induces local structural changes that strengthen the interactions 
between the YKL-39 and that facilitated the accommodation of incoming ligand. 
 
4.3.4  Specific interactions of YKL-39 with chitooligosaccharides 
Examination of the substrate binding cleft of ligand-free YKL-39 and all 
sugar-bound YKL-39 structures reveals the binding behaviors of individual 
chitooligosaccharides. The strongly binding interaction was found at the center of the 
binding cleft and extended in both directions with weaker-affinity interactions. This 
was supported by GlcNAc2 model that bound at the center covering subsite -2/-1. Two 
or three molecules of GlcNAc2 could bind within the chitin-binding site of YKL-39 
based on its size, but only a single bound GlcNAc2 was observed, suggesting that an 
incoming chitin chain would preferentially interact at the center of the binding 
groove. Where a longer chain chitooligosaccharide, four sugar rings GlcNAc4 
extended over subsites -3 to +1, and GlcNAc6 bound at subsites -3 to +3. This affinity 
gradient is well supported by lower B-factors for -2GlcNAc (43.63 Å2),                       
-1GlcNAc (44.76 Å2) and +1GlcNAc (44.75 Å2) that are located at the center of the 
binding sites, indicating more rigid and tight interactions at the internal sites. 
Increases in B-factor for bound sugar were found to increase with the extending 
subsites. Especially, +3GlcNAc, showed the highest of B-factor, reflecting high 
flexibility of the sugar rings forming weak interactions with the binding residues at 
such subsites.  
The protein-ligand binding interaction was considered with the structure of 
YKL-39 in complex with the longest chitin chain, GlcNAc6, as model. The critical 
binding features are aromatic residues, which interact with the GlcNAc rings mainly 
 
 
 
 
 
 
 
 
163 
 
  
through hydrophobic interactions, and charged or polar side chain residues that form 
hydrogen bonding interactions with the saccharide chain. For hydrophobic 
interactions, three key residues, Trp36 at subsite -3, Trp360 at subsite -1, and Trp218 
at +2, are found to stack with the plane of GlcNAc rings, resulting in the increasing 
strength of its binding affinity. The first two residues (Trp36 and Trp360) are 
completely conserved in other GH-18 homologues and act as key binding residues 
(Fusetti et al., 2003; Fusetti et al., 2002; Meng et al., 2010; Schimpl et al., 2012; 
Songsiriritthigul et al., 2008; van Aalten et al., 2001). The conserved aromatics 
Trp36, located at the edges of the binding cleft, marks the non-reducing end of long 
chain chitin fragment by stacking against the planes of the bound sugar at -3GlcNAc, 
while Trp218 marks the reducing end of chitin sugar, and is in the position suitable 
for binding with the subsite +2GlcNAc. For the subsite +3GlcNAc, no hydrophobic 
interaction was found. It is presumed that there is a weak binding at this subsite. This 
observation was confirmed by ITC results, which showed the insignificantly different 
values of binding affinity and binding energy for GlcNAc5 and GlcNAc6, suggesting 
insignificant differences in the binding strength for these two chitooligosaccharides. 
The electron density of YKL-39/GlcNAc6 complex suggested that the sugar units at 
the central subsites are held by a larger number of weak interaction, including salt 
bridges, H-bond, and hydrophobic interactions. Trp360 seems to play a particular role 
in ligand recognition by making hydrogen bonds with the C7-O of -2GlcNAc. This 
residue is conserved in GH-18 chitinases and CLPs (Fusetti et al., 2003; Fusetti et al., 
2002; Meng et al., 2010; Schimpl et al., 2012; Songsiriritthigul et al., 2008; van 
Aalten et al., 2001). Figure 4.1B displays a number of hydrogen bonds that help to 
stabilize the sugar/protein complexes. Such hydrogen bonds are formed either directly 
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between the sugar rings and the binding residues or mediated by water molecules. 
High densities of interactions are seen at subsites -2, -1, and +1, which are likely to 
determine the preferential binding at these sites.  
 
4.3.5  Structural comparison with other human GH-18 members 
Superimposition of the structure of YKL39:GlcNAc6 complex obtained 
in this study on YKL39:GlcNAc6 complex (4AY1) reported by Schimpl et al. 
(Schimpl et al., 2012) was found to be essentially identical, even though they are 
derived from crystals with different space groups. The two proteins differed in 
sequences at residues 35 and 318, resulting in dissimilarity of interactions around 
these residues. Although residue 35 in both structures is located near subsite -3, it 
makes no contact with the GlcNAc ring. Residue 318 lies in a region distant from 
binding site, Trp318 in native YKL-39 forms hydrophobic interactions with Pro325 
and the stalk of Lys340, while Arg318 in structure 4AY1 forms a salt bridge with 
Asp338. In addition, all six GlcNAc rings could be fitted into subsites -3 to +3 in our 
structure, whereas only four GlcNAc rings of GlcNAc6 were fitted into subsites -2 to 
+2 in the 4AY1 structure.  
The sugar-binding grooves of YKL-39, CHIT1 (Fusetti et al., 2002), and   
YKL-40 (Fusetti et al., 2002; Houston et al., 2003) were compared and found to be 
very similar with a few significant differences in the chitin binding subsites. These 
explain divergent binding features between YKL-39 and other two homologues. The 
most different variation is at subsite -4. In CHIT1 and YKL-40, the sugar ring formed 
a hydrophobic stack against the key residue Tyr34, but this residue is missing in 
YKL-39, causing no affinity at subsite -4 in the YKL-39 structure (see Figure 3.3.13). 
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Another considerable difference was observed at subsite +3. In YKL-40, this subsite 
sugar stacks directly against the Trp212 residue. In contrast, Tyr243 in YKL-39 forms 
a hydrogen bond with the subsite +3GlcNAc, suggesting that the interaction at this 
position is weaker than that in YKL-40. Weak affinity at the reducing end of the sugar 
chain is suggested by a high B-factor for +3GlcNAc (81.64 Å2), reflecting high 
flexibility due to loose fitting at this location. Within the YKL-40 structure, the 
chitosugar occupies two positions between subsites -4 to +2 and subsites -3 to +3 due 
to its more extended binding cleft. The catalytic residue Glu140 in CHIT1 at bottom 
of subsite -1 is clearly substituted by Ile145 in YKL-39 and Leu140 in YKL-40, 
making them lack chitinase activity.  
The chitin-protein complex suggested that GlcNAc containing oligosaccharide 
could act as the physiological ligand for YKL-39. It has been explained recently that 
YKL-39 enhances colony forming activity, cell proliferation, and type II collagen 
expression in mouse chondrogenic cells. These data suggest that YKL-39 may be a 
novel growth and differentiation factor involved in regulating cartilage homeostasis 
(Miyatake et al., 2013). This report demonstrates that YKL-39 could participate in 
specific signaling processes and could function as a lectin able to recognize specific 
glycan structures present in mammalian tissues. 
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Figure 4.1 Specific interactions within the chitin binding cleft of YKL-39. 
(A) The aromatic residues that are involved hydrophobic interactions with the sugar 
molecule at each subsite. (B) The amino acid residues and water molecules that 
mediate the formation of hydrogen bonding network. Water molecules are shown as 
blue diamonds and hydrogen bonds are shown as red dashed lines. 
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4.4  The binding thermodynamics of YKL-39 with chitin 
oligosaccharides 
Isothermal titration calorimetry (ITC) and intrinsic tryptophan fluorescence were 
used to determine binding thermodynamics of YKL-39 towards various chitin 
fragments. For ITC measurements, YKL-39 was titrated with chitooligosaccharides 
until the binding isotherms were saturated, allowing the determination of binding 
affinities and thermodynamic parameters for YKL-39 (Agnieszka, 2011; 
Baranauskiene et al., 2009; Pierce et al., 1999). All data obtained from the binding 
reactions were fitted using a single-site binding model with calculated stoichiometry 
(n) of approximately 1.0, indicating that one molecule of the sugar interacts within the 
binding cleft of YKL-39. This is consistent with that found in the crystal structures, 
each of which shows only a single chitin chain, even GlcNAc2, as described in Results 
(Section 4.3.4). Analysis of the ITC data gave the equilibrium binding constants (Kd), 
which indicated the binding affinities that clearly increased with increasing 
chitooligosaccharide length. These binding kinetics are consistent with the structural 
observations that GlcNAc2 occupies the center of the protein binding cleft at subsites  
-2 and -1, whereas GlcNAc4 and GlcNAc6 stretches along the entire binding groove in 
both direction, having the most stable binding of the chitooligosaccharides studied. 
The binding affinity of GlcNAc5 (0.06 μM) and GlcNAc6 (0.04 μM) are 
insignificantly difference. These correspond to the structure of the YKL-39/GlcNAc6 
complex that suggests strong interactions from subsites -3 to +2. It shows 
hydrophobic stacking interaction by Trp36 at -3GlcNAc and Trp218 at +2GlcNAc, 
respectively, but no interaction was observed at +3GlcNAc. These binding 
characteristics also correlated with fluorescence spectroscopy measurements in which 
 
 
 
 
 
 
 
 
168 
 
  
the data fit well to the single-site binding model of a non-linear regression function as 
described in Section 3.4.1. The estimated Kd values are in the following order: 
GlcNAc6 ≅ GlcNAc5 > GlcNAc4 > GlcNAc3 > GlcNAc2.  
Comparing the data from both the fluorescence measurements and ITC 
experiments found that the values of Kd obtained from fluorescence measurements are 
in general higher than those from ITC measurements, reflecting the different binding 
concepts of the two binding methods. ITC assay account for all interactions, while in 
the fluorescence assay, quenching tryptophan residues that are located within binding 
cleft is measured. Nevertheless, both show the difference in Kd values is small for 
short chain chitooligosaccharides, and becomes greater with increasing chain length 
and tighter binding. Both binding methods showed insignificantly different Kd for 
GlcNAc2 (see Table 3.4.3). The results suggested that important key residue Trp360 
that stacks against the face of two GlcNAc rings at subsites -2/-1 plays an exclusive 
role in the sugarprotein interactions at such central subsites. The enthalpy change 
(ΔH), the entropy change (-TΔS) and the free energy change (ΔG) obtained from the 
ITC experiments clearly demonstrate that all chitooligosaccharides bind to YKL-39 in 
spontaneous, exothermic reactions (see Table 3.4.2). As shown in Figure 3.4.7A, 
similar values of the binding energies estimated for GlcNAc5 and GlcNAc6 suggest 
insignificant differences in the binding strengths for these two chitooligosaccharides. 
The results of these kinetic analyses are consistent with  the crystal structure showed 
strong binding covering subsites (-3)(-2)(-1)(+1)(+2), instead of six subsites, as 
observed for its closely-related homologs CHIT1 and YKL-40 (Fusetti et al., 2003; 
Fusetti et al., 2002; Meng et al., 2010). Thermodynamic parameters revealed that all 
ligands bind to YKL-39 (see Figure 3.4.7B), were mainly driven by enthalpy, as 
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indicated by the dominant negative enthalpy change with unfavorable entropy. The 
dominant -∆H reflected the strength of binding that was caused from hydrogen bonds 
and electrostatic interactions (Richard, 2012). 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER V 
CONCLUSIONS 
  
The CHI3L2 gene encoding YKL-39 was successfully cloned into the 
pET32a(+) expression vector, yielding the construct named pET32a(+)/CHI3L2. 
Employing this vector system, the recombinant YKL-39 was expressed as a fusion 
protein that contains the thioredoxin (Trx) fragment, followed by six histidine 
residues (His6) attached at the N-terminus of the YKL-39 polypeptide. Colony PCR, 
restriction enzyme digestion and DNA sequencing confirmed that the newly generated 
construct pET32a(+)/CHI3L2 had a correct structure, and the CHI3L2 gene insertion 
did not introduce any reading frame shift. 
The recombinant YKL-39 polypeptide lacking its 26-aa signal sequence was 
successfully expressed in a soluble form with E. coli strain BL21(DE3) as host. The 
protein was expressed as a Trx-His6/YKL-39 fusion protein with the total molecular 
weight of approximately 55 kDa. The expression level of the soluble YKL-39 was 
dependent on the IPTG concentration, temperature and time of induction, with the 
optimal expression conditions being 0.5 mM IPTG concentration at 25°C for 16 h.  
For polyclonal and monoclonal antibody production, the Trx-His6/YKL-39 
fusion protein was purified by gravity flow Ni-NTA agarose chromatography, 
followed by Sepharose Q HP anion exchange chromatography, to eliminate the 
contaminating proteins for high purity fusion protein. After enterokinase digestion to 
remove the Trx/His6 N-terminal tag fragment, the free tag YKL-39 was further 
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purified by a second round of Ni-NTA agarose column chromatography. The entire 
YKL-39 polypeptide had seven extra residues (A-M-A-D-I-G-S) preceding the YKL 
sequence. The protein was seen on SDS-PAGE gel at the molecular weight between 
35 and 45 kDa, which corresponded to the predicted mass of 41.5 kDa. The  YKL-39 
was evaluated to be about 95% pure, with the overall yield of about 3.4 mg per liter of 
culture. For crystallization of YKL-39, a large amount of homogeneous protein is 
required. Therefore, after the thioredoxin fusion tag removal, the tag-free protein was 
purified by Ni-NTA agarose, followed by S200 gel filtration chromatography. The 
purified YKL-39 appeared to be a single protein with MW of about 40 kDa on SDS-
PAGE and was evaluated to be >95% pure. This highly purified protein was 
considered appropriate for crystallization trials and protein-ligand binding studies. 
For anti-YKL39 polyclonal antibody production, data obtained from indirect 
ELISA assay showed that YKL-39 protein was able to stimulate a response in the 
immunized rabbits to produce highly specific anti-YKL39 antisera. The Ag:Ab 
binding curves showed hyperbolic concentration dependence of anti-YKL39 
antiserum towards the recombinant YKL-39, while pre-immune serum showed no 
reactivity to YKL-39. The results suggested that anti-YKL39 antiserum was 
specifically and strongly reactive towards the purified YKL-39 protein. The raised 
antisera were further purified via a protein A column. Two bands with molecular 
weights of 55 kDa and 25 kDa, representing the heavy and light chains of IgG, 
respectively, appeared on SDS-PAGE analysis, as expected. The specificity and 
sensitivity of the purified anti-YKL39 antisera were further characterized by indirect 
ELISA and Western blot immunoassay.  Our raised polyclonal antibodies were found 
to be highly sensitive, reacting strongly with the YKL-39 protein even when only 5 ng 
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of the purified antibody was used. The Ag:Ab binding curves which gave the 
saturated hyperbolic feature also showed concentration dependence of anti-YKL39 
antisera towards the recombinant YKL-39. To determine the specificity of anti-
YKL39 pAbs, other GH-18 homologs YKL-40, AMCase, and chitinase A were used 
as immunogens. It was found that no significant increase in the signal was observed. 
The binding intensity of each antigen was further tested. It was found that the 
absorbance obtained for YKL-39 was 15-19 folds greater than that for human     
YKL-40, AMCase, and chitinase A. These further confirmed a high specificity of the 
purified antibodies towards YKL-39.  
For anti-YKL39 monoclonal antibodies were generated by the hybridoma 
method. Spleen cells, which produced antibody against YKL-39, were fused with 
myeloma cells using 50% (v/v) PEG. Finally, two positive clones, namely 6H11 and 
8H3, were obtained after a limiting dilution screen of about 200 hybridoma clones. 
Isotype mapping of these clones were determined by capture ELISA, which was 
found that both a single clones belonged to the IgM isotype. Crude anti-YKL39 mAb, 
which was obtained from cultured serum free media were further purified via a 
specific HiTrap IgM HP column. The purified IgM titers were further tested against 
recombinant YKL-39 by Western blot analysis. It revealed that the strongest titer was 
seen at a ratio of 10:5 (µg/µg) of mAb:Ag, while the slightest titer of the antibody that 
recognized the YKL-39 Ag was 2.5:5 (µg/µg). The antibodies were found to 
recognize both fused and free forms of human YKL-39, but did not recognize     
YKL-40, AMCase, and bacterial chitinase. The antibodies also did not cross-react 
with proteins in human serum. Based on these findings, it has been suggested that the 
anti-YKL39 mAb was highly specific for YKL-39. The anti-YKL39 mAb could react 
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with YKL-39 in synovial fluid of a patient with osteoarthritis and various human cell 
lines, as well as in the whole cell lysate of Jurkat cells. Such results suggested that our 
monoclonal antibody was functionally active and exhibited cell type specificity.  
For structural determination of YKL-39 in the presence and absence chitin 
fragments, the suitable conditions for crystallization of YKL-39 were screened by the 
sitting drop technique. It was found that the precipitants, which were suitable to 
crystallize this protein, were PEG derivatives of the molecular weight from 1500 to 
8000, containing the Li2SO4 and Ca(OAc)2. The most suitable buffers were Bis Tris, 
citrate and imidazole at pH 5.5 and 8.0. After optimization using the hanging drop 
method with various concentrations of precipitants PEG 3350 and lithium sulfate in 
0.1 M Bis Tris pH 8.0, the X-ray diffracting quality crystals of ligand- free YKL-39 
were obtained under a condition of 27% (w/v) PEG 3350, 0.2 M lithium sulfate in 0.1 
M Bis Tris, pH 8.0. Ligand-free crystals were soaked with chitin fragments of 
GlcNAc2 to GlcNAc6. Finally, four crystal structures of YKL-39 in the free form and 
in complex with GlcNAc2, GlcNAc4 and GlcNAc6 were solved to resolutions of 2.48-
1.53 Å. All the crystals belong to space group P41212 with one molecule in an 
asymmetric unit and unit cell dimensions of approximately 71x71x40 Å. 
The overall structure of YKL-39 contains the major (β/α)8 TIM barrel domain 
with the small insertion domain between stand B7 and helix A7 as in GH-18 chitinase 
and CLPs. In contrast to other subfamilies, YKL-39 contains no chitin binding 
domain. The catalytic residue Glu145, which is part of a conserved DxxDxDxE 
sequence motif is substituted to Ile, so YKL-39 lacks chitinase hydrolytic activity. In 
the structures of YKL-39 in the presence of chitin fragments, the ligand-binding cleft 
is observed to be long and open at both ends in order to facilitate the accessibility to 
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the sugar ligand. Superimposition of the free form YKL-39 to the                         
YKL-39/chitooligosaccharide structures revealed that their TIM barrel domains are 
identical with only a few differences in the binding cleft. In addition, the presence of 
chitin fragment in the binding site induces local conformational changes, which 
potentially reflect the structural movement upon the ligand binding event. The 2Fo–Fc 
Fourier maps showed that GlcNAc2 bound to protein covers subsites -2 to -1, 
GlcNAc4 bound from subsites -3 to +1, while GlcNAc6 bound from subsites -3 to +3. 
These findings suggested that the short chitin fragment bound primarily at the center 
of the binding groove. For the YKL-39/GlcNAc6 structure, it was found that YKL-39 
interacted with its sugar counterpart mainly through a combination of hydrogen 
bonding network and hydrophobic interactions. A larger number of contacts at the 
non-reducing end binding sites probably reflect stronger interactions. When the  
YKL-39 structure was compared with those of CHIT1, AMCase, and YKL-40, it was 
observed that their overall structures had high similarity with a few differences, 
within the chitin binding cleft.  
       The thermodynamics of binding of YKL-39 with chitooligosaccharides (GlcNAc2 
to GlcNAc6) was investigated by intrinsic tryptophan fluorescence and ITC. All data 
from the binding reactions fitted well to a single-site binding model with a calculated 
n (stoichiometry) of 0.9-1.1. ITC experimental data for binding demonstrated that the 
binding affinity of YKL-39 for ligands increased with the increasing length of ligands 
in the micromolar range for Kd. The chitin binding cleft of YKL-39 contains a 
maximum of five subsites, namely (-3)(-2)(-1)(+1)(+2). Thermodynamic parameter 
determination clearly demonstrated that all ligands bind to protein with exothermic 
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and spontaneous reactions, which were mainly driven by enthalpy, as indicated by the 
dominant negative enthalpy change with unfavorable entropy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
Adams, P. D.,  Grosse-Kunstleve, R. W.,  Hung, L.-W.,  Ioerger, T. R.,  McCoy, A. J.,  
Moriarty, N. W.,  Read, R. J.,  Sacchettini, J. C.,  Sauter, N. K., and Terwilliger, 
T. C. (2002). PHENIX: building new software for automated crystallographic 
structure determination. Acta Crystallogr. Sect. D-Biol. Crystallogr. 58(11): 
1948-1954.  
Afonine, P. V.,  Grosse-Kunstleve, R. W.,  Chen, V. B.,  Headd, J. J.,  Moriarty, N. 
W.,  Richardson, J. S.,  Richardson, D. C.,  Urzhumtsev, A.,  Zwart, P. H., and 
Adams, P. D. (2010). phenix.model_vs_data: a high-level tool for the 
calculation of crystallographic model and data statistics. J. Appl. Crystallogr. 
43(4): 669-676.  
Agnieszka, K. B. (2011). Thermodynamics of Ligand-Protein Interactions: 
Implications for Molecular Design. 
Areshkov, P. A. and Kavsan, V. M. (2010). Chitinase 3-like protein 2 (CHI3L2, 
YKL-39) activates phosphorylation of extracellular signal-regulated kinases 
ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma 
(U87 MG) cells. Tsitol. Genet. 44(1): 3-9.  
Areshkov, P. O.,  Avdieiev, S. S.,  Balynska, O. V.,  Leroith, D., and Kavsan, V. M. 
(2012). Two closely related human members of chitinase-like family, CHI3L1 
and CHI3L2, activate ERK1/2 in 293 and U373 cells but have the different 
influence on cell proliferation. Int. J. Biol. Sci. 8(1): 39-48.  
 
 
 
 
 
 
 
 
178 
 
  
Arias, E. B., Verhage, H. G., and Jaffe, R. C. (1994). Complementary 
deoxyribonucleic acid cloning and molecular characterization of an estrogen-
dependent human oviductal glycoprotein. Biol. Reprod. 51(4): 685-694.  
Arlian, L. G. and Platts-Mills, T. A. (2001). The biology of dust mites and the 
remediation of mite allergens in allergic disease. J. Allergy Clin. Immunol. 
107(3 Suppl): 406-413.  
Avdieiev, S.,  Savinska, L.,  Filonenko, V., and Kavsan, V. (2012). Chitinase 3-like 2 
protein monoclonal antibodies. Hybridoma (Larchmt). 31(1): 32-39.  
Bissantz, C.,  Kuhn, B., and Stahl, M. (2010). A medicinal chemist's guide to 
molecular interactions. J. Med. Chem. 53(14): 5061-5084.  
Boot, R. G.,  Blommaart, E. F.,  Swart, E.,  Ghauharali-van der Vlugt, K.,  Bijl, N.,  
Moe, C.,  Place, A., and Aerts, J. M. (2001). Identification of a novel acidic 
mammalian chitinase distinct from chitotriosidase. J. Biol. Chem. 276(9): 
6770-6778.  
Boot, R. G.,  Bussink, A. P., and Aerts, J. M. (2005). Human acidic mammalian 
chitinase erroneously known as eosinophil chemotactic cytokine is not the 
ortholog of mouse YM1. J. Immunol. 175(4): 2041-2042.  
Boot, R. G.,  Renkema, G. H.,  Strijland, A.,  van Zonneveld, A. J., and Aerts, J. M. 
(1995). Cloning of a cDNA encoding chitotriosidase, a human chitinase 
produced by macrophages. J. Biol. Chem. 270(44): 26252-26256.  
Boot, R. G.,  Renkema, G. H.,  Verhoek, M.,  Strijland, A.,  Bliek, J.,  de 
Meulemeester, T. M.,  Mannens, M. M., and Aerts, J. M. (1998). The human 
chitotriosidase gene. Nature of inherited enzyme deficiency. J. Biol. Chem. 
273(40): 25680-25685.  
 
 
 
 
 
 
 
 
179 
 
  
Boot, R. G.,  van Achterberg, T. A.,  van Aken, B. E.,  Renkema, G. H.,  Jacobs, M. 
J.,  Aerts, J. M., and de Vries, C. J. (1999). Strong induction of members of the 
chitinase family of proteins in atherosclerosis: chitotriosidase and human 
cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb. Vasc. 
Biol. 19(3): 687-694.  
Brameld, K. A. and Goddard, W. A. (1998). Substrate Distortion to a Boat 
Conformation at Subsite -1 Is Critical in the Mechanism of Family 18 
Chitinases. J. Am. Chem. Soc. 120(15): 3571-3580.  
Brasso, K.,  Christensen, I. J.,  Johansen, J. S.,  Teisner, B.,  Garnero, P.,  Price, P. A., 
and Iversen, P. (2006). Prognostic value of PINP, bone alkaline phosphatase, 
CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 
66(5): 503-513.  
Briton-Jones, C.,  Lok, I. H.,  Yuen, P. M.,  Chiu, T. T.,  Cheung, L. P., and Haines, 
C. (2001). Regulation of human oviductin mRNA expression in vivo. Fertil. 
Steril. 75(5): 942-946.  
Bussink, A. P.,  Speijer, D.,  Aerts, J. M., and Boot, R. G. (2007). Evolution of 
mammalian chitinase(-like) members of family 18 glycosyl hydrolases. 
Genetics. 177(2): 959-970.  
Chayen, N. E. (1999). Crystallization with oils: a new dimension in macromolecular 
crystal growth. J. Cryst. Growth. 196(2-4): 434-441.  
Chew, G. L.,  Perzanowski, M. S.,  Canfield, S. M.,  Goldstein, I. F.,  Mellins, R. B.,  
Hoepner, L. A.,  Ashby-Thompson, M., and Jacobson, J. S. (2008). Cockroach 
allergen levels and associations with cockroach-specific IgE. J. Allergy Clin. 
Immunol. 121(1): 240-245.  
 
 
 
 
 
 
 
 
180 
 
  
Chupp, G. L.,  Lee, C. G.,  Jarjour, N.,  Shim, Y. M.,  Holm, C. T.,  He, S.,  Dziura, J. 
D.,  Reed, J.,  Coyle, A. J.,  Kiener, P.,  Cullen, M.,  Grandsaigne, M.,  
Dombret, M. C.,  Aubier, M.,  Pretolani, M., and Elias, J. A. (2007). A 
chitinase-like protein in the lung and circulation of patients with severe asthma. 
N. Engl. J. Med. 357(20): 2016-2027. 
Cintin, C.,  Johansen, J. S.,  Christensen, I. J.,  Price, P. A.,  Sorensen, S., and Nielsen, 
H. J. (2002). High serum YKL-40 level after surgery for colorectal carcinoma is 
related to short survival. Cancer. 95(2): 267-274.  
Cohen-Kupiec, R. and Chet, I. (1998). The molecular biology of chitin digestion. 
Curr. Opin. Biotechnol. 9(3): 270-277. 
 Collaborative Computing Project Number 4. (1994). The CCP4 suite: programs for 
protein crystallography. Acta Crystallogr. Sect. D-Biol. Crystallogr. 50(Pt 5): 
760-763.  
Colton, C. A., Mott, R. T., Sharpe, H., Xu, Q., Van Nostrand, W. E., and Vitek, M. P. 
(2006). Expression profiles for macrophage alternative activation genes in AD 
and in mouse models of AD. J. Neuroinflammation. 3: 27.  
Cottrell, M. T., Moore, J. A., and Kirchman, D. L. (1999). Chitinases from uncultured 
marine microorganisms. Appl. Environ. Microbiol. 65(6): 2553-2557.  
Davies, G. and Henrissat, B. (1995). Structures and mechanisms of glycosyl 
hydrolases. Structure. 3(9): 853-859.  
De Ceuninck, F.,  Marcheteau, E.,  Berger, S.,  Caliez, A.,  Dumont, V.,  Raes, M.,  
Anract, P.,  Leclerc, G.,  Boutin, J. A., and Ferry, G. (2005). Assessment of 
some tools for the characterization of the human osteoarthritic cartilage 
proteome. J. Biomol. Tech. 16(3): 256-265.  
 
 
 
 
 
 
 
 
181 
 
  
De Fost, M.,  Hollak, C. E.,  Groener, J. E.,  Aerts, J. M.,  Maas, M.,  Poll, L. W.,  
Wiersma, M. G.,  Haussinger, D.,  Brett, S.,  Brill, N., and vom Dahl, S. (2006). 
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher 
disease on bone marrow involvement and chitotriosidase levels: a 2-center 
retrospective analysis. Blood. 108(3): 830-835.  
Dehn, H.,  Hogdall, E. V.,  Johansen, J. S.,  Jorgensen, M.,  Price, P. A.,  Engelholm, 
S. A., and Hogdall, C. K. (2003). Plasma YKL-40, as a prognostic tumor marker 
in recurrent ovarian cancer. Acta. Obstet. Gynecol. Scand. 82(3): 287-293.  
Di Rosa, M.,  Dell'Ombra, N.,  Zambito, A. M.,  Malaguarnera, M.,  Nicoletti, F., and 
Malaguarnera, L. (2006). Chitotriosidase and inflammatory mediator levels in 
Alzheimer's disease and cerebrovascular dementia. Eur. J. Neurosci. 23(10): 
2648-2656.  
Du, H.,  Masuko-Hongo, K.,  Nakamura, H.,  Xiang, Y.,  Bao, C. D.,  Wang, X. D.,  
Chen, S. L.,  Nishioka, K., and Kato, T. (2005). The prevalence of 
autoantibodies against cartilage intermediate layer protein, YKL-39, 
osteopontin, and cyclic citrullinated peptide in patients with early-stage knee 
osteoarthritis: evidence of a variety of autoimmune processes. Rheumatol. Int. 
26(1): 35-41.  
Dupont, J.,  Tanwar, M. K.,  Thaler, H. T.,  Fleisher, M.,  Kauff, N.,  Hensley, M. L.,  
Sabbatini, P.,  Anderson, S.,  Aghajanian, C.,  Holland, E. C., and Spriggs, D. R. 
(2004). Early detection and prognosis of ovarian cancer using serum YKL-40. 
J. Clin. Oncol. 22(16): 3330-3339.  
 
 
 
 
 
 
 
 
182 
 
  
Elias, J. A.,  Homer, R. J.,  Hamid, Q., and Lee, C. G. (2005). Chitinases and 
chitinase-like proteins in T(H)2 inflammation and asthma. J. Allergy Clin. 
Immunol. 116(3): 497-500.  
Emsley, P. and Cowtan, K. (2004). Coot: model-building tools for molecular 
graphics. Acta Crystallogr. Sect. D-Biol. Crystallogr. 60(12 Part 1): 2126-
2132.  
Francescone, R. A.,  Scully, S.,  Faibish, M.,  Taylor, S. L.,  Oh, D.,  Moral, L.,  Yan, 
W.,  Bentley, B., and Shao, R. (2011). Role of YKL-40 in the angiogenesis, 
radioresistance, and progression of glioblastoma. J. Biol. Chem. 286(17): 
15332-15343.  
Fusetti, F.,  Pijning, T.,  Kalk, K. H.,  Bos, E., and Dijkstra, B. W. (2003). Crystal 
structure and carbohydrate-binding properties of the human cartilage 
glycoprotein-39. J. Biol. Chem. 278(39): 37753-37760.  
Fusetti, F.,  von Moeller, H.,  Houston, D.,  Rozeboom, H. J.,  Dijkstra, B. W.,  Boot, 
R. G.,  Aerts, J. M., and van Aalten, D. M. (2002). Structure of human 
chitotriosidase. Implications for specific inhibitor design and function of 
mammalian chitinase-like lectins. J. Biol. Chem. 277(28): 25537-25544.  
Gouet, P.,  Courcelle, E.,  Stuart, D. I., and Metoz, F. (1999). ESPript: analysis of 
multiple sequence alignments in PostScript. Bioinformatics. 15(4): 305-308.  
Gratchev, A.,  Schmuttermaier, C.,  Mamidi, S.,  Gooi, L.,  Goerdt, S., and 
Kzhyshkowska, J. (2008). Expression of Osteoarthritis Marker YKL-39 is 
Stimulated by Transforming Growth Factor Beta (TGF-beta) and IL-4 in 
Differentiating Macrophages. Biomark. Insights. 3: 39-44.  
 
 
 
 
 
 
 
 
183 
 
  
Hakala, B. E.,  White, C., and Recklies, A. D. (1993). Human cartilage gp-39, a major 
secretory product of articular chondrocytes and synovial cells, is a mammalian 
member of a chitinase protein family. J. Biol. Chem. 268(34): 25803-25810.  
Hart, P. J.,  Pfluger, H. D.,  Monzingo, A. F.,  Hollis, T., and Robertus, J. D. (1995). 
The refined crystal structure of an endochitinase from Hordeum vulgare L. 
seeds at 1.8 A resolution. J. Mol. Biol. 248(2): 402-413.  
Henrissat, B. and Bairoch, A. (1993). New families in the classification of glycosyl 
hydrolases based on amino acid sequence similarities. Biochem. J. 293( Pt 3): 
781-788.  
Henrissat, B. and Davies, G. J. (2000). Glycoside hydrolases and glycosyltransferases. 
Families, modules, and implications for genomics. Plant Physiol. 124(4): 1515-
1519.  
Hollak, C. E.,  van Weely, S.,  van Oers, M. H., and Aerts, J. M. (1994). Marked 
elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher 
disease. J. Clin. Invest. 93(3): 1288-1292.  
Holliday, R. and Ho, T. (1998). Evidence for gene silencing by endogenous DNA 
methylation. Proc. Natl. Acad. Sci. USA. 95(15): 8727-8732.  
Houston, D. R.,  Recklies, A. D.,  Krupa, J. C., and van Aalten, D. M. (2003). 
Structure and ligand-induced conformational change of the 39-kDa glycoprotein 
from human articular chondrocytes. J. Biol. Chem. 278(32): 30206-30212.  
Hu, B.,  Trinh, K.,  Figueira, W. F., and Price, P. A. (1996). Isolation and sequence of 
a novel human chondrocyte protein related to mammalian members of the 
chitinase protein family. J. Biol. Chem. 271(32): 19415-19420.  
 
 
 
 
 
 
 
 
184 
 
  
Iseli, B.,  Armand, S.,  Boller, T.,  Neuhaus, J. M., and Henrissat, B. (1996). Plant 
chitinases use two different hydrolytic mechanisms. FEBS Lett. 382(1-2): 186-
188.  
Jensen, B. V.,  Johansen, J. S., and Price, P. A. (2003). High levels of serum HER-
2/neu and YKL-40 independently reflect aggressiveness of metastatic breast 
cancer. Clin. Cancer Res. 9(12): 4423-4434. 
 Johansen, J. S.,  Williamson, M. K.,  Rice, J. S., and Price, P. A. (1992). 
Identification of proteins secreted by human osteoblastic cells in culture. J. 
Bone. Miner. Res. 7(5): 501-512.  
Johansen, J. S.,  Baslund, B.,  Garbarsch, C.,  Hansen, M.,  Stoltenberg, M.,  
Lorenzen, I., and Price, P. A. (1999). YKL-40 in giant cells and macrophages 
from patients with giant cell arteritis. Arthritis Rheum. 42(12): 2624-2630.  
Johansen, J. S.,  Bojesen, S. E.,  Mylin, A. K.,  Frikke-Schmidt, R.,  Price, P. A., and 
Nordestgaard, B. G. (2009). Elevated plasma YKL-40 predicts increased risk of 
gastrointestinal cancer and decreased survival after any cancer diagnosis in the 
general population. J. Clin. Oncol. 27(4): 572-578.  
Johansen, J. S.,  Christensen, I. J.,  Riisbro, R.,  Greenall, M.,  Han, C.,  Price, P. A.,  
Smith, K.,  Brunner, N., and Harris, A. L. (2003). High serum YKL-40 levels in 
patients with primary breast cancer is related to short recurrence free survival. 
Breast Cancer Res. Treat. 80(1): 15-21.  
Johansen, J. S.,  Drivsholm, L.,  Price, P. A., and Christensen, I. J. (2004). High serum 
YKL-40 level in patients with small cell lung cancer is related to early death. 
Lung Cancer. 46(3): 333-340.  
 
 
 
 
 
 
 
 
185 
 
  
Johansen, J. S.,  Hvolris, J.,  Hansen, M.,  Backer, V.,  Lorenzen, I., and Price, P. A. 
(1996). Serum YKL-40 levels in healthy children and adults. Comparison with 
serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or 
trauma of the knee joint. Br. J. Rheumatol. 35(6): 553-559.  
Johansen, J. S.,  Jensen, B. V.,  Roslind, A.,  Nielsen, D., and Price, P. A. (2006). 
Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer 
Epidemiol Biomarkers Prev. 15(2): 194-202.  
Junker, N.,  Johansen, J. S.,  Hansen, L. T.,  Lund, E. L., and Kristjansen, P. E. 
(2005). Regulation of YKL-40 expression during genotoxic or 
microenvironmental stress in human glioblastoma cells. Cancer Sci. 96(3): 183-
190.  
Kavsan, V.,  Dmitrenko, V.,  Boyko, O.,  Filonenko, V.,  Avdeev, S.,  Areshkov, P.,  
Marusyk, A.,  Malisheva, T.,  Rozumenko, V., and Zozulya, Y. (2008). 
Overexpression of YKL-39 Gene in Glial Brain Tumors. Scholarly Research 
Exchange. 2008.  
Kawada, M.,  Hachiya, Y.,  Arihiro, A., and Mizoguchi, E. (2007). Role of 
mammalian chitinases in inflammatory conditions. Keio. J. Med. 56(1): 21-27.  
Kirkpatrick, R. B.,  Emery, J. G.,  Connor, J. R.,  Dodds, R.,  Lysko, P. G., and 
Rosenberg, M. (1997). Induction and expression of human cartilage 
glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-
derived macrophages. Exp Cell Res. 237(1): 46-54.  
Knorr, T.,  Obermayr, F.,  Bartnik, E.,  Zien, A., and Aigner, T. (2003). YKL-39 
(chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up 
regulated in osteoarthritic chondrocytes. Ann. Rheum. Dis. 62(10): 995-998.  
 
 
 
 
 
 
 
 
186 
 
  
Kohler, G. and Milstein, C. (1975). Continuous cultures of fused cells secreting 
antibody of predefined specificity. Nature. 256(5517): 495-497.  
Kuranda, M. J. and Robbins, P. W. (1991). Chitinase is required for cell separation 
during growth of Saccharomyces cerevisiae. J. Biol. Chem. 266(29): 19758-
19767.  
Kzhyshkowska, J.,  Gratchev, A., and Goerdt, S. (2007). Human chitinases and 
chitinase-like proteins as indicators for inflammation and cancer. Biomark. 
Insights. 2: 128-146.  
Kzhyshkowska, J.,  Mamidi, S.,  Gratchev, A.,  Kremmer, E.,  Schmuttermaier, C.,  
Krusell, L.,  Haus, G.,  Utikal, J.,  Schledzewski, K.,  Scholtze, J., and Goerdt, 
S. (2006). Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-
regulated in alternatively activated macrophages and secreted via lysosomal 
pathway. Blood. 107(8): 3221-3228.  
Labadaridis, I.,  Dimitriou, E.,  Theodorakis, M.,  Kafalidis, G.,  Velegraki, A., and 
Michelakakis, H. (2005). Chitotriosidase in neonates with fungal and bacterial 
infections. Arch. Dis. Child Fetal Neonatal Ed. 90(6): F531-532.  
Lapensee, L.,  Paquette, Y., and Bleau, G. (1997). Allelic polymorphism and 
chromosomal localization of the human oviductin gene (MUC9). Fertil Steril. 
68(4): 702-708.  
Laskowski, R. A.,  MacArthur, M. W.,  Moss, D. S., and Thornton, J. M. (1993). 
PROCHECK: a program to check the stereochemical quality of protein 
structures. J. Appl. Crystallogr. 26(2): 283-291.  
 
 
 
 
 
 
 
 
187 
 
  
Laskowski, R. A.,  MacArthur, M. W.,  Moss, D. S., and Thornton, J. M. (1993). 
PROCHECK: a program to check the stereochemical quality of protein 
structures. J. Appl. Crystallogr. 26(2): 283-291.  
Leavitt, S. and Freire, E. (2001). Direct measurement of protein binding energetics by 
isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11(5): 560-566.  
Lee, C. G. (2009). Chitin, chitinases and chitinase-like proteins in allergic 
inflammation and tissue remodeling. Yonsei. Med. J. 50(1): 22-30.  
Lee, C. G.,  Da Silva, C. A.,  Dela Cruz, C. S.,  Ahangari, F.,  Ma, B.,  Kang, M. J.,  
He, C. H.,  Takyar, S., and Elias, J. A. (2011). Role of chitin and 
chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. 
Annu. Rev. Physiol. 73: 479-501.  
Lee, C. G.,  Da Silva, C. A.,  Lee, J. Y.,  Hartl, D., and Elias, J. A. (2008). Chitin 
regulation of immune responses: an old molecule with new roles. Curr. Opin. 
Immunol. 20(6): 684-689.  
Lok, I. H.,  Briton-Jones, C. M.,  Yuen, P. M., and Haines, C. J. (2002). Variable 
expression of oviductin mRNA at different stages of human reproductive cycle. 
J. Assist. Reprod. Genet. 19(12): 569-576.  
Malaguarnera, L.,  Musumeci, M.,  Di Rosa, M.,  Scuto, A., and Musumeci, S. (2005). 
Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote 
chitotriosidase gene expression in human macrophages. J. Clin. Lab. Anal. 
19(3): 128-132.  
Malette, B.,  Filion, B.,  St-Jacques, S.,  Kan, F. W., and Bleau, G. (1995). Hormonal 
control of the biosynthesis of hamster oviductin. Microsc. Res. Tech. 31(6): 
470-477.  
 
 
 
 
 
 
 
 
188 
 
  
Malinda, K. M.,  Ponce, L.,  Kleinman, H. K.,  Shackelton, L. M., and Millis, A. J. 
(1999). Gp38k, a protein synthesized by vascular smooth muscle cells, 
stimulates directional migration of human umbilical vein endothelial cells. Exp. 
Cell Res. 250(1): 168-173.  
Meng, G.,  Zhao, Y.,  Bai, X.,  Liu, Y.,  Green, T. J.,  Luo, M., and Zheng, X. (2010). 
Structure of human stabilin-1 interacting chitinase-like protein (SI-CLP) reveals 
a saccharide-binding cleft with lower sugar-binding selectivity. J. Biol. Chem. 
285(51): 39898-39904.  
Mitsuhashi, A.,  Matsui, H.,  Usui, H.,  Nagai, Y.,  Tate, S.,  Unno, Y.,  Hirashiki, K.,  
Seki, K., and Shozu, M. (2009). Serum YKL-40 as a marker for cervical 
adenocarcinoma. Annals of Oncology. 20(1): 71-77.  
Miyatake, K.,  Tsuji, K.,  Yamaga, M.,  Yamada, J.,  Matsukura, Y.,  Abula, K.,  
Sekiya, I., and Muneta, T. (2013). Human YKL39 (chitinase 3-like protein 2), 
an osteoarthritis-associated gene, enhances proliferation and type II collagen 
expression in ATDC5 cells. Biochem. Biophys. Res. Commun. 431(1): 52-57.  
Monzingo, A. F.,  Marcotte, E. M.,  Hart, P. J., and Robertus, J. D. (1996). Chitinases, 
chitosanases, and lysozymes can be divided into procaryotic and eucaryotic 
families sharing a conserved core. Nat. Struct. Biol. 3(2): 133-140. 
Nyati, M. K.,  Morgan, M. A.,  Feng, F. Y., and Lawrence, T. S. (2006). Integration of 
EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer. 6(11): 876-885.  
Ohno, T.,  Armand, S.,  Hata, T.,  Nikaidou, N.,  Henrissat, B.,  Mitsutomi, M., and 
Watanabe, T. (1996). A modular family 19 chitinase found in the prokaryotic 
organism Streptomyces griseus HUT 6037. J. Bacteriol. 178(17): 5065-5070.  
 
 
 
 
 
 
 
 
189 
 
  
Olland, A. M.,  Strand, J.,  Presman, E.,  Czerwinski, R.,  Joseph-McCarthy, D.,  
Krykbaev, R.,  Schlingmann, G.,  Chopra, R.,  Lin, L.,  Fleming, M.,  Kriz, R.,  
Stahl, M.,  Somers, W.,  Fitz, L., and Mosyak, L. (2009). Triad of polar residues 
implicated in pH specificity of acidic mammalian chitinase. Protein Sci. 18(3): 
569-578.  
Otwinowski, Z. and Minor, W. (1997). Processing of X-ray diffraction data collected 
in oscillation mode (Vol. 276, pp. 307-326): Elsevier. 
Pastores, G. M. and Barnett, N. L. (2005). Current and emerging therapies for the 
lysosomal storage disorders. Expert Opin. Emerg. Drugs. 10(4): 891-902.  
Perozzo, R.,  Folkers, G., and Scapozza, L. (2004). Thermodynamics of protein-ligand 
interactions: history, presence, and future aspects. J. Recept. Signal Transduct 
Res. 24(1-2): 1-52.  
Ramachandran, G. N. and Sasisekharan, V. (1968). Conformation of polypeptides and 
proteins. Adv. Protein Chem. 23: 283-438.  
Ray, A. and Cohn, L. (1999). Th2 cells and GATA-3 in asthma: new insights into the 
regulation of airway inflammation. J. Clin. Invest. 104(8): 985-993.  
Rehli, M.,  Krause, S. W., and Andreesen, R. (1997). Molecular characterization of 
the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein 
family and marker for late stages of macrophage differentiation. Genomics. 
43(2): 221-225.  
Renkema, G. H.,  Boot, R. G.,  Au, F. L.,  Donker-Koopman, W. E.,  Strijland, A.,  
Muijsers, A. O.,  Hrebicek, M., and Aerts, J. M. (1998). Chitotriosidase, a 
chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, 
 
 
 
 
 
 
 
 
190 
 
  
are homologues of family 18 glycosyl hydrolases secreted by human 
macrophages. Eur. J. Biochem. 251(1-2): 504-509.  
Renkema, G. H.,  Boot, R. G.,  Muijsers, A. O.,  Donker-Koopman, W. E., and Aerts, 
J. M. (1995). Purification and characterization of human chitotriosidase, a novel 
member of the chitinase family of proteins. J. Biol. Chem. 270(5): 2198-2202.  
Renkema, G. H.,  Boot, R. G.,  Strijland, A.,  Donker-Koopman, W. E.,  van den 
Berg, M.,  Muijsers, A. O., and Aerts, J. M. (1997). Synthesis, sorting, and 
processing into distinct isoforms of human macrophage chitotriosidase. Eur. J. 
Biochem. 244(2): 279-285.  
Sahai, A. S. and Manocha, M. S. (1993). Chitinases of fungi and plants: their 
involvement in morphogenesis and host-parasite interaction. FEMS 
Microbiology Reviews. 11(4): 317-338.  
Sakata, M.,  Masuko-Hongo, K.,  Tsuruha, J.,  Sekine, T.,  Nakamura, H.,  Takigawa, 
M.,  Nishioka, K., and Kato, T. (2002). YKL-39, a human cartilage-related 
protein, induces arthritis in mice. Clin. Exp. Rheumatol. 20(3): 343-350.  
Schimpl, M.,  Rush, C. L.,  Betou, M.,  Eggleston, I. M.,  Recklies, A. D., and van 
Aalten, D. M. (2012). Human YKL-39 is a pseudo-chitinase with retained 
chitooligosaccharide-binding properties. Biochem. J. 446(1): 149-157.  
Schmidt, H.,  Johansen, J. S.,  Sjoegren, P.,  Christensen, I. J.,  Sorensen, B. S.,  Fode, 
K.,  Larsen, J., and von der Maase, H. (2006). Serum YKL-40 predicts relapse-
free and overall survival in patients with American Joint Committee on Cancer 
stage I and II melanoma. J. Clin. Oncol. 24(5): 798-804.  
 
 
 
 
 
 
 
 
 
191 
 
  
Sekine, T.,  Masuko-Hongo, K.,  Matsui, T.,  Asahara, H.,  Takigawa, M.,  Nishioka, 
K., and Kato, T. (2001). Recognition of YKL-39, a human cartilage related 
protein, as a target antigen in patients with rheumatoid arthritis. Ann. Rheum. 
Dis. 60(1): 49-54. 
Shackelton, L. M.,  Mann, D. M., and Millis, A. J. (1995). Identification of a 38-kDa 
heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle 
cells as a member of a group of proteins associated with tissue remodeling. J. 
Biol. Chem. 270(22): 13076-13083.  
Shuhui, L.,  Mok, Y. K., and Wong, W. S. (2009). Role of mammalian chitinases in 
asthma. Int. Arch. Allergy Immunol. 149(4): 369-377.  
Songsiriritthigul, C.,  Pantoom, S.,  Aguda, A. H.,  Robinson, R. C., and Suginta, W. 
(2008). Crystal structures of Vibrio harveyi chitinase A complexed with 
chitooligosaccharides: implications for the catalytic mechanism. J. Struct. Biol. 
162(3): 491-499.  
Steck, E.,  Breit, S.,  Breusch, S. J.,  Axt, M., and Richter, W. (2002). Enhanced 
expression of the human chitinase 3-like 2 gene (YKL-39) but not chitinase 3-
like 1 gene (YKL-40) in osteoarthritic cartilage. Biochem. Biophys. Res. 
Commun. 299(1): 109-115. 
Terpe, K. (2003). Overview of tag protein fusions: from molecular and biochemical 
fundamentals to commercial systems. Appl. Microbiol. Biotechnol. 60(5), 523-
533.  
Tews, I., Terwisscha van Scheltinga, A. C.,  Perrakis, A.,  Wilson, K. S., and Dijkstra, 
B. W. (1997). Substrate-Assisted Catalysis Unifies Two Families of Chitinolytic 
Enzymes. J. Am. Chem. Soc. 119(34): 7954-7959. 
 
 
 
 
 
 
 
 
192 
 
  
Tolia, N. H. and Joshua-Tor, L. (2006). Strategies for protein coexpression in 
Escherichia coli. Nat. Methods. 3(1): 55-64. 
Turnbull, W. B. and Daranas, A. H. (2003). On the value of c: can low affinity 
systems be studied by isothermal titration calorimetry? J Am Chem Soc. 
125(48): 14859-14866. 
Vagin, A. and Teplyakov, A. (1997). MOLREP: an Automated Program for 
Molecular Replacement. J. Appl. Crystallogr. 30(6): 1022-1025.  
Vagin, A. and Teplyakov, A. (2010). Molecular replacement with MOLREP. Acta 
Crystallogr. Sect. D-Biol. Crystallogr. 66(Pt 1): 22-25.  
van Aalten, D. M.,  Komander, D.,  Synstad, B.,  Gaseidnes, S.,  Peter, M. G., and 
Eijsink, V. G. (2001). Structural insights into the catalytic mechanism of a 
family 18 exo-chitinase. Proc. Natl. Acad. Sci. USA. 98(16): 8979-8984.  
van Eijk, M.,  van Roomen, C. P.,  Renkema, G. H.,  Bussink, A. P.,  Andrews, L.,  
Blommaart, E. F.,  Sugar, A.,  Verhoeven, A. J.,  Boot, R. G., and Aerts, J. M. 
(2005). Characterization of human phagocyte-derived chitotriosidase, a 
component of innate immunity. Int. Immunol. 17(11): 1505-1512.  
Vedder, A. C.,  Cox-Brinkman, J.,  Hollak, C. E.,  Linthorst, G. E.,  Groener, J. E.,  
Helmond, M. T.,  Scheij, S., and Aerts, J. M. (2006). Plasma chitotriosidase in 
male Fabry patients: a marker for monitoring lipid-laden macrophages and their 
correction by enzyme replacement therapy. Mol. Genet. Metab. 89(3): 239-
244.  
Volck, B.,  Johansen, J. S.,  Stoltenberg, M.,  Garbarsch, C.,  Price, P. A.,  Ostergaard, 
M.,  Ostergaard, K.,  Lovgreen-Nielsen, P.,  Sonne-Holm, S., and Lorenzen, I. 
(2001). Studies on YKL-40 in knee joints of patients with rheumatoid arthritis 
 
 
 
 
 
 
 
 
193 
 
  
and osteoarthritis. Involvement of YKL-40 in the joint pathology. 
Osteoarthritis Cartilage. 9(3): 203-214.  
Volck, B.,  Price, P. A.,  Johansen, J. S.,  Sorensen, O.,  Benfield, T. L.,  Nielsen, H. 
J.,  Calafat, J., and Borregaard, N. (1998). YKL-40, a mammalian member of 
the chitinase family, is a matrix protein of specific granules in human 
neutrophils. Proc. Assoc. Am. Physicians. 110(4): 351-360.  
Watanabe, T.,  Kimura, K.,  Sumiya, T.,  Nikaidou, N.,  Suzuki, K.,  Suzuki, M.,  
Taiyoji, M.,  Ferrer, S., and Regue, M. (1997). Genetic analysis of the chitinase 
system of Serratia marcescens 2170. J. Bacteriol. 179(22): 7111-7117. 
Weber, P.C. (1997). Methods Enzymol. 276: 13-23.  
Wiseman, T.,  Williston, S.,  Brandts, J. F., and Lin, L. N. (1989). Rapid measurement 
of binding constants and heats of binding using a new titration calorimeter. 
Anal Biochem. 179(1): 131-137. 
Yamac, D.,  Ozturk, B.,  Coskun, U.,  Tekin, E.,  Sancak, B.,  Yildiz, R., and Atalay, 
C. (2008). Serum YKL-40 levels as a prognostic factor in patients with locally 
advanced breast cancer. Adv. Ther. 25(8): 801-809. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CURRICULUM VITAE 
 
Name:   Miss Araya Ranok 
Date of Birth: October 10th, 1977 
Place of Birth: Nakhon Ratchasima, Thailand 
Education: 
2008- 2013:   School of Biochemistry, Suranaree University of Technology, 
Nakhon Ratchasima, Thailand 
Ph.D. in Biochemistry 
2006-2008:  School of Health Science, Sukhothai Thammathirat Open 
University, Bangkok, Thailand 
B.Sc. in Occupation Health and Safety 
2004-2006  Public Health Department, Khon Kaen University, Khon Kaen, 
Thailand 
M. Public Health in Environmental Health. 
1995-1999:   Biochemistry Department, Khon Kaen University, Khon Kaen, 
Thailand 
B.Sc. in Biochemistry 
Fellowships:    The Office of the Higher Education Commission, Thailand 
 
 
 
 
 
 
 
 
 
